Document:

EX-10.1

 Exhibit 10.1 

***Text Omitted and Filed Separately with the Securities and Exchange Commission 

Confidential Treatment Requested Under 

17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 

Execution Version 

Amended and Restated 
 Ex-US Commercialization Agreement 
 This Amended and Restated Ex-US
Commercialization Agreement is entered into as of February 28, 2018 (the “Restatement Date”) 
 by and between 

F. Hoffmann-La Roche Ltd 

with an office and place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche”) 

on the one hand 
 and 

Foundation Medicine, Inc. 
 with an office and place of
business at 150 Second Street, Cambridge, Massachusetts 02141 (“FMI”) 
 on the other hand. 

  

					
		  		  	***Confidential Treatment Requested***

 Table of Contents 
  

									
	1.	 	Definitions	  	 	1	
		 	1.1	  	 [...***...] Region
	  	 	1	
		 	1.2	  	 Affiliate
	  	 	1	
		 	1.3	  	 Agreement
	  	 	2	
		 	1.4	  	 Agreement Term
	  	 	2	
		 	1.5	  	 Allocable Overhead Expenses
	  	 	2	
		 	1.6	  	 Applicable Law
	  	 	2	
		 	1.7	  	 Business Day
	  	 	2	
		 	1.8	  	 Calendar Quarter
	  	 	3	
		 	1.9	  	 Calendar Year
	  	 	3	
		 	1.10	  	 Commercial Launch or Commercially Launch(ed)
	  	 	3	
		 	1.11	  	 Commercially Reasonable Efforts
	  	 	3	
		 	1.12	  	 Confidential Information
	  	 	3	
		 	1.13	  	 Control
	  	 	3	
		 	1.14	  	 Core Countries
	  	 	4	
		 	1.15	  	 Cost of Services
	  	 	4	
		 	1.16	  	 Cover
	  	 	4	
		 	1.17	  	 Critical Core Countries
	  	 	4	
		 	1.18	  	 Dedicated Sales Force
	  	 	4	
		 	1.19	  	 Effective Date
	  	 	5	
		 	1.20	  	 EMA
	  	 	5	
		 	1.21	  	 EU
	  	 	5	
		 	1.22	  	 Existing Third Party Rights
	  	 	5	
		 	1.23	  	 FDA
	  	 	5	
		 	1.24	  	 FMI Know-How
	  	 	5	
		 	1.25	  	 FMI Patent Rights
	  	 	5	
		 	1.26	  	 FMI Territory
	  	 	5	
		 	1.27	  	 FMI Trademarks
	  	 	5	
		 	1.28	  	 FTE
	  	 	5	
		 	1.29	  	 GAAP
	  	 	5	
		 	1.30	  	 Gross Margin
	  	 	5	
		 	1.31	  	 HSR
	  	 	5	
		 	1.32	  	 IFRS
	  	 	5	
		 	1.33	  	 Initial Filing
	  	 	6	
		 	1.34	  	 Initial Launch
	  	 	6	
		 	1.35	  	 Insolvency Event
	  	 	6	
		 	1.36	  	 Invention
	  	 	6	
		 	1.37	  	 JMC
	  	 	6	
		 	1.38	  	 JOC
	  	 	6	
		 	1.39	  	 Know-How
	  	 	6	
		 	1.40	  	 MSL
	  	 	6	
		 	1.41	  	 Net Sales
	  	 	6	
		 	1.42	  	 Non-Europe Region
	  	 	6	
		 	1.43	  	 Non-Regulated Market
	  	 	7	
		 	1.44	  	 [...***...] Region
	  	 	7	
		 	1.45	  	 Party
	  	 	7	
		 	1.46	  	 Patent Rights
	  	 	7	
		 	1.47	  	 Post Approval Plan
	  	 	7	
		 	1.48	  	 Product
	  	 	7	

  

					
		  		  	***Confidential Treatment Requested***

 - i - 

									
		 	1.49	  	 Quality Standards
	  	 	8	
		 	1.50	  	 Region
	  	 	8	
		 	1.51	  	 Regulated Market
	  	 	8	
		 	1.52	  	 Regulatory Approval
	  	 	8	
		 	1.53	  	 Regulatory Authority
	  	 	8	
		 	1.54	  	 Roche Group
	  	 	8	
		 	1.55	  	 Roche Region
	  	 	8	
		 	1.56	  	 Sales
	  	 	9	
		 	1.57	  	 Sublicensee
	  	 	9	
		 	1.58	  	 Subsequent Claim Filing
	  	 	9	
		 	1.59	  	 Tactical Plan
	  	 	9	
		 	1.60	  	 Territory
	  	 	9	
		 	1.61	  	 Territory Revision Event
	  	 	10	
		 	1.62	  	 Third Party
	  	 	10	
		 	1.63	  	 Transitional Services Agreement
	  	 	10	
		 	1.64	  	 US
	  	 	10	
		 	1.65	  	 US$
	  	 	10	
		 	1.66	  	 Additional Definitions
	  	 	10	
	2.	 	Licenses and Exclusivity	  	 	12	
		 	2.1	  	 Licenses
	  	 	12	
		 	2.2	  	 Exclusive Right to Commercialize Products
	  	 	13	
		 	2.3	  	 Product Specifications; Modifications
	  	 	14	
	3.	 	Right to Include Future Products	  	 	14	
	4.	 	Governance	  	 	14	
		 	4.1	  	 Joint Management Committee
	  	 	14	
		 	4.2	  	 Joint Operational Committee
	  	 	14	
		 	4.3	  	 Members
	  	 	14	
		 	4.4	  	 Responsibilities of the JOC
	  	 	15	
		 	4.5	  	 Meetings
	  	 	16	
		 	4.6	  	 Minutes
	  	 	16	
		 	4.7	  	 Decisions
	  	 	16	
		 	4.8	  	 Information Exchange
	  	 	17	
		 	4.9	  	 Joint Operational Teams
	  	 	17	
		 	4.10	  	 Alliance Director
	  	 	17	
		 	4.11	  	 Limitations of Authority
	  	 	17	
		 	4.12	  	 Expenses
	  	 	17	
		 	4.13	  	 Lifetime
	  	 	17	
	5.	 	Supply	  	 	17	
	6.	 	Regulatory	  	 	18	
		 	6.1	  	 Responsibility
	  	 	18	
		 	6.2	  	 Clinical Trials
	  	 	22	
		 	6.3	  	 Reporting Adverse Events
	  	 	22	
		 	6.4	  	 Reimbursement
	  	 	22	
	7.	 	Commercialization	  	 	23	
		 	7.1	  	 Strategies
	  	 	23	
		 	7.2	  	 Sales
	  	 	23	
		 	7.3	  	 F1CDx Initial Launch Plan, Subsequent Claim Filings, and
Non-Regulated Updates
	  	 	23	
		 	7.4	  	 Additional Responsibilities
	  	 	25	
		 	7.5	  	 Branding and Pricing
	  	 	30	
		 	7.6	  	 Product Promotional Materials and Promotional Obligations
	  	 	30	
		 	7.7	  	 F1CDx Report
	  	 	30	

  

					
		  		  	***Confidential Treatment Requested***

 - ii - 

									
	8.	 	Payment	  	 	31	
		 	8.1	  	 General
	  	 	31	
		 	8.2	  	 Costs of Services
	  	 	31	
		 	8.3	  	 Royalty Payments and Sales Milestones
	  	 	32	
		 	8.4	  	 Disclosure of Payments
	  	 	34	
	9.	 	Accounting and Reporting	  	 	34	
		 	9.1	  	 Timing of Payments
	  	 	34	
		 	9.2	  	 Late Payment
	  	 	35	
		 	9.3	  	 Method of Payment
	  	 	35	
		 	9.4	  	 Currency Conversion
	  	 	35	
		 	9.5	  	 Reporting
	  	 	35	
	10.	 	Taxes	  		  	 	35	
	11.	 	Auditing	  	 	35	
		 	11.1	  	 Right to Audit
	  	 	35	
		 	11.2	  	 Audit Reports
	  	 	36	
		 	11.3	  	 Over-or Underpayment
	  	 	36	
		 	11.4	  	 Duration of Audit Rights
	  	 	36	
	12.	 	Intellectual Property	  	 	36	
		 	12.1	  	 Ownership of Inventions
	  	 	36	
		 	12.2	  	 Trademarks and Labeling
	  	 	36	
		 	12.3	  	 Prosecution of Patent Rights
	  	 	37	
		 	12.4	  	 Patent Coordination Team
	  	 	37	
		 	12.5	  	 Infringement
	  	 	37	
		 	12.6	  	 Defense
	  	 	38	
		 	12.7	  	 Common Interest Disclosures
	  	 	38	
	13.	 	Representations and Warranties	  	 	38	
		 	13.1	  	 FMI Representations and Warranties
	  	 	38	
		 	13.2	  	 Mutual Representations of the Parties
	  	 	39	
	14.	 	Indemnification	  	 	40	
		 	14.1	  	 Indemnification by Roche
	  	 	40	
		 	14.2	  	 Indemnification by FMI
	  	 	40	
		 	14.3	  	 Procedure
	  	 	40	
	15.	 	Liability	  	 	40	
		 	15.1	  	 Disclaimer
	  	 	40	
	16.	 	Obligation Not to Disclose Confidential Information	  	 	41	
		 	16.1	  	 Non-Use and
Non-Disclosure
	  	 	41	
		 	16.2	  	 Permitted Disclosure
	  	 	41	
		 	16.3	  	 Press Releases
	  	 	41	
		 	16.4	  	 Publications
	  	 	41	
		 	16.5	  	 Commercial Considerations
	  	 	42	
	17.	 	Term and Termination	  	 	42	
		 	17.1	  	 Commencement and Term
	  	 	42	
		 	17.2	  	 Termination
	  	 	42	
		 	17.3	  	 Consequences of Termination and Expiration
	  	 	43	
		 	17.4	  	 Survival
	  	 	46	
	18.	 	Bankruptcy	  	 	46	
	19.	 	Miscellaneous	  	 	47	
		 	19.1	  	 Governing Law
	  	 	47	

  

					
		  		  	***Confidential Treatment Requested***

 - iii - 

									
		 	19.2	  	Disputes	  	 	47	
		 	19.3	  	Arbitration	  	 	47	
		 	19.4	  	Assignment	  	 	48	
		 	19.5	  	Compliance with Applicable Law	  	 	48	
		 	19.6	  	Debarment	  	 	49	
		 	19.7	  	Independent Contractor	  	 	49	
		 	19.8	  	Unenforceable Provisions and Severability	  	 	49	
		 	19.9	  	Waiver	  	 	49	
		 	19.10	  	Appendices	  	 	49	
		 	19.11	  	Entire Understanding	  	 	50	
		 	19.12	  	Amendments	  	 	50	
		 	19.13	  	Invoices	  	 	50	
		 	19.14	  	Notice	  	 	50	
		 	19.15	  	Subcontractors	  	 	50	
		 	19.16	  	Force Majeure	  	 	51	
		 	19.17	  	Rules of Construction	  	 	51	

  

					
		  		  	***Confidential Treatment Requested***

 - iv - 

 Amended and Restated Ex-US Commercialization Agreement

 WHEREAS, FMI has certain products that it currently commercializes, and additional products that it would like to commercialize in the future, either
by itself or through a collaborator; 
 WHEREAS, Roche has expertise in the commercialization of pharmaceutical and diagnostic products; and 

WHEREAS, pursuant to that certain Ex-Us Commercialization Agreement, effective as of April 7, 2015 (as amended,
the “Original Agreement”), Roche and FMI agreed to collaborate on the commercialization of certain FMI products outside of the US; 

WHEREAS, concurrently with the Original Agreement, Roche and FMI entered into that certain transaction agreement which provided, among other things, for Roche
to acquire a majority ownership of FMI upon the terms and subject to the conditions set forth therein (as it may be amended from time to time, the “Transaction Agreement”); a related investor rights agreement (as it may be amended
from time to time, the “Investor Rights Agreement”); that certain United States education collaboration agreement pursuant to which Roche agreed to work with FMI in the United States to educate relevant persons on next generation
sequencing and/or comprehensive genomic profiling technology (as it may be amended from time to time, the “US Education Collaboration Agreement”); that certain collaboration agreement pursuant to which Roche agreed to collaborate
with FMI on the development of genomic testing platforms (as it may be amended from time to time, the “Collaboration Agreement”); and that certain master IVD collaboration agreement pursuant to which Roche and FMI agreed to
establish a framework for a collaboration to develop, manufacture, distribute, and commercialize IVD Kit Products (as defined therein) (as it may be amended from time to time, the “Master IVD Collaboration Agreement” and, together
with the US Education Collaboration Agreement and the Collaboration Agreement, the “Related Agreements”); 
 WHEREAS, FMI and Roche intend
that assays and other products generated under the Collaboration Agreement will be commercialized in accordance with this Agreement; and 
 WHEREAS, FMI and
Roche desire to amend and restate the Original Agreement in its entirety; 
 NOW, THEREFORE, in consideration of the mutual covenants and promises contained
in this Agreement and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, do hereby agree as follows: 

1. Definitions 
 As used in this Agreement, the following
terms, whether used in the singular or plural, shall have the following meanings: 
 1.1 [...***...] Region 

The term “[...***...] Region” shall mean the [...***...]. 

1.2 Affiliate 
 The term “Affiliate” shall mean
any individual, corporation, association or other business entity that directly or indirectly controls, is controlled by, or is under common control with the Party in 

  

					
		 		 	***Confidential Treatment Requested***

 
question. As used in this definition of “Affiliate,” the term “control” shall mean the direct or indirect ownership of more than fifty percent (>50%) of the stock having
the right to vote for directors thereof or the ability to otherwise control the management of the corporation or other business entity whether through the ownership of voting securities, by contract, resolution, regulation or otherwise. Anything to
the contrary in this paragraph notwithstanding, Chugai Pharmaceutical Co., Ltd, a Japanese corporation (“Chugai”), shall not be deemed an Affiliate of Roche unless Roche provides written notice to FMI of its desire to include Chugai as an
Affiliate of Roche. Moreover, FMI and its Affiliates existing as of the Restatement Date shall not be deemed Affiliates of Roche and its Affiliates existing as of the Restatement Date, and Roche and its Affiliates existing as of the Restatement Date
shall not be deemed Affiliates of FMI and its Affiliates existing as of the Restatement Date. Affiliates coming into existence after the Restatement Date shall be classified by the Parties as either Roche Affiliates or FMI Affiliates for the
purposes of this Agreement. 
 1.3 Agreement 
 The term
“Agreement” shall mean this document including any and all appendices and amendments to it as may be added and/or amended from time to time in accordance with the provisions of this Agreement. 

1.4 Agreement Term 
 The term “Agreement Term”
shall mean the period of time commencing on the Effective Date and, unless this Agreement is terminated sooner as provided in Article 17, expiring five (5) years from the Effective Date (“Initial Term”) unless extended by Roche
in writing at least [...***...] prior to the expiration of the Initial Term (or any Renewal Term) (i) in its entirety, (ii) on a country-by-country,
Region by Region and/or Product-by-Product basis, or (iii) by mutual agreement of the Parties, in each case for additional two (2) year periods (each a
“Renewal Term”) during any period of time in which the Aggregate Ownership Percentage (as defined in the Investor Rights Agreement) of Roche and its Affiliates is at least 50.1% (it being understood that this requirement is subject
to Section 4.04 of the Investor Rights Agreement). 
 1.5 Allocable Overhead Expenses 

The term “Allocable Overhead Expenses” shall mean costs incurred by a Party for its account which are attributable to the Party’s supervisory,
services, occupancy costs, corporate bonus (to the extent not charged directly to department), and its payroll, information systems, human relations or purchasing functions and which are allocated to company departments based on space occupied or
headcount or other activity-based method. Allocable Overhead Expenses shall not include any costs attributable to general corporate activities including executive management, investor relations, business development, legal affairs and finance. 

1.6 Applicable Law 
 The term “Applicable Law”
shall mean any law, statute, ordinance, code, rule or regulation that has been enacted by a government authority (including without limitation, any Regulatory Authority) and is in force as of the Effective Date or comes into force during the
Agreement Term, in each case to the extent that the same is applicable to the performance by the Parties of their respective obligations under this Agreement. 

1.7 Business Day 
 The term “Business Day” shall
mean 9:00 a.m. to 5:00 p.m. local time on a day other than a Saturday, Sunday or bank or other public or federal holiday in Switzerland, New Jersey or Massachusetts. 

  

					
		 	- 2 -	 	***Confidential Treatment Requested***

 1.8 Calendar Quarter 

The term “Calendar Quarter” shall mean each period of three (3) consecutive calendar months, ending March 31, June 30,
September 30, and December 31. 
 1.9 Calendar Year 

The term “Calendar Year” shall mean the period of time beginning on January 1 and ending December 31, except for the first Calendar Year of
the Agreement Term, which shall begin on the Effective Date and end on December 31. 
 1.10 Commercial Launch or Commercially Launch(ed) 

The term “Commercial Launch” or “Commercially Launch(ed)” shall mean a commercial launch of a particular Product, which shall at a minimum
require at least commercial scale sales, marketing and promotional activities using Commercially Reasonable Efforts. 
 1.11 Commercially Reasonable
Efforts 
 The term “Commercially Reasonable Efforts” shall mean such level of efforts required to carry out such obligation in a sustained
manner consistent with the efforts that Roche or FMI, as applicable, devotes at the same stage of development or commercialization, as applicable, for its own products with similar market potential, at a similar stage of their product life taking
into account the existence of other competitive products in the market place or under development, the proprietary position of the product, the regulatory structure involved, the anticipated profitability of the product and other relevant factors.
It is understood that such product potential may change from time to time based upon changing scientific, business and marketing and return on investment considerations. 

1.12 Confidential Information 
 The term
“Confidential Information” shall mean any and all information, data or know-how (including Know-How), whether technical or
non-technical, oral or written, that is disclosed by one Party or its Affiliates (“Disclosing Party”) to the other Party or its Affiliates (“Receiving Party”). Confidential
Information shall not include any information, data or know-how that: 
  

	 	(i)	was generally available to the public at the time of disclosure, or becomes available to the public after disclosure by the Disclosing Party other than through fault (whether by action or inaction) of the Receiving
Party or its Affiliates, 

  

	 	(ii)	can be evidenced by written records to have been already known to the Receiving Party or its Affiliates prior to its receipt from the Disclosing Party, 

 

	 	(iii)	is obtained at any time lawfully from a Third Party under circumstances permitting its use or disclosure, 

  

	 	(iv)	is developed independently by the Receiving Party or its Affiliates as evidenced by written records other than through knowledge of Confidential Information, or 

 

	 	(vi)	is approved in writing by the Disclosing Party for release by the Receiving Party. 

 The terms of this
Agreement shall be considered Confidential Information of the Parties. 
 1.13 Control 

The term “Control” shall mean (as an adjective or as a verb including conjugations and variations such as “Controls” “Controlled”
or “Controlling”) (a) with respect to Patent Rights and/or Know-How, the possession by a Party of the ability to grant a license or sublicense of such Patent Rights and/or Know-How without violating the terms of any agreement or arrangement between such Party and any other party and (b) with respect to proprietary materials, the possession by a Party of the ability to supply such
proprietary materials to the other Party as provided herein without violating the terms of any agreement or arrangement between such Party and any other party. 

  

					
		 	- 3 -	 	***Confidential Treatment Requested***

 1.14 Core Countries 

The term “Core Countries” shall mean [...***...]. The term “Core Countries” may be updated, without further amendment to this
Agreement, to include additional countries approved by the JOC. 
 1.15 Cost of Services 

The term “Cost of Services” means, as applicable to a Product, FMI’s costs incurred in connection with sample preparation, sequencing, data
analysis, medical curation and report generation for such Product (collectively, “Service Activities”), equal to [...***...]. The Cost of Services shall be calculated in accordance with GAAP or IFRS, as applicable, and as
consistently applied by FMI in preparing its audited consolidated financial statements. FMI shall be solely responsible for all capital costs incurred in connection with providing the Service Activities for Products for use in the Territory,
including without limitation building out capacity for such Products, provided that depreciation for any equipment used to provide the Service Activities will be included in the Cost of Services to the extent allocable to a Product in a manner
consistent with FMI’s internal and external accounting principles as consistently applied. Except as provided for in Section 8.2, Cost of Services will not include any transfer pricing mark-up. For
clarity, any given deduction utilized in calculating Cost of Services (including the components thereof) shall be taken only once. 
 Notwithstanding the
foregoing, to the extent the Parties have agreed to other calculations for the Cost of Services in a given country in the Territory, the Cost of Services in such country in the Territory shall be governed by the separate terms agreed to between the
Parties. 
 1.16 Cover 
 The term “Cover”
shall mean (as an adjective or as a verb including conjugations and variations such as “Covered,” “Coverage” or “Covering”) that the developing, making, using, offering for sale, promoting, selling, exporting or
importing of a given compound, formulation or product would infringe a valid claim in the absence of a license under the Patent Rights to which such valid claim pertains. The determination of whether a compound, formulation, process or product is
covered by a particular valid claim shall be made on a country-by-country basis. As used in the previous sentence, “valid claim” means, with respect to a
particular country a claim in an issued and unexpired patent that has not lapsed or been disclaimed, revoked, held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable
or unappealed within the time allowed for appeal and that has not been admitted to be invalid or unenforceable through re-examination, re-issue, disclaimer or otherwise,
or lost in an interference proceeding. 
 1.17 Critical Core Countries 

The term “Critical Core Countries” shall mean [...***...]. The term “Critical Core Countries” may be updated, without further
amendment to this Agreement, to include additional countries approved by the JOC. 
 1.18 Dedicated Sales Force 

The term “Dedicated Sales Force” shall mean a Roche sales force promoting F1CDx that (i) does not promote, and is prohibited from promoting, any
oncology therapeutics and (ii) is not directly, on an individual basis or on a Roche sales force promoting F1CDx basis, compensated or financially incentivized by sales of oncology therapeutics. 

  

					
		 	- 4 -	 	***Confidential Treatment Requested***

 1.19 Effective Date 

The term “Effective Date” shall mean the effective date of the Collaboration Agreement. 

1.20 EMA 
 The term “EMA” shall mean the
European Medicines Agency or any successor agency with responsibilities comparable to those of the European Medicines Agency. 
 1.21 EU 

The term “EU” shall mean the European Union and all its then-current member countries. 

1.22 Existing Third Party Rights 
 The term “Existing
Third Party Rights” shall mean any Third Party rights granted by FMI to such Third Party relating to the Products in the Territory under an agreement with FMI existing as of the Effective Date. The Existing Third Party Rights are listed in
Appendix 1.22. 
 1.23 FDA 
 The term
“FDA” shall mean the US Food and Drug Administration. 
 1.24 FMI Know-How 

The term “FMI Know-How” shall mean the Know-How that FMI Controls at
the Effective Date and during the Agreement Term. 
 1.25 FMI Patent Rights 

The term “FMI Patent Rights” shall mean the Patent Rights that FMI Controls Covering a Product or its use. 

1.26 FMI Territory 
 The term “FMI Territory”
shall mean (i) the US, and (ii) any countries that have been removed from the Territory pursuant to the terms of this Agreement. 
 1.27 FMI
Trademarks 
 The term “FMI Trademarks” shall mean all trademarks Controlled by FMI which are necessary or useful for use in connection with
the commercialization of Products. 
 1.28 FTE 
 The
term “FTE” shall mean a full-time equivalent person-year, based upon a total of no less than one thousand eight hundred (1,800) working hours per year. In no circumstance can the work of any given person exceed one (1) FTE. 

1.29 GAAP 
 The term “GAAP” shall mean US
generally accepted accounting principles. 
 1.30 Gross Margin 

The term “Gross Margin” shall mean Net Sales minus Cost of Services. 

1.31 HSR 
 The term “HSR” shall mean the
Hart-Scott-Rodino Antitrust Improvements Act. 
 1.32 IFRS 

The term “IFRS” shall mean International Financial Reporting Standards. 

  

					
		 	- 5 -	 	***Confidential Treatment Requested***

 1.33 Initial Filing 

The term “Initial Filing” shall mean the initial filing for the F1CDx platform in a Regulated Market to obtain Regulatory Approval for such product.

 1.34 Initial Launch 
 The term “Initial
Launch” shall mean: (a) as it relates to a Regulated Market, the Commercial Launch of F1CDx in such country following an Initial Filing and (b) as it relates to a Non-Regulated Market, the
Commercial Launch of F1CDx in such country following delivery of FMI’s F1CDx Launch Notice. 
 1.35 Insolvency Event 

The term “Insolvency Event” shall mean circumstances under which a Party (i) has a receiver or similar officer appointed over all or a material
part of its assets or undertaking; (ii) passes a resolution for winding-up (other than a winding-up for the purpose of, or in connection with, any solvent
amalgamation or reconstruction) or a court makes an order to that effect or a court makes an order for administration (or any equivalent order in any jurisdiction); (iii) enters into any composition or arrangement with its creditors (other than
relating to a solvent restructuring); (iv) ceases to carry on business; (v) is unable to pay its debts as they become due in the ordinary course of business. 

1.36 Invention 
 The term “Invention” shall mean
an invention that is made, i.e., conceived and reduced to practice, in performance of activities under this Agreement. 
 1.37 JMC 

The term “JMC” shall mean the joint management committee described in Article 6 of the Collaboration Agreement. If the Collaboration Agreement
terminates before this Agreement, then the provisions of the Collaboration Agreement to the necessary to interpret or implement this Agreement shall be incorporated by reference into this Agreement. 

1.38 JOC 
 The term “JOC” shall mean the joint
operating committee as mentioned in the Collaboration Agreement and the US Education Collaboration Agreement, and described in Section 4.2. 
 1.39 Know-How 
 The term “Know-How” shall mean data, knowledge and
information, including chemical manufacturing data, toxicological data, pharmacological data, preclinical data, assays, platforms, formulations, specifications, quality control testing data, that are necessary or useful for the discovery,
manufacture, development or commercialization of Products. 
 1.40 MSL 

The term “MSL” shall mean a medical science liaison. 

1.41 Net Sales 
 The term “Net Sales” shall
mean, for a Product in a particular period, the amount calculated by subtracting from the Sales of such Product for such period: [...***...]. 

1.42 Non-Europe Region 

The “Non-Europe Region” shall mean all countries in the Territory excluding the [...***...] Region and
the [...***...] Region. 

  

					
		 	- 6 -	 	***Confidential Treatment Requested***

 1.43 Non-Regulated Market 

The term “Non-Regulated Market” shall mean a market other than a Regulated Market. 

1.44 [...***...] Region 

The term “[...***...] Region” shall mean [...***...]. 

1.45 Party 
 The term “Party” shall mean FMI or
Roche, as the case may be, and “Parties” shall mean FMI and Roche collectively. 
 1.46 Patent Rights 

The term “Patent Rights” shall mean all rights under any patent or patent application, in any country of the Territory, including any patents issuing
on such patent application, and further including any substitution, extension or supplementary protection certificate, reissue, reexamination, renewal, division, continuation or
continuation-in-part of any of the foregoing. 
 1.47 Post Approval Plan

 The term “Post Approval Plan” shall mean the plan for regulatory (including the strategy with respect to Regulatory Approvals and
reimbursement approvals for Products) and clinical activities associated with a Product in the Territory. 
 1.48 Product 

The term “Product” shall mean (i) the FoundationOne® clinical diagnostic testing
commercial product (the “FoundationOne Product” or “FoundationOne”) and the FoundationOne® Heme clinical diagnostic testing commercial product
(“FoundationOne Heme” and, together with FoundationOne, collectively, “Initial Products”), (ii) the FoundationACT® clinical diagnostic testing
commercial product (“FACT”, and together with the Initial Products, collectively, the “First Year Products”), (iii) the FoundationOne CDxTM clinical diagnostic
testing commercial product (“FoundationOne CDx” or “F1CDx”) and (iv) any other clinical diagnostic testing commercial products developed under the Immunotherapy Testing Platform Development Program (as defined
in the Collaboration Agreement), the ctDNA Platform Development Program (as defined in the Collaboration Agreement), or the CDx Development Program (as defined in the Collaboration Agreement), including, to the extent developed under any such
development program under the Collaboration Agreement, any product that becomes subject to a Regulatory Approval by a Regulatory Authority in the US after the Restatement Date (clause (iv), subject to the terms of Section 8.3.5, collectively,
“Collaboration Products”) and (v) any other products that the Parties mutually agree to include under this Agreement. The term “Product” shall include associated Service Activities provided in connection with Sales,
[...***...]. For clarity, (a) in vitro diagnostic kit products, (b) companion diagnostic assay products developed by FMI for Third Parties, and (c) any standalone data or molecular information products (i.e. other than clinical
diagnostic testing commercial products), are excluded from the definition of a Product. 
 For clarity, the term “clinical diagnostic testing
commercial product” as used in this Agreement specifically excludes the provision of any testing products or services related to research and development activities, including any activities related to the sale of diagnostic testing products
and services to biopharmaceutical companies, or genomic profiling for clinical trials sponsored or otherwise funded by biopharmaceutical companies. Nothing herein will exclude sales to clinicians for market development purposes in connection with
Commercially Launching a Product in the Territory, on terms that are mutually agreed to by the Parties. 

  

					
		 	- 7 -	 	***Confidential Treatment Requested***

 1.49 Quality Standards 

The term “Quality Standards” shall mean (i) FMI’s standard specifications in accordance with Section 2.3, with respect to the Products
and performance of Service Activities, which shall include technical specifications on such Product and standards for the validation of such Product, and (ii) Clinical Laboratory Improvements Amendments (CLIA) or Quality Standard Regulations
(QSR) requirements, each as applicable to a Product, and other standards required by Applicable Laws in the Territory. 
 1.50 Region 

The term “Region” shall mean the [...***...] Region, the [...***...] Region, and the [...***...] Region. 

1.51 Regulated Market 
 The term “Regulated
Market” shall mean a market in the Territory in which Regulatory Approval is required in order to manufacture, have manufactured, sell, have sold, market (including place on the market or put into service), have marketed, import or have
imported all or any portion of F1CDx, including any companion diagnostic claims. 
 1.52 Regulatory Approval 

The term “Regulatory Approval” shall mean any approvals (including, specifically in Japan, National Health Insurance price listing), licenses,
registrations, authorizations, by any Regulatory Authority necessary to manufacture, have manufactured, sell, have sold, market (including place on the market or put into service), have marketed, import or have imported any Product in the Territory.

 1.53 Regulatory Authority 
 The term “Regulatory
Authority” shall mean any national, supranational (e.g., the European Commission, the Council of the European Union, the European Medicines Agency), regional, state or local regulatory agency, department, bureau, commission, council or other
governmental entity including the EMA, in any country involved in the granting of Regulatory Approval for the Product. 
 1.54 Roche Group 

The term “Roche Group” shall mean collectively Roche and its Affiliates and Sublicensees. 

1.55 Roche Region 
 The term “Roche
Region” shall mean each of [...***...] (each as defined below in this Section 1.55). 
  

	 	•	 	The “[...***...]” shall mean the country of [...***...]. 

  

	 	•	 	The “[...***...]” shall mean the country of [...***...]. 

  

	 	•	 	The “[...***...]” shall mean the countries of [...***...]. 

  

	 	•	 	The term “[...***...]” shall mean the countries [...***...]. 

  

	 	•	 	The term “[...***...]” shall mean the countries of [...***...]. 

  

	 	•	 	The term “[...***...]” shall mean the countries of [...***...]. 

  

					
		 	- 8 -	 	***Confidential Treatment Requested***

 For clarity, any countries listed in this Section 1.55 that are in the Territory but that the Parties have
otherwise mutually agreed to exclude from the Virtual Gross Margin Calculation shall be excluded from the applicable Roche Region even if such country is otherwise listed in this Section 1.55. Any countries in the Territory that are not
otherwise listed in the definitions of the [...***...], the [...***...], the [...***...], the [...***...], the [...***...], and the [...***...] shall be assigned to a specific Roche Region by mutual agreement of
the Parties. 
 1.56 Sales 
 The term “Sales”
shall mean, for a Product in a particular period, the sum of (i) and (ii): 
  

	(i)	the amount stated [...***...] for such period [...***...]. This amount reflects [...***...] in such period reduced by [...***...] taken in accordance with [...***...]. By way of example
[...***...] taken in accordance [...***...]: 

 [...***...] 

[...***...] 

[...***...] 

[...***...] 

[...***...] 
 For purposes
of clarity, [...***...] shall be excluded from “Sales”. Notwithstanding the foregoing, to the extent the Parties have agreed to other calculations for Sales in a given country in the Territory, the Sales in such country in the
Territory shall be governed by the separate terms agreed to between the Parties. 
  

	(ii)	[...***...]. 

 1.57 Sublicensee 

The term “Sublicensee” shall mean a permitted entity to which Roche has licensed rights in accordance with Section 2.1.2 of this Agreement. 

1.58 Subsequent Claim Filing 
 The term “Subsequent
Claim Filing” shall mean any subsequent filing made following the Initial Filing to add any companion diagnostic claims to F1CDx not included in the Initial Filing, that requires Regulatory Approval, including any additional biomarkers added
following the Initial Filing specifically in connection with the addition of any companion diagnostic claim included in such subsequent filing. 
 1.59
Tactical Plan 
 The term “Tactical Plan” shall mean the plan describing the tactics and logistics for marketing, promotion and sale of a
Product in a specific country or Region, which shall address matters such as (i) annual minimum amounts of Product to be sold in such country or Region, (ii) details regarding the marketing support for the Products, and (iii) other
activities to be conducted by either Party. 
 1.60 Territory 

The term “Territory” shall mean all countries of the world, excluding the FMI Territory. 

  

					
		 	- 9 -	 	***Confidential Treatment Requested***

 1.61 Territory Revision Event 

The term “Territory Revision Event” shall mean a Territory Revision Event 1, Territory Revision Event 2, Territory Revision Event 3, Territory
Revision Event 4, Territory Revision Event 5, Territory Revision Event 6 or Territory Revision Event 7. 
 1.62 Third Party 

The term “Third Party” shall mean a person or entity other than (i) FMI or any of its Affiliates or (ii) a member of the Roche Group. 

1.63 Transitional Services Agreement 
 The term
“Transitional Services Agreement” shall mean that certain transitional services agreement, effective as of December 1, 2016, by and between the Parties, pursuant to which FMI agreed to perform certain “Transitional Services”
(as defined therein) for Roche in certain countries in the Territory. 
 1.64 US 

The term “US” shall mean the United States of America and its territories and possessions. 

1.65 US$ 
 The term “US$” shall mean US dollars.

 1.66 Additional Definitions 
 Each of the following
definitions is set forth in the Section of this Agreement indicated below: 
  

			
	 Definition
	  	Section
	 AAA
	  	19.3
	 AAA Arbitration Rules
	  	19.3
	 Accounting Period
	  	9.1
	 Adverse Event
	  	6.3
	 Alliance Director
	  	4.10
	 APAC Region
	  	1.55
	 Arbitration Offer
	  	8.3.5
	 Arbitration Commencement Date
	  	8.3.5
	 Average Delivery Time Metric
	  	7.4.2.3
	 Bankruptcy Code
	  	18
	 Breaching Party
	  	17.2.1
	 Chairperson
	  	4.3
	 Chugai
	  	1.2
	 Collaboration Agreement
	  	Whereas clause
	 Collaboration Products
	  	1.38
	 Dependent Obligation
	  	7.4.1.5
	 Disclosing Party
	  	1.12
	 [...***...]
	  	1.55
	 [...***...]
	  	1.55
	 Expert
	  	8.3.5
	 F1CDx
	  	1.48
	 F1CDx Initial Launch Plan
	  	7.3.1
	 F1CDx Launch Notice
	  	7.3.1
	 F1CDx Personnel
	  	6.1.2.3

  

					
		 	- 10 -	 	***Confidential Treatment Requested***

			
	 Definition
	  	Section
	 F1CDx Report
	  	7.7
	 FACT
	  	1.48
	 FCPA
	  	19.5
	 Firewall
	  	6.1.2.3
	 Firewall Policies
	  	6.1.2.3
	 FMI
	  	Cover page
	 FMI-Originated Transfer
Activities
	  	17.3.4.3
	 FoundationOne
	  	1.48
	 FoundationOne CDx
	  	1.48
	 FoundationOne Product
	  	1.48
	 Global Cost
	  	8.2.1
	 Global Test Fixed Fee
	  	8.2.1
	 Indemnified Party
	  	14.3
	 Indemnifying Party
	  	14.3
	 Initial Discussion Period
	  	8.3.5
	 Initial Launch Requirement
	  	7.3.1
	 Initial Products
	  	1.48
	 Initial Term
	  	1.4
	 Investor Rights Agreement
	  	Whereas clause
	 [...***...]
	  	1.55
	 JOT
	  	4.9
	 [...***...]
	  	1.55
	 Local Cost
	  	8.2.1
	 Local Test Fixed Fee
	  	8.2.1
	 Master IVD Collaboration Agreement
	  	Whereas clause
	 Material Average Delivery Time Failure
	  	7.4.2.3
	 Members
	  	4.3
	 Minimum Price
	  	7.5
	 Minimum Revenue Requirements
	  	7.4.1.2
	 Minimum Transfer Payment
	  	17.3.4.3
	 NGS
	  	7.4.2.3
	 Non-Breaching Party
	  	17.2.2
	 Non-Regulated
Update
	  	7.3.2
	 [...***...]
	  	1.55
	 Original Agreement
	  	Whereas clause
	 Panel
	  	8.3.5
	 Payment Currency
	  	9.3
	 Penalty Payment
	  	8.3.6
	 Peremptory Notice Period
	  	17.2.2
	 Precedent Obligation
	  	7.4.1.5
	 Product Documentation Requirements
	  	7.4.1.4
	 Product Trademarks
	  	12.2
	 Professional Services
	  	7.7
	 Publishing Notice
	  	16.4
	 Publishing Party
	  	16.4
	 Qualified Sample
	  	7.4.2.3
	 Quarterly Average Delivery Time Failure
	  	7.4.2.3
	 Rebuttal
	  	8.3.5

  

					
		 	- 11 -	 	***Confidential Treatment Requested***

			
	 Definition
	  	Section
	 Receiving Party
	  	1.12
	 Regulated Claims
	  	7.7
	 Regulatory Partner
	  	6.1.2.4
	 Regulatory Partner Notice
	  	6.1.2.4
	 Related Agreements
	  	Whereas clause
	 Renewal Term
	  	1.4
	 Restatement Date
	  	Cover page
	 Roche
	  	Cover page
	 Roche Regulatory Support
	  	6.1.2.4
	 Roche Transfer Activities
	  	17.3.4.3
	 ROFN Negotiation Period
	  	3
	 Royalty Term
	  	8.3.1
	 Samples
	  	17.3.4.3
	 Selected Agreement
	  	8.3.5
	 Service Activities
	  	1.15
	 Supporting Memorandum
	  	8.3.5
	 Territory Revision Event 1
	  	6.1.2.3
	 Territory Revision Event 2
	  	6.1.2.4
	 Territory Revision Event 3
	  	7.3.1
	 Territory Revision Event 4
	  	7.3.1
	 Territory Revision Event 5
	  	7.3.2
	 Territory Revision Event 6
	  	7.4.1.4
	 Territory Revision Event 7
	  	7.4.1.6
	 Third Party F1CDx Regulatory Information
	  	6.1.2.3
	 Third Party Test Fee
	  	8.2.2
	 Transaction Agreement
	  	Whereas clause
	 Universal CDx Product
	  	2.2
	 US Cost
	  	8.2.1
	 US Education Collaboration Agreement
	  	Whereas clause
	 Virtual Gross Margin Calculation
	  	8.3.2.1

 2. Licenses and Exclusivity 

2.1 Licenses 
 2.1.1 Patents and Know-How 
 Subject to the terms and conditions of this Agreement, FMI hereby grants to Roche a right and license,
including the right to sublicense solely as permitted in Section 2.1.2, under FMI’s interest in the FMI Patent Rights and FMI Know-How to use, have used, import, have imported, export, have exported,
market, have marketed, distribute, have distributed, sell and have sold Products in the Territory. Subject to Section 2.2 and the other terms of this Agreement, the foregoing license shall be exclusive (even as to FMI). 

2.1.2 Sublicenses 
 The licenses granted by FMI to Roche in
Section 2.1.1 and 2.1.3 may be sublicensed by Roche to any Affiliate of Roche for so long as such Affiliate remains an Affiliate. Any such sublicense 

  

					
		 	- 12 -	 	***Confidential Treatment Requested***

 
automatically terminates if such Affiliate Sublicensee ceases to be an Affiliate of Roche. In addition, the licenses granted by FMI to Roche in Section 2.1.1 and 2.1.3 (and any sublicense by
Roche to an Affiliate of Roche) may be sublicensed (through one or more tiers) by Roche (and its Affiliates) to a Third Party (i) without the prior written consent of FMI in countries where Roche customarily utilizes such Third Party to conduct
commercialization activities on behalf of Roche or its Affiliates or (ii) otherwise with the prior written consent of FMI, not to be unreasonably withheld. Roche shall be liable for any act or omission of any such Sublicensee that is a breach
of any of Roche’s obligations under this Agreement as though the same were a breach by Roche, and FMI shall have the right to proceed directly against Roche without any obligation to first proceed against such Sublicensee. 

2.1.3 Trademarks 
 Subject to the terms and conditions of this
Agreement, FMI hereby grants to Roche a right and license, including the right to sublicense solely as permitted in Section 2.1.2, under FMI’s interest in the FMI Trademarks to use, have used, import, have imported, export, have exported,
market, have marketed, distribute, have distributed, sell and have sold Products in the Territory. Subject to Section 2.2 and the other terms of this Agreement, the foregoing license shall be exclusive (even as to FMI). Such trademark licenses
shall be non-transferable, except that FMI shall have the right to sublicense such rights to its licensees in the FMI Territory, and Roche shall have the right to sublicense such rights to its permitted
Sublicensees in the Territory. 
 2.2 Exclusive Right to Commercialize Products 

Subject to the terms of this Agreement, Roche and its Sublicensees shall have the exclusive right (even as to FMI) to market, distribute and sell Products in
the Territory, subject to activities designated for FMI to conduct under a Tactical Plan approved by the JOC. To the extent applicable, the foregoing right shall be subject to the rights granted under the Existing Third Party Rights. If FMI receives
any order from a prospective purchaser located in a country in the Territory, FMI shall promptly refer that order to Roche, and Roche shall process such order for such purchaser in the Territory in accordance with the terms of this Agreement. If
Roche receives any order from a prospective purchaser located in the FMI Territory, then Roche shall promptly refer that order to FMI. The Parties will discuss an appropriate transition plan for the Existing Third Party Rights. At Roche’s
request, and to the extent possible under the Existing Third Party Rights without incurring any termination fee, penalty or similar fee, FMI will terminate any or all of the Existing Third Party Rights. Notwithstanding the above, if there is any
termination fee, penalty or similar fee, Roche shall have the right to pay such termination fee, penalty or similar fee to terminate any or all of the Existing Third Party Rights. Moreover, Roche shall have the right, in coordination with FMI, to
engage in negotiations with the Third Parties to which the Existing Third Party Rights pertain, with the intent of allowing Roche to intervene to terminate such Existing Third Party Rights. 

Unless otherwise agreed expressly by the Parties, for any companion diagnostic assay Product, that is also for use in indicating a therapeutic or referencing
a clinical trial of a Third Party (“Universal CDx Product”), such Third Party shall have the right to recommend use of such Universal CDx Product in the Territory to the extent allowable under Applicable Law, including using or
referencing such Universal CDx Product name, logo and trade dress in such Third Party therapeutics label, package insert, or in its promotional and regulatory materials. Without limiting the foregoing, Third Parties with Regulated Claims on a
Universal CDx Product, including F1CDx, in any country shall be permitted, to the extent permitted by Applicable Law, to recommend the use of and promote a Universal CDx Product, including F1CDx, to their customers, including as a companion
diagnostic for such Third Party’s therapeutics. To the extent that FMI enters into any in vitro diagnostic development agreement with any Third Party that contemplates a Regulated 

  

					
		 	- 13 -	 	***Confidential Treatment Requested***

 
Claim on F1CDx in the Territory, and to the extent such Third Party desires to promote F1CDx in the Territory, FMI will include in its in vitro diagnostic development agreement with such
Third Party an obligation that any promotion of F1CDx by such Third Party will comply with Applicable Laws and be consistent with the F1CDx brand and product messaging guidelines provided by FMI and the terms and conditions set forth in this
Agreement. 
 2.3 Product Specifications; Modifications 

Product specifications for the Initial Products as of the Effective Date are attached hereto as Appendix 2.3 and Product specifications for FACT and F1CDx as
of the Restatement Date have been provided to Roche. FMI will develop product specifications for all other Products during development of each such Product. FMI will provide a copy of draft product specifications for such Products to Roche for such
Products as such specifications are substantially completed, except for any specifications that incorporate Third Party proprietary or confidential information. FMI will provide a copy of any material modifications to any Product specifications
(other than F1CDx) to Roche prior to such implementation. FMI shall consider in good faith any and all comments or concerns timely raised by Roche in connection with its review of such draft specifications or such modifications (in each case,
excluding Third Party confidential information relating to F1CDx). FMI shall only be authorized to adopt modifications to the First Year Product specifications that result in a diminution to the analytical performance as measured by the metrics set
forth in Appendix 2.3, either (i) with the prior written consent of Roche or (ii) without such consent if FMI has or is adopting the same modification to the specifications for the same Product as it has developed and commercialized in the
US. In the event that clause (ii) above is applicable for an Initial Product, the JOC may reset the Minimum Revenue Requirement in such year in accordance with Section 7.4.1.2. 

3. Right to Include Future Products 
 During the Agreement
Term, Roche shall have a first right to negotiate with FMI to include in the Territory future clinical diagnostic testing commercial products Controlled by FMI (excluding (i) in vitro diagnostics kit products, (ii) any companion
diagnostic assay products developed by FMI for a Third Party, and (iii) any standalone data or molecular information products (i.e. other than clinical diagnostic testing commercial products)), as a Product to market, distribute and sell in the
Territory, on terms to be mutually agreed upon by the Parties. If FMI plans to Commercially Launch a clinical diagnostic testing commercial product in the Territory or grant such product rights to a Third Party, then FMI shall provide Roche with
written notice of such plan and a copy of draft specifications for such Product. [...***...]. 
 4. Governance 

4.1 Joint Management Committee 
 The roles and
responsibilities of the JMC are set forth in the Collaboration Agreement. 
 4.2 Joint Operational Committee 

The JOC serves to oversee all activities under this Agreement. The JOC will strive to reach consensus on any matters within its authority with each Party
having one (1) vote. The JOC will reasonably consider all information, proposals and advice received from each Party in relation to the matters for which it has responsibility. Unresolved disputes at the JOC will be escalated to the JMC using
the procedures outlined in the Collaboration Agreement. 
 4.3 Members 

The JOC shall be composed of an equal number of persons from each Party (“Members”). Roche and FMI each shall be entitled to appoint three
(3) Members with appropriate seniority and functional expertise, unless otherwise agreed by the Parties. Each Party may replace any of its 

  

					
		 	- 14 -	 	***Confidential Treatment Requested***

 
Members and appoint a person to fill the vacancy arising from each such replacement. A Party that replaces a Member shall notify the other Party at least [...***...] prior to the next
scheduled meeting of the JOC. Both Parties shall use reasonable efforts to keep an appropriate level of continuity in representation. Both Parties may invite a reasonable number of additional experts and/or advisors to attend part of or the whole
JOC meeting with prior notification to the JOC. Members may be represented at any meeting by another person designated by the absent Member. The JOC shall be chaired [...***...], and then alternating between the Parties on a [...***...]
basis thereafter (“Chairperson”). 
 4.4 Responsibilities of the JOC 

The JOC shall have the responsibility and authority to: 
  

	(a)	create and approve a transition plan for Existing Third Party Rights; 

  

	(b)	review and recommend for approval by the JMC Tactical Plans and Post Approval Plans for Products that Roche intends to Commercially Launch or has Commercially Launched; 

 

	(c)	review and recommend for approval by the JMC any revisions to the Tactical Plans and Post Approval Plans; 

  

	(d)	review and oversee execution of the Tactical Plans and Post Approval Plans; 

  

	(e)	establish timelines for the Commercial Launch of any Products and the marketing, distribution and sale of such Products; 

  

	(f)	identify appropriate resources necessary to conduct the Tactical Plans and Post Approval Plans; 

  

	(g)	create, oversee or disband JOTs as deemed appropriate; 

  

	(h)	establish and set expectations and mandates for JOTs, if applicable; 

  

	(i)	resolve disputes of the ESWG (as such term is defined in the US Education Collaboration Agreement) in accordance with Section 2.2.3 of the US Education Collaboration Agreement; 

 

	(j)	monitor and implement plans to ensure adequate Product supply in the Territory; 

  

	(k)	review and approve product and corporate level branding for Products subject to Section 12.2 (Trademarks & Labeling); 

  

	(l)	[...***...]; 

  

	(m)	review and recommend for approval by the JMC promotional materials outside of FMI’s approved guidelines; 

  

	(n)	review and recommend for approval by the JMC any clinical research for Products in the Territory; provided that the Parties may conduct clinical research without approval of the JMC in accordance with Section 6.2
(Clinical Trials); 

  

	(o)	[...***...]; 

  

	(p)	recommend action items to its respective decision making bodies; 

  

	(q)	review Quality Standards and modifications thereto in accordance with Section 2.3 (Product Specifications and Modifications); 

  

	(r)	review customer service practices and performance in accordance with Section 7.4.1.6 (Customer Service); 

  

	(s)	review strategies for reimbursement approvals in accordance with Section 6.4 (Reimbursement); 

  

					
		 	- 15 -	 	***Confidential Treatment Requested***

	(t)	review Average Delivery Time Metric in accordance with Section 7.4.2.3 (NGS Sequencing and Supply of Products and Service Activities); 

 

	(u)	agree upon the timeline for the Initial Launch of F1CDx in each country in the Territory and the other provisions of each F1CDx Initial Launch Plan; 

 

	(v)	discuss any changes to the F1CDx bait set following the Restatement Date; 

  

	(w)	assign countries in the Territory that are not part of the [...***...], the [...***...], the [...***...], the [...***...], the [...***...], or the [...***...] to a specific Roche
Region; 

  

	(x)	add additional countries as Core Countries and/or Critical Core Countries; and 

  

	(y)	attempt in good faith to resolve any disputes between the Parties. 

 The JOC shall have no responsibility and
authority other than that expressly set forth in this Section, in the Related Agreements or as otherwise agreed to in writing by both Parties. 
 4.5
Meetings 
 The Chairperson or his/her delegate will be responsible for sending invitations and agendas for all JOC meetings to all Members at least
[...***...] before the next scheduled meeting of the JOC. The venue for the meetings shall be agreed by the JOC. The JOC shall hold meetings at least [...***...], either in person or by tele-/video-conference, and in any case as
frequently as the Members of the JOC may agree shall be necessary, but not less than [...***...]. The Alliance Director of each Party may attend the JOC meetings as a permanent participant. 

4.6 Minutes 
 The Chairperson will be responsible for
designating a Member to record in reasonable detail and circulate draft minutes of JOC meetings to all members of the JOC for comment and review within [...***...] after the relevant meeting. The Members of the JOC shall have [...***...]
to provide comments. The Party preparing the minutes shall incorporate timely received comments and distribute finalized minutes to all Members of the JOC within [...***...] of the relevant meeting. The Chairperson approves the final version
of the minutes before its distribution. 
 4.7 Decisions 

4.7.1 Decision Making Authority 
 The JOC shall decide matters
within its responsibilities set forth in Section 4.4. 
 4.7.2 Consensus; Good Faith 

The Members of the JOC shall act in good faith to cooperate with one another and seek agreement with respect to issues to be decided by the JOC. The Parties
shall endeavor to make decisions by consensus with each Party having one (1) vote. 
 4.7.3 Failure to Reach Consensus 

If the JOC is unable to decide a matter requiring JOC approval by consensus, then the matter shall be escalated to the [...***...]. However: 

 

	(1)	decisions related to the responsibilities in Sections 4.4(l) [...***...], (m) (promotional materials outside of the FMI guidelines), and (t) (Average Delivery Time Metric) shall require agreement by the Parties;

  

	(2)	decisions related to Section 4.4(o) [...***...] shall be referred to the CEO of the Roche Group; 

  

					
		 	- 16 -	 	***Confidential Treatment Requested***

	(3)	decisions related to Section 4.4(u) (Initial Launch and F1CDx Initial Launch Plan) shall be escalated to the JMC as set forth in the Collaboration Agreement, provided that if the JMC is unable to decide such
matter, FMI shall have final decision-making authority; and 

  

	(4)	decisions related to Section 4.4(v) (changes to F1CDx bait set) shall be subject to FMI’s final decision-making authority. 

4.8 Information Exchange 
 FMI and Roche shall exchange
the information in relation to its activities under this Agreement through the JOC. FMI and Roche may ask reasonable questions in relation to the above information and offer advice in relation thereto and each Party shall give due consideration to
the other Party’s input. The JOC may determine other routes of information exchange. Notwithstanding anything to the contrary in this Agreement, if FMI, FMI’s Affiliates or sublicensees have sales forces in a country/Region outside of the
FMI Territory for a product (excluding any sublicensees approved by Roche), then Roche shall have the right to redact competitively sensitive information, including within the Tactical Plans or Post Approval Plans provided to FMI for any Product in
such country/Region. The Tactical Plans and Post Approval Plans for F1CDx in a given country/Region in the Territory may be shared by FMI with any Third Party that is in active negotiations, or has entered into an agreement, with FMI to add a
Regulated Claim on F1CDx, provided that any such Third Party agrees to maintain the confidentiality of such Tactical Plans and Post Approval Plans. 

4.9 Joint Operational Teams 
 The JOC shall have the right
to establish joint operational teams (“JOT”), which shall have the authority granted to them by the JOC and shall be comprised of members from both Parties. 

4.10 Alliance Director 
 Each Party shall appoint one
person to be its point of contact with responsibility for facilitating communication and collaboration between the Parties (each, an “Alliance Director”). The Alliance Directors shall be permanent participants of the JOC meetings
(but not Members of the JOC). The Alliance Directors shall facilitate resolution of potential and pending issues and potential disputes to enable the JOC to reach consensus and avert escalation of such issues or potential disputes. 

4.11 Limitations of Authority 
 The JOC shall have no
authority to amend or waive any terms of this Agreement. 
 4.12 Expenses 

Each Party shall be responsible for its own expenses including travel and accommodation costs incurred in connection with the JOC. 

4.13 Lifetime 
 The JOC shall exist during the Agreement
Term. 
 5. Supply 
 Subject to Sections 7.3.3
(FMI’s Decision Not to Offer F1CDx in a Country in the Territory) and 7.4.2.3 (NGS Sequencing and Supply of Products and Service Activities), FMI shall be solely and exclusively responsible [...***...] for the commercial supply of
Products for sale in the Territory by or on behalf of Roche, and FMI shall use Commercially Reasonable Efforts to provide Products and Service Activities in the amounts requested by Roche meeting the Quality Standards and Average Delivery Time
Metric. 

  

					
		 	- 17 -	 	***Confidential Treatment Requested***

 For a given Product, if FMI fails to complete the Service Activities associated with such Product in a manner
that meets such Product’s Quality Standards for at least [...***...] of the Qualified Samples received from Roche in the Territory in a given Calendar Quarter (a “Quarterly Quality Standards Failure”) and such failure
exists for [...***...], then, prior to the end of such second Calendar Quarter, the JOC shall prepare a plan for improving such performance, which plan will be implemented in the [...***...]. The JOC will monitor the implementation and
effectiveness of such plan with a goal of achieving and maintaining compliance on a consistent basis for such Quality Standards. If, following the implementation of a plan by the JOC to improve such performance, FMI is unable to improve performance,
and there is a Quarterly Quality Standards Failure for [...***...] (a “Material Performance Standards Failure”), then this shall be considered a material breach of this Agreement by FMI. 

[...***...]. Roche shall have the right, during normal business hours and upon reasonable advanced notice, to audit any Third Party used by FMI or its
Affiliates in the supply of Products and services related to Products to the extent permitted in any existing agreements with such Third Party contractors and in accordance with the terms and conditions of such agreements. Any new agreements entered
into by FMI with respect to commercial supply of Products for sale in the Territory by or on behalf of Roche, shall provide Roche with the right to audit such Third Party contractor to review performance against the foregoing metrics, provided that
Roche shall not be permitted to access or review any Third Party confidential or proprietary information in connection with any audit pursuant to this Article 5. 

6. Regulatory 
 6.1 Responsibility 

6.1.1 Responsibility for Products Other than F1CDx 
 Subject to
Roche’s obligation under Section 7.4.1.4 to satisfy the Product Documentation Requirements, unless otherwise agreed to by the Parties, FMI, [...***...], shall be responsible for, in consultation with Roche, and shall use Commercially
Reasonable Efforts in the preparation of applications for Regulatory Approvals, as well as all governmental approvals required to market, import, have imported, sell and have sold Products (other than F1CDx, which is addressed in Section 6.1.2)
in the Territory. FMI shall be responsible for pursuing and compiling all regulatory filing documentation, and Roche shall reasonably assist FMI in preparing and submitting such regulatory filing documentation and interacting with Regulatory
Authorities, for Products (other than F1CDx) in the Territory. FMI or its Affiliates shall use Commercially Reasonable Efforts to prepare, or have prepared for it, all regulatory filings and Regulatory Approvals for all Products (other than F1CDx)
that are required to be submitted in each country of the Territory where Roche intends to Commercially Launch such Product or has Commercially Launched such Product. Roche shall reasonably assist FMI in submitting all such regulatory filings and
Regulatory Approvals in FMI’s name, unless prohibited by Applicable Law, in which case, to the extent required under Applicable Law, Roche shall file such regulatory filings and Regulatory Approvals in Roche’s name. Each Party shall
promptly supply the other Party with a copy of all material communications related to such Product to or from any Regulatory Authority in the Territory, including (i) communications with respect to any visits by any governmental authority or
Regulatory Authority to any facilities at which any Product is manufactured or sold in the Territory and (ii) any written or oral inquiries about, any procedures in connection with any Product in the Territory. 

  

					
		 	- 18 -	 	***Confidential Treatment Requested***

 6.1.2 Responsibility for F1CDx 

FMI shall control (a) all regulatory filings for F1CDx, including all submissions, applications and documents in connection with obtaining a Regulatory
Approval, and (b) all regulatory strategy, including (i) determination of the filings, data and documentation to submit to the applicable Regulatory Authorities, (ii) the timing of submitting regulatory filings, including any data and
documentation, to the applicable Regulatory Authorities, and (iii) any communications with the applicable Regulatory Authorities in connection with F1CDx. 

6.1.2.1 Initial Filing 
 For the Initial Filing in any Regulated
Market in the Territory, FMI shall be responsible for, [...***...] providing to Roche and/or its Affiliates (as directed by Roche) the regulatory file that resulted in the Regulatory Approval by the FDA in the US for F1CDx. 

Roche will pay [...***...]. FMI and Roche will share equally [...***...]. 

6.1.2.2 Subsequent Claim Filing 
 For any Subsequent Claim Filing
in any Regulated Market in the Territory, FMI shall be responsible for, at FMI’s sole cost, [...***...]. 
 Notwithstanding the foregoing, if the
Subsequent Claim Filing relates to [...***...], then Roche (or its Affiliate or Sublicensee, as applicable) will be responsible [...***...] as set forth herein based upon contracted terms agreed upon by Roche (or its Affiliate or
Sublicensee, as applicable) and FMI for such [...***...]. 
 6.1.2.3 Firewall 

In a Regulated Market, Roche agrees to establish, or cause to be established, a firewall to protect Third Party information not in the public domain (the
“Firewall”). At a minimum, such Firewall will ensure that: 
  

	 	(i)	individuals receiving Third Party confidential or proprietary information, including data, related to the F1CDx regulatory filing from FMI on either (a) an Initial Launch, including a F1CDx Initial Launch Plan or
the Initial Filing, or (b) a Subsequent Claim Filing, including any documentation submitted in connection with such Subsequent Claim Filing (such individuals, the “F1CDx Personnel”), will be the only persons at Roche (or its
Affiliate or Sublicensee, as applicable) to receive such Third Party confidential or proprietary information, including data, related to the F1CDx regulatory filing (“Third Party F1CDx Regulatory Information”); 

 

	 	(ii)	the names and titles of the F1CDx Personnel will be disclosed to FMI and other F1CDx Personnel prior to such persons’ working on any such regulatory filings; 

 

	 	(iii)	the F1CDx Personnel will be available for meetings, either in person or by tele-/video-conference, to discuss the Third Party F1CDx Regulatory Information and the regulatory strategy in connection with pursuing the
Regulatory Approval for F1CDx; 

  

	 	(iv)	the F1CDx Personnel will only use the Third Party F1CDx Regulatory Information for the F1CDx regulatory filing and will not use or rely upon the Third Party F1CDx Regulatory Information for any other purpose; and

  

	 	(v)	the F1CDx Personnel will not disclose any Third Party F1CDx Regulatory Information to persons other than other F1CDx Personnel and the applicable Regulatory Authority in connection with the regulatory filing.

  

					
		 	- 19 -	 	***Confidential Treatment Requested***

 FMI will identify any Third Party F1CDx Regulatory Information to the F1CDx Personnel (a) at the time such
information is provided to the F1CDx Personnel or (b) if FMI inadvertently fails to so identify such information at the time FMI provides such information to the F1CDx Personnel, provided that if FMI subsequently identifies such information as
Third Party F1CDx Regulatory Information, then Roche will not be liable under this Section 6.1.2.3 for any failure to comply with its obligations related to such information prior to such subsequent identification by FMI. For clarity, FMI shall
by solely liable for any damages caused by its failure to identify any Third Party F1CDx Regulatory Information to the F1CDx Personnel at the time such information is provided to the F1CDx Personnel. 

Roche agrees to execute, and shall cause any Affiliates or Sublicensees to execute, any additional documentation reasonably requested by FMI to confirm the
Firewall has been implemented and maintained in a Regulated Market in the Territory. 
 In the event that any portion of Third Party F1CDx Regulatory
Information becomes generally known to the public other than as a result of a breach by the Roche Group or any F1CDx Personnel of the Firewall obligations contained in this Section 6.1.2.3, such Firewall obligations will no longer apply to such
portion of the Third Party F1CDX Regulatory Information. For clarity, in such event, the Firewall obligations will continue to apply to the remainder of the Third Party F1CDx Regulatory Information. 

Roche shall make available (and shall require its Affiliates or Sublicensees to make available) policies, and procedures relating to the Firewall and the use
of Third Party F1CDx Regulatory Information (collectively, “Firewall Policies”) to FMI during regular business hours in such a manner as to not unnecessarily interfere with Roche’s (or its Affiliate’s or Sublicense’s,
as applicable) normal business activities. FMI or its agents shall have the right to audit such Firewall Policies and relevant records to confirm that the Firewall has been implemented and maintained in accordance with the terms of this Agreement in
a given Regulated Market in the Territory. FMI shall use the Firewall Policies only for the purpose of confirming compliance with the Firewall requirements herein, and such Firewall Policies and records shall be considered Roche’s Confidential
Information. 
 Without limiting any other rights or remedies available to FMI (including pursuant to Section 14.1), if Roche fails to fulfill its
obligations under Section 6.1.2.3(i), (iv) or (v), upon notice from FMI of such failure, Roche will have a [...***...] cure period. If, after such fifteen (15) Business Day cure period, Roche has not cured its failure to fulfill such
obligations, FMI may, in its sole discretion, elect to either (a) remove such country from the Territory upon written notice to Roche or (b) convert the licenses under Section 2.1 to
non-exclusive (either of clause (a) or (b), a “Territory Revision Event 1”). Upon a Territory Revision Event 1, Roche shall comply with its obligations under Section 17.3.1
(Termination by FMI for Breach by Roche or by Roche without a Cause, or Expiration of the Agreement Term). 
 6.1.2.4 Regulatory Partner 

FMI may elect to designate Roche as its local regulatory partner in a given country in the Territory (“Regulatory Partner”) to fulfill any
portion of the responsibilities of FMI pursuant to Section 6.1.2 (Responsibility for F1CDx) and, upon such election, Roche shall collaborate with FMI on any regulatory filing (including an Initial Filing, Subsequent Claim Filing, CE marking or
any other 

  

					
		 	- 20 -	 	***Confidential Treatment Requested***

 
activity in connection with obtaining Regulatory Approval or any other governmental approvals in a given country in the Territory) and will perform such requested regulatory activities in
accordance with an agreed upon timeline (“Roche Regulatory Support”). 
 If FMI does not designate Roche as its Regulatory Partner in a
given country in the Territory and instead seeks to use a Third Party for such regulatory support services for such country, before engaging such Third Party, FMI shall first offer Roche the right to become its Regulatory Partner for such country on
the same terms and conditions (including with respect to the scope of regulatory support services and any fees associated therewith) as were offered by the applicable Third Party. Roche shall have [...***...] during which to provide written
notice to FMI accepting such offer (“Regulatory Partner Notice”). If Roche does not accept such offer within such [...***...] period, FMI shall be permitted to engage any Third Party as its Regulatory Partner for such country
on terms and conditions substantially similar to the terms and conditions offered to Roche. If Roche provides the Regulatory Partner Notice in accordance with the terms of this Agreement, Roche shall be the Regulatory Partner for such country. 

If Roche is the Regulatory Partner in accordance with Section 6.1.2 (Responsibility for F1CDx) for a given market in the Territory, Roche shall perform
such Roche Regulatory Support in a diligent manner and shall use Commercially Reasonable Efforts to perform such Roche Regulatory Support in accordance with the regulatory strategy and instructions provided by FMI and within the time period
specified by FMI. 
 For any Non-Regulated Market, Roche will be responsible for the Roche internal FTE costs for
providing the Roche Regulatory Support pursuant to this Section 6.1.2.4, and FMI will be responsible for any FMI internal FTE costs. 
 Any Roche
Regulatory Support performed by Roche to file a Subsequent Claim Filing and obtain Regulatory Approval on such Subsequent Claim Filing on behalf of a Third Party pursuant to Section 6.1.2.2 (Subsequent Claim Filing) that is subject to payment
by FMI shall be reimbursed by [...***...], provided that Roche provides an estimate of the anticipated costs for the Roche Regulatory Support in a given country. The actual costs that FMI shall reimburse Roche shall not exceed such estimate by
more than [...***...] without FMI’s prior approval, such approval not to be unreasonably withheld. 
 Without limiting any other rights or
remedies available to FMI (including pursuant to Section 14.1), if Roche fails to fulfill the Roche Regulatory Support obligations as set forth in this Section 6.1.2.4, including by failing to make a timely filing (or response) in order to
obtain Regulatory Approval, and there is a delay in the process for obtaining Regulatory Approval or for the Commercial Launch of the therapeutic product and/or the companion diagnostic claim, upon notice from FMI of such failure, Roche will have a
[...***...] period to cure its failure and make the relevant filings or response, as applicable. In the event that Roche fails to make the relevant filing or response, as applicable, within such [...***...] period, Roche shall pay FMI
the following amounts: (x) in the case of a Critical Core Country, [...***...] for such failure or (y) in the case of a Core Country that is not a Critical Core Country, [...***...]. If, after an additional [...***...]
cure period, Roche has not provided the Roche Regulatory Support, FMI may, in its sole discretion, elect to either (a) remove such country from the Territory upon written notice to Roche or (b) convert the licenses under Section 2.1
to non-exclusive (either of clause (a) or (b), a “Territory Revision Event 2”). Upon a Territory Revision Event 2, Roche shall comply with its obligations under Section 17.3.1
(Termination by FMI for Breach by Roche or by Roche without a Cause, or Expiration of the Agreement Term). 

  

					
		 	- 21 -	 	***Confidential Treatment Requested***

 6.2 Clinical Trials 

The Parties shall discuss at the JOC and consider any clinical research (including, without limitation, any investigator sponsored studies and studies with key
opinion leaders) to be conducted for the Products during the Agreement Term that may be necessary or reasonably useful in furtherance of market development and access for Products in the Territory. Except as otherwise agreed to by the Parties or as
otherwise set forth in this Agreement, Roche shall have the right to conduct local clinical studies (including investigator sponsored studies and clinical studies with key opinion leaders) where such clinical research is for such local country or
Region, provided that Roche shall consult with FMI through the JOC and consider in good faith any comments provided by FMI with respect to such strategy and conduct of such local clinical studies, [...***...] in a given country in the
Territory during the Agreement Term. Except as otherwise agreed to by the Parties or as otherwise set forth in this Agreement, with respect to any global clinical studies, FMI shall have the right to conduct, [...***...] and shall be
responsible for the strategy and conduct of such global clinical studies, provided that FMI shall consult with Roche through the JOC and consider in good faith any comments provided by Roche with respect to such strategy and conduct of such global
clinical studies. If the Parties do not mutually agree to conduct additional global clinical research for the Territory, FMI shall have the right, but not the obligation, to pursue such global clinical research in its sole discretion and shall be
responsible for [...***...]. 
 6.3 Reporting Adverse Events 

If the development or commercialization or a given Product mandates the mutual reporting of Adverse Events, then the Parties will establish procedures for
tracking and informing each other concerning such Adverse Events as required by Applicable Law, and shall maintain such databases and execute such agreements as needed for this purpose. 

If in the course of the activity covered by this Agreement, FMI employees (i) in FMI’s medical affairs group or pathology group or (ii) who are
client services representatives or sales account executives, become aware of a suspected Adverse Events/special situation report (pregnancy, breastfeeding, lack of efficacy, overdose, misuse, abuse, off-label
use, medication errors (including intercepted and potential), occupational exposure, suspected transmission of an infectious agent via a medicinal product, death, quality defect or falsified medicinal product) associated the use of a Roche medicinal
product, this should be reported to the Roche Drug Safety department at welwyn.pds-pc@roche.com promptly. As used herein, “Adverse Event” means any untoward medical occurrence in a
patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An Adverse Event can therefore be any unfavorable or unintended sign (including an
abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. 

6.4 Reimbursement 
 Roche will be responsible,
[...***...] in cooperation with FMI, for all activities related to reimbursement approval for Products in the Territory. Prior to submission, Roche shall discuss its proposed filings for reimbursement approval of Products at the JOC and shall
consider in good faith any comments provided by FMI with respect to such filings. After those materials have been submitted to the appropriate pricing authority, Roche shall permit FMI to obtain copies of such materials, including in electronic
format, at reasonable times. However, if FMI or its Affiliates or sublicensees (other than any sublicensees that have been approved by Roche) have sales forces 

  

					
		 	- 22 -	 	***Confidential Treatment Requested***

 
in a country/Region outside of the FMI Territory for a FMI clinical diagnostic product, then Roche shall have the right to redact from such filings competitively sensitive information on
reimbursement approvals to FMI for any Product in such country/Region. Roche shall use Commercially Reasonable Efforts to file submissions for reimbursement approval in each country where it intends to, or has, Commercially Launched a Product. For
clarity, submissions for reimbursement approval in the Territory shall be consistent with the [...***...] agreed upon by the Parties. 
 7.
Commercialization 
 7.1 Strategies 
 The Parties
will implement on the strategies agreed to at the JOC and JMC, in a staged approach and according to detailed Tactical Plans and Post-Approval Plans for each country/Region. Subject to the terms of this Agreement, unless otherwise agreed by the
Parties, Roche shall have the exclusive right (even as to FMI) to market, distribute and sell Products in the Territory in accordance with the terms of this Agreement. Notwithstanding this exclusive right, the JOC shall consider utilizing FMI to
conduct certain medical educational and/or medical affairs activities in connection with a Tactical Plan. 
 7.2 Sales 

Except as otherwise expressly agreed between the Parties: 
  

	 	(a)	Subject to the Existing Third Party Rights and the Transitional Services Agreement, Roche will book all sales of Products in the Territory. 

 

	 	(b)	Subject to the Existing Third Party Rights and the Transitional Services Agreement, Roche will be responsible for billing and collections of Products in the Territory. 

7.3 F1CDx Initial Launch Plan, Subsequent Claim Filings, and Non-Regulated Updates 

7.3.1 F1CDx Initial Launch Plan 
 During the Agreement Term,
FoundationOne will be replaced with F1CDx, in each market in the Territory, following notice from FMI that FMI desires to Commercially Launch F1CDx in a given market (“F1CDx Launch Notice”). The timeline of implementing the updated
F1CDx bait set will be determined by FMI. FMI will be responsible for the preparation of a plan with respect to the timing of the Initial Launch for F1CDx in a given country or region in the Territory (each, an “F1CDx Initial Launch
Plan”), which will be agreed upon by the JOC pursuant to Section 4.4. 
 Each F1CDx Initial Launch Plan shall include, at a minimum,
the following, in each case, as related to the specific country or region in the Territory: (i) the projected timeline of the Initial Launch of F1CDx (either a target date or by reference to the date on which the required approvals have been
received), (ii) the date by which the Parties anticipate that the FoundationOne Product will no longer be commercially available in such country and will instead be fully replaced by F1CDx, and (iii) the appropriate size for the Dedicated Sales
Force. The Parties acknowledge and agree that FMI will use the same F1CDx bait set in the Territory that it uses in the US (based on the F1CDx Product approved by the FDA), as the same may be modified over time, with any modifications to the bait
set to be reviewed by the JOC pursuant to Section 4.4. The F1CDx Initial Launch Plan will be in addition to the Tactical Plan and Post Approval Plan for F1CDx in a given country in the Territory. 

As of the date FMI provides the F1CDx Launch Notice for a given country or region in the Territory: (a) if Roche has not Commercially Launched the
FoundationOne Product in such 

  

					
		 	- 23 -	 	***Confidential Treatment Requested***

 
country or region, Roche shall not Commercially Launch the FoundationOne Product and shall instead Commercially Launch F1CDx in such country or region in accordance with the applicable F1CDx
Initial Launch Plan, (b) if Roche has Commercially Launched the FoundationOne Product in such country or region, and such country or region is a Regulated Market, Roche shall continue to make the FoundationOne Product commercially available
until the necessary Regulatory Approvals have been received to commercialize F1CDx in such country, after which time Roche shall Commercially Launch F1CDx in accordance with the terms of this Agreement and the applicable F1CDx Initial Launch Plan
(and following Commercial Launch of F1CDx in such country, Roche will stop commercializing FoundationOne in such country), and (c) if Roche has Commercially Launched the FoundationOne Product in such country or region, and such country or
region is a Non-Regulated Market, FMI shall incorporate the F1CDx bait set on the timeline outlined by FMI in the F1CDx Initial Launch Plan for such country or region (which shall be subject to FMI’s sole
discretion), after which incorporation, Roche shall Commercially Launch F1CDx and stop commercializing FoundationOne in such country. Appendix 7.3.1 lists all of the countries in which Roche has launched FoundationOne as of the Restatement Date.

 During the Agreement Term, Roche will use Commercially Reasonable Efforts to Commercially Launch F1CDx (1) in each country in the Territory for
which FMI has delivered an F1CDx Launch Notice and (2) in accordance with the timelines set forth in the applicable F1CDx Initial Launch Plan for each Core Country. Roche shall ensure that F1CDx is Commercially Launched in each country or
region in the Territory: (a) by the target date set forth in the F1CDx Initial Launch Plan or (b) in the absence of a launch target date as set forth in the F1CDx Initial Launch Plan, within [...***...] following the Parties’
agreement that all required Regulatory Approvals have been received in such market (either of clause (a) or (b), the “Initial Launch Requirement”). 

In a given country in the Territory, (a) if Roche determines not to commercialize F1CDx in such country, or (b) subject to Section 7.3.2
(Subsequent Claim Filings and Non-Regulated Updates) and 7.4.1.4 (Commercial Launch Obligations), if Roche fails to use Commercially Reasonable Efforts to satisfy its commercialization obligations with respect
to F1CDx (including a Subsequent Claim Filing or Non-Regulated Update, as applicable) in such country, FMI may, in its sole discretion, elect to either (i) remove such country from the Territory upon
written notice to Roche or (ii) convert the licenses under Section 2.1 to non-exclusive (either of clause (i) or (ii), a “Territory Revision Event 3”). Upon a Territory Revision
Event 3, Roche shall comply with its obligations under Section 17.3.1 (Termination by FMI for Breach by Roche or by Roche without a Cause, or Expiration of the Agreement Term). 

Without limiting any other rights or remedies available to FMI (including pursuant to Section 14.1), if Roche does not satisfy the Initial Launch
Requirement with respect to a given country, FMI shall provide written notice to Roche identifying such non-compliance in the given country, and Roche shall have a period of [...***...] after such notice
is provided to cure such non-compliance. If Roche has not cured such non-compliance within such [...***...] period, Roche shall pay FMI [...***...] for any
country that is a Critical Core Country and (ii) [...***...] for any Core Country that is not a Critical Core Country. Following such [...***...] cure period, Roche will have an additional [...***...] period to ensure compliance
with the foregoing requirements in this Section 7.5.1. If Roche has not cured such non-compliance within such additional [...***...] period, FMI may, in its sole discretion, elect to either
(x) remove such country from the Territory upon written notice to Roche or (y) convert the licenses under Section 2.1 to non-exclusive (either of clause (x) or (y), a “Territory
Revision Event 4”). Upon a Territory Revision Event 4, Roche shall comply with its obligations under Section 17.3.1 (Termination by FMI for Breach by Roche or by Roche without a Cause, or Expiration of the Agreement Term). 

  

					
		 	- 24 -	 	***Confidential Treatment Requested***

 7.3.2 Subsequent Claim Filings and Non-Regulated Updates

 Following the Initial Launch in a Regulated Market, FMI will provide reasonable notice to Roche regarding the anticipated timeline for any Subsequent
Claim Filing. Roche will ensure that any Subsequent Claim Filings, and any updates to F1CDx in a Non-Regulated Market (“Non-Regulated Updates”), are
Commercially Launched in such market in the time period mutually agreed to by the Parties. In the absence of a mutually agreed date, Roche will ensure that (a) any updates to F1CDx that include Subsequent Claim Filings are Commercially Launched
in the applicable market following the Parties’ agreement that all required Regulatory Approvals have been received for such Subsequent Claim Filing within a time period that is consistent with the time period that Roche would apply if the
companion diagnostic claim in such Subsequent Claim Filing were for a Roche Group therapeutic (but no longer than [...***...] following the issuance of all required Regulatory Approvals for such Subsequent Claim Filing), and (b) any Non-Regulated Updates are Commercially Launched within a time period that is consistent with the time period that Roche would apply if the companion diagnostic claim in such
Non-Regulated Update were for a Roche Group therapeutic (but no longer than [...***...] following the proposed addition by FMI of the Non-Regulated Update). 

Without limiting any other rights or remedies available to FMI (including pursuant to Section 14.1), if Roche does not satisfy the timing of the
Subsequent Claim Filing or the Non-Regulated Update set forth in this Section 7.3.2 with respect to a given country in the Territory, FMI shall provide written notice to Roche identifying such non-compliance in the given country, and Roche shall have a period of [...***...] after such notice is provided to cure such non-compliance. If Roche has not cured such non-compliance within such [...***...] period, Roche shall pay FMI (i) [...***...] for any country that is a Critical Core Country and (ii) [...***...] for any Core Country that is not a Critical
Core Country. Following such [...***...] cure period, Roche will have an additional [...***...] period to ensure compliance with the foregoing requirements in this Section 7.3.2 for any country in the Territory. If Roche has not
cured such non-compliance within such additional [...***...] period, FMI may, in its sole discretion, elect to either (x) remove such country from the Territory upon written notice to Roche or
(y) convert the licenses under Section 2.1 to non-exclusive (either of clause (x) or (y), a “Territory Revision Event 5”). Upon a Territory Revision Event 5, Roche shall comply
with its obligations under Section 17.3.1 (Termination by FMI for Breach by Roche or by Roche without a Cause, or Expiration of the Agreement Term). 

7.3.3 FMI’s Decision Not to Offer F1CDx in a Country in the Territory 

Notwithstanding anything to the contrary in Section 7.3.1, if the Commercial Launch of F1CDx in any country in the Territory requires the conduct of any
Service Activities for F1CDx in such country (for example, establishing new infrastructure such as a wet and/or dry laboratory) or establishes or maintains requirements that could reasonably be expected to have a material adverse effect on
FMI’s business or operations, FMI may, in its sole discretion, decide: (i) not to offer F1CDx in such country in the Territory, or (ii) to otherwise work with Roche on mutually agreeable terms to make F1CDx available in such country.

 7.4 Additional Responsibilities 
 7.4.1 Roche
Responsibilities 
 7.4.1.1 Funding Commitment 
 Subject to FMI
meeting its obligations under this Agreement, during the first [...***...] of the Initial Term, Roche will commit at least [...***...] in Roche FTE resources (based on Roche’s standard FTE rates as consistently applied) and out-of-pocket expenditures for the activities under this 

  

					
		 	- 25 -	 	***Confidential Treatment Requested***

 
Agreement. FMI may audit Roche in accordance with Article 11 to ensure compliance with this Section. Notwithstanding the above, if there is a reduction in the scope of the Territory pursuant to
Section 7.2, then FMI and Roche shall negotiate in good faith an adjustment to the [...***...] commitment to equitably reflect the reduction in the market value of the Territory. 

7.4.1.2 Minimum Revenue Requirement 
 Commencing in
[...***...], in connection with the review of the Tactical Plan, [...***...] (the “Minimum Revenue Requirements”). If the specifications for a Product are modified pursuant to Section 2.3, the JOC may establish new
Minimum Revenue Requirements for such Product for the year in which such modification occurs. Roche will [...***...]. If Roche fails to meet the Minimum Revenue Requirements for a Product in any country in the Territory for [...***...],
then FMI will have the right, in its sole discretion, to either (i) remove such country from the Territory (and upon such election such country shall be deemed to be included in the FMI Territory) or (ii) convert the license for such
country to non-exclusive. 
 7.4.1.3 Commercial Activities 

Throughout the Agreement Term, subject to Sections 4.4(u) (JOC responsibility relating to Initial Launch of F1CDx and F1CDx Initial Launch Plan), 4.4(v) (JOC
responsibility regarding changes to F1CDx bait set), 6.1.2 (Responsibility for F1CDx), 7.3.1 (F1CDx Initial Launch Plan), and 7.3.3 (FMI’s Decision Not to Offer F1CDx in a Country in the Territory), Roche will be responsible for the preparation
of country-or Region-specific Tactical Plans and Post-Approval Plans for Products in the Territory, which shall be updated [...***...] and submitted to the JOC for review and comment. All activities
under this Agreement will be conducted in accordance with country- or Region-specific Tactical Plans and Post-Approval Plans to be developed by Roche, working in cooperation with FMI, subject to review and approval by the JMC. 

Roche will use Commercially Reasonable Efforts to initiate and pursue market development and Commercially Launch (i) Products (other than F1CDx) in the
Territory in accordance with the Tactical Plans, Post Approval Plans and the terms of this Agreement and (ii) F1CDx in each country in the Territory in accordance with the F1CDx Initial Launch Plan, Tactical Plan and Post Approval Plan, in each
case specific to such country and in accordance with the terms of this Agreement. 
 7.4.1.4 Commercial Launch Obligations 

Roche will be responsible for Commercially Launching each Product in a given country in the Territory for which FMI has delivered a launch notice, and will
ensure such Product remains Commercially Launched in such country in the Territory. To satisfy such obligations, Roche will be responsible for: 
  

	 	(a)	maintaining (i) a dedicated MSL to support, and (ii) a Dedicated Sales Force to promote, such Product in such country or region, as applicable (for clarity, an MSL or Dedicated Sales Force may serve a country
or group of countries, i.e. a region, in the case of countries with smaller markets; provided, however, that each Critical Core Country shall have its own Dedicated Sales Force dedicated solely to promoting the Products); 

 

	 	(b)	in each country or region, as applicable, that has launched a Product, including any country listed on Appendix 7.3.1 (with respect to FoundationOne) and any country or region, as applicable, that Commercially Launches
a Product after the Restatement Date, maintaining (i) an MSL to support, and (ii) a Dedicated Sales Force to promote, such Product in such country or region, as applicable; provided, however, that each Critical Core Country shall have its
own Dedicated Sales Force dedicated solely to promoting the Products; 

  

					
		 	- 26 -	 	***Confidential Treatment Requested***

	 	(c)	providing marketing messaging (including Product marketing materials, collateral and Product communications by any MSL or Dedicated Sales Force) with respect to each Product in such country or region, as applicable, in
a manner that is consistent with FMI’s messaging relating to such Product in the US (e.g., for F1CDx, mentioning that F1CDx may be used as a companion diagnostic for multiple therapies); 

 

	 	(d)	specific to F1CDx, ensuring that, in such country or region (subject to clauses (a) and (b) above in this Section 7.4.1.4), as applicable: (i) the Dedicated Sales Force is fairly presenting all
companies’ (including Third Parties’ and Roche’s and its Affiliates’) therapies and claims on F1CDx in the process of promoting F1CDx, without any bias and without favoring any of Roche’s or its Affiliates’ therapies or
claims and (ii) any MSL is fairly presenting all companies’ (including Third Parties’ and Roche’s and its Affiliates’) therapies and claims on F1CDx in its communications related to the Products, without any bias and without
favoring any of Roche’s or its Affiliates’ therapies or claims; 

  

	 	(e)	ensuring that all Product documentation, including documents necessary to order a Product in such country (e.g., patient consents, order forms, and patient information), is obtained and maintained in compliance
with Applicable Laws (“Product Documentation Requirements”); and 

  

	 	(f)	providing sufficient customer service support for such Product to support such Product’s customers in such country or region, as applicable. 

Roche shall satisfy the ongoing obligations required for the Commercial Launch of each Product (as set forth in this Section 7.4.1.4). Without limiting
any other rights or remedies available to FMI (including pursuant to Section 14.1), if, during the Agreement Term, following the Commercial Launch of a Product, Roche no longer satisfies any of its ongoing obligations for the Commercial Launch
of such Product (as set forth in this Section 7.4.1.4) with respect to a given Product in a given country, FMI shall provide written notice to Roche identifying such non-compliance in the given country,
and Roche shall have a period of [...***...] after such notice is provided to cure such non-compliance. If Roche has not been cured such non-compliance within such
[...***...] period, FMI may, in its sole discretion, elect to either (x) remove such country from the Territory upon written notice to Roche or (y) convert the licenses under Section 2.1 to
non-exclusive (either of clause (x) or (y), a “Territory Revision Event 6”). Upon a Territory Revision Event 6, Roche shall comply with its obligations under Section 17.3.1
(Termination by FMI for Breach by Roche or by Roche without a Cause, or Expiration of the Agreement Term). 
 7.4.1.5 Equitable Adjustments 

Where either Roche or FMI has an obligation under this Agreement (each such a “Dependent Obligation”) that can only reasonably be fulfilled if
the other Party first performs one or more of its specific contractual obligations hereunder (each, a “Precedent Obligation”), then, any deadline for the performance by Roche or FMI, as applicable, of such Dependent Obligation shall
be tolled (i.e., the deadline shall be extended) for a period of time equal to the delay in the performance by such other Party of the relevant Precedent Obligation. For avoidance of doubt, each such deadline shall be similarly tolled to the extent
achievement of an obligation under this Agreement is prevented by an event of force majeure as and to the extent provided in Section 19.16. 

  

					
		 	- 27 -	 	***Confidential Treatment Requested***

 7.4.1.6 Customer Service 

During the Agreement Term, Roche shall implement, in each country in the Territory and consistent with the Tactical Plans (including in which local country
languages and in which manner such customer service shall be provided) and the F1CDx Initial Launch Plan, if applicable, reasonable levels of customer service assistance to support Product customers in such country regarding sales and technical
support issues, customer inquiries, defective product and service replacements. Roche shall be responsible for all costs and expenses associated with the provision of such customer service. Upon FMI’s request, but no more than once per Calendar
Year, Roche shall provide FMI with a report summarizing customer service assistance requests and inquiries received by Roche. Upon Roche’s request, but no more than once per Calendar Year, FMI shall provide Roche with a report summarizing
customer service assistance requests and inquiries received by FMI in the Territory. 
 Without limiting any other rights or remedies available to FMI
(including pursuant to Section 14.1), if Roche does not comply with any of its obligations set forth in this Section 7.4.1.6 with respect to a given country, FMI shall provide written notice to Roche identifying such non-compliance in the given country, and Roche shall have a period of [...***...] after such notice is provided to cure such non-compliance. If Roche has not cured such non-compliance within such [...***...] period, FMI may, in its sole discretion, elect either to (i) remove such country from the Territory upon written notice to Roche or (ii) convert the licenses
under Section 2.1 to non-exclusive (either of clause (i) or (ii), a “Territory Revision Event 7”). Upon a Territory Revision Event 7, Roche shall comply with its obligations under
Section 17.3.1 (Termination by FMI for Breach by Roche or by Roche without a Cause, or Expiration of the Agreement Term). 
 7.4.2 FMI Responsibilities

 7.4.2.1 Product Training 
 FMI will provide Roche with NGS
and Product training using Commercially Reasonable Efforts, including samples of each related training material used by FMI in the FMI Territory throughout the Agreement Term. Such training will be provided in the locations and on the schedule
agreed to in the Tactical Plans. Each Party shall be responsible for their respective costs in relation thereto. For clarity, FMI trainers will provide this training at no charge to Roche. 

7.4.2.2 Materials 
 [...***...], or more frequently when
available throughout the Agreement Term, FMI will provide Roche with copies of its then current Product marketing material, and will share with Roche any Product brand, promotional, or similar plans, any market research plans and results, any
educational materials or other information or analysis prepared by or for FMI related to the Products in the FMI Territory or in the Territory. 
 7.4.2.3
NGS Sequencing and Supply of Products and Service Activities 
 Subject to Section 7.3.3 (FMI’s Decision Not to Offer F1CDx in a Country in the
Territory), FMI shall use Commercially Reasonable Efforts to provide Roche with the Service Activities (including next generation sequencing (“NGS”)) necessary for Roche to implement the Tactical Plan and to meet the commercial need
for Products sold by Roche in the Territory. Such Service Activities will meet the Quality Standards and the Average Delivery Time Metric. In the event of a shortfall/limited capacity of Products or Service Activities needed by both FMI and Roche,
such available capacity shall be distributed [...***...] with respect to the then-current volume used by each Party. 

  

					
		 	- 28 -	 	***Confidential Treatment Requested***

 For each Product, FMI will provide the JOC with the average time between receipt by FMI of a processable sample
meeting minimum tissue or other specimen requirements as set forth in FMI’s standard operating procedures (such sample, a “Qualified Sample”) and delivery by FMI of the results of testing for such Product (the “Average
Delivery Time Metric”). Such Average Delivery Time Metric will initially be [...***...] for FoundationOne® and F1CDx, and [...***...] days for FoundationOne® Heme and FoundationACT®, in each case, solely to the extent Service Activities for such Product are conducted by FMI at FMI’s
laboratory and facilities in the US. Periodically, the Average Delivery Time Metric may be revised by mutual written agreement of the Parties for differences in logistical, regulatory and other relevant factors. For a given Product, if FMI fails to
achieve the Average Delivery Time Metric for at least [...***...] of the Qualified Samples received from Roche in the Territory in [...***...] Calendar Quarter (a “Quarterly Average Delivery Time Failure”) and such
failure exists [...***...], then prior to the end of such [...***...], the JOC shall prepare a plan for improving such performance, which plan will be implemented in the [...***...]. The JOC will monitor the implementation and
effectiveness of such plan with a goal of achieving and maintaining compliance on a consistent basis for such Average Delivery Time Metric. If, following the implementation of a plan by the JOC to improve such performance, FMI is unable to improve
performance, and there is a Quarterly Average Delivery Time Failure for an additional [...***...] (a “Material Average Delivery Time Failure”), then this shall be considered a material breach of this Agreement by FMI. 

To the extent feasible and permitted by Applicable Law and regulatory guidelines of applicable Regulatory Authorities, the initial sequencing will be
conducted by FMI at FMI’s laboratory and facilities in the US. 
 FMI shall use Commercially Reasonable Efforts to conduct or have conducted genomic
sequencing locally (i) for its FoundationOne Product [...***...] and (ii) for its other First Year Products [...***...]. FMI shall provide Roche with a written plan for the set-up of such
[...***...] laboratories, and shall consider Roche’s reasonable comments thereto. FMI shall update Roche on the progress of the establishment of local testing. Such [...***...] activities shall be provided in at least the same
quality and standards as the [...***...] testing in effect as of the Effective Date. To the extent that local Third Party costs are passed through to Roche, such costs shall be negotiated in good faith and at arms’ length with no benefits
being given to FMI to the advantage or FMI, its Affiliates, sublicensees or customers that cause a disadvantage or do not similarly benefit the Roche Group and its customers. 

FMI will be solely responsible, [...***...], for the establishment of such laboratories and all Regulatory Approvals necessary for the establishment and
operation of such laboratory(ies). Without limiting the foregoing, the Parties expressly acknowledge that FMI may choose to work with [...***...]. 

Unless otherwise expressly agreed by the Parties, data and final analysis, including medical curation and report generation will be conducted by FMI. Final
reports for the First Year Products will be provided from FMI in English or in the local language, to the extent requested by Roche and agreed to by FMI. If FMI is unable to provide local sequencing on the timeline set forth in this
Section 7.4.2.3, or if FMI is unable to provide the NGS sequencing necessary to meet Roche’s commercial requirements for a period of [...***...], then the JOC shall meet to determine a plan for improving such performance and the JOC
will monitor the implementation and effectiveness of such plan, and FMI will provide reasonable support, with a goal of ensuring ongoing access to sufficient local sequencing, which may include Roche (itself or with or through a Third Party
acceptable to FMI) performing such local sequencing in a manner approved by FMI that meets FMI’s requirements for performing subsequent Service Activities. 

  

					
		 	- 29 -	 	***Confidential Treatment Requested***

 7.5 Branding and Pricing 

Product branding and corporate-level branding will be discussed and agreed to at the JOC. The Parties will discuss at the JOC a [...***...] in the
Territory (the “[...***...]”). Unless otherwise expressly agreed by the Parties, the list price for each Product in the Territory will be equal to or greater than the [...***...] for such Product. 

7.6 Product Promotional Materials and Promotional Obligations 

The Parties will collaborate and coordinate around development of any promotional or educational materials to be utilized for Products in the Territory
leveraging FMI’s existing materials. 
 Roche shall be responsible for the preparation of all product promotional material for use with the Products by
Roche in the Territory. All such Product promotional material shall be consistent with reasonable brand and Product guidelines provided to Roche by FMI. Any Product promotional materials not consistent with such approved guidelines shall be subject
to review and approval by FMI. Notwithstanding the foregoing, any Product promotional guidelines and materials approved by FMI to be used by Roche will be subject to final review and approval by Roche. 

To the extent permitted by Applicable Law, Roche’s sales and commercial representatives who promote Roche therapeutics shall be permitted to promote
F1CDx, provided, for the avoidance of doubt, that this shall not relieve Roche of its obligation to maintain a Dedicated Sales Force as provided herein. 

7.7 F1CDx Report 
 The content of the F1CDx report
generated for any customers, whether in paper or electronic format (the “F1CDx Report”), shall contain the following: 
  

	 	(a)	in a Regulated Market: (i) a section reviewed and approved by the applicable Regulatory Authority, including any companion diagnostic claims and associated approved therapies (the “Regulated
Claims”); and (ii) a section describing professional services, including variants, associated therapies, and clinical trials, based on the professional services section used in the United States (the “Professional
Services”). For clarity, the F1CDx Report in a Regulated Market will be developed based on the requirements of the applicable Regulatory Authority. 

  

	 	(b)	in a Non-Regulated Market: the Professional Services section only. For clarity, the F1CDx Report in a Non-Regulated Market shall not
include a Regulated Claims section. 

 If (i) required by the applicable Regulatory Authority for a country in which Roche Commercially
Launches F1CDx or (ii) FMI otherwise elects to, FMI will generate an F1CDx Report that only includes Regulated Claims as approved in such country, subject to Roche providing localized content on approved companion diagnostics and approved
therapies in the English language as set forth below. All of FMI’s expenses and internal FTE costs (based on the then-current FTE Rate pursuant to the Collaboration Agreement) to develop, implement and maintain the Regulated Claims section of
the F1CDx Report with localized reporting in a given country in the Territory will be borne [...***...] by Roche and [...***...] by FMI, as such country is a Regulated Market. 

If (a) requested by Roche and approved by FMI or (b) FMI otherwise elects to, FMI will localize, in accordance with the “in scope”
localization provisions set forth on Appendix 7.7, the Professional Services section, and if applicable (according to the preceding paragraph in this Section 7.7), the 

  

					
		 	- 30 -	 	***Confidential Treatment Requested***

 
Regulated Claims section, of the F1CDx Report to generate a report with localized content including approved therapies. In such event, Roche will, at its cost, provide localized content in the
English language, and FMI will implement the localized reporting of the Professional Services section, and if applicable (according to the preceding paragraph in this Section 7.7), the Regulated Claims section. All of FMI’s expenses and
internal FTE costs (based on the then-current FTE Rate pursuant to the Collaboration Agreement) to develop, implement and maintain such localized reporting in a given country in the Territory (i) will be shared equally be FMI and Roche if such
country is a Non-Regulated Market and (ii) will be borne [...***...] by Roche and [...***...] by FMI if such country is a Regulated Market. If the applicable Regulatory Authority in a
Regulated Market requires a localized Professional Services section, and such requirement will have a material adverse impact on Roche (other than on account of competitive products being developed or becoming available in a given market), then FMI
and Roche shall discuss in good faith an alternative plan. 
 If neither Roche nor FMI elects to localize the F1CDx Report content on approved therapies in
a given country, FMI will provide to Roche a copy of the then-current US version of the F1CDx Report template. 
 Roche shall be solely responsible for
providing FMI with any F1CDx Report localized content on approved companion diagnostics and approved therapies in the English language. Subject to Applicable Law, Roche, in its sole discretion, may perform translation of parts of, or the whole,
F1CDx Report into local languages, and Roche will be required to perform such translation into local languages to the extent required by Applicable Law or a Regulatory Authority. Roche will be responsible and liable for (i) ensuring the
accuracy and completeness of any localized content provided in English to FMI and any translation of the F1CDx Report into the local language, and (ii) all cost associated with providing such content and translation. If Roche, in its sole
discretion, elects to, or is required to, provide a translation (into the local language) of the F1CDx Report to customers, Roche must also provide a copy of the version in the English language to the customers, unless the same would be prohibited
by Applicable Law. 
 8. Payment 
 8.1 General

 Except as otherwise expressly provided for in this Agreement, each Party shall bear its own costs, expenses, and fees for its activities under this
Agreement, including without limitation, costs incurred in connection with the Tactical Plans. For clarity, all costs, expenses, and fees (including any costs incurred with Third Parties and any internal FTE costs), relating to F1CDx incurred prior
to the Restatement Date shall be borne by the Party that incurred such costs, expenses, and fees. 
 8.2 Costs of Services 

8.2.1 FMI Service Costs 
 For each Product sold in the Territory,
if FMI provides Service Activities for such Product at FMI’s laboratories and facilities in the United States, Roche will pay FMI [...***...] (collectively the “Global Cost”) [...***...] (collectively, the
“Global Test Fixed Fee”). The Global Test Fixed Fee for a Product will be calculated on a trailing [...***...] basis, and the Global Test Fixed Fee and calculation shall be provided to Roche within [...***...] after each
[...***...] in the Agreement Term, based on the Global Test Fixed Fee as determined from the preceding [...***...] and [...***...] during the Agreement Term, subject to audit by Roche in accordance with Article 11. 

For each Product sold in the Territory, if FMI provides initial sequencing in laboratories and facilities outside of the US, Roche will pay FMI
[...***...] (collectively, the “Local Cost”), [...***...], 

  

					
		 	- 31 -	 	***Confidential Treatment Requested***

 
and (ii) [...***...] (collectively, the “US Cost”), [...***...] (clause (i) and clause (ii), collectively, the “Local Test Fixed Fee”). The
Local Test Fixed Fee for a Product will be calculated on a trailing [...***...] basis, and the Local Test Fixed Fee and calculation shall be provided to Roche within fifteen (15) days after each [...***...] in the Agreement Term,
based on the Local Test Fixed Fee as determined from the preceding [...***...] and [...***...] during the Agreement Term, subject to audit by Roche in accordance with Article 11. 

FMI will submit invoices on a [...***...] basis, and Roche shall pay all Global Test Fixed Fees and Local Test Fixed Fees within [...***...]
following Roche’s receipt of an invoice for such fees. 
 8.2.2 Third Party Service Costs 

FMI may have all or part of the Service Activities for Products in the Territory performed by a Third Party, subject to the terms and conditions for Third
Parties set forth in Section 7.4.2.3(NGS Sequencing and Supply of Products and Service Activities) or as otherwise agreed to in writing by Roche. In the event that all or part of the Service Activities are performed by a Third Party, Roche
shall reimburse FMI for the amount paid by FMI to such Third Party for such Service Activities (the “Third Party Test Fee”), provided that (i) such Third Party Test Fees are negotiated in good faith and at arms’ length
with no benefits being given to FMI to the advantage or FMI, its Affiliates, sublicensees or customers that cause a disadvantage or do not similarly benefit the Roche Group and its customers and (ii) [...***...]. 

Roche shall pay all Third Party Test Fees within [...***...] following Roche’s receipt of an invoice for such fees. 

8.3 Royalty Payments and Sales Milestones 
 8.3.1 Royalty
Term 
 Royalties shall be payable by Roche on [...***...] of Products on an aggregated basis for all Products commencing on the first commercial sale
of a Product and continuing for so long as Roche is selling any Product (“Royalty Term”). 
 8.3.2 Royalty Rates 

The following royalty rates shall apply to the respective tiers of aggregate [...***...] of Products in the Territory, on an incremental basis, as
follows: 
  

			
	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]
	 [...***...]
	  	[...***...]
	 [...***...]
	  	[...***...]
	 [...***...]
	  	[...***...]

 For example, if [...***...] of Products in the Territory on an aggregated basis, for the first [...***...] in a
given [...***...], is [...***...]: 
 [...***...] 

If then in the [...***...] of such [...***...], the [...***...] of Products [...***...] is [...***...] for such
[...***...] thus far[...***...]: 
 [...***...] 

  

					
		 	- 32 -	 	***Confidential Treatment Requested***

 For the purpose of calculating royalties of a Product, [...***...] and the royalty rates shall be subject
to the following adjustments, as applicable. 
 8.3.2.1 Virtual Gross Margin 

If the Sales of a given Product anywhere in the Territory (excluding any countries in the Territory as otherwise mutually agreed to by the Parties) is below
[...***...] per unit for such Product, then the Gross Margin for such units of Product shall be calculated by Roche Region (as described below) [...***...] (the “Virtual Gross Margin Calculation”). 

For purposes of determining the Virtual Gross Margin Calculation, the aggregate Sales of each Product in the Territory (excluding any countries in the
Territory as otherwise mutually agreed to by the Parties) on a Calendar Quarter basis shall be calculated on a regional basis as the greater of: [...***...]. The Virtual Gross Margin Calculation shall be calculated on a Roche Region by Roche
Region basis. 
 8.3.3 Third Party Payments 
 In the event that
it is necessary for Roche to obtain a license from a Third Party for Third Party intellectual property rights to use or sell the Product in the Territory following the Effective Date, Roche shall have the right to deduct [...***...] of any
consideration actually paid to such Third Party for such license from the royalties otherwise due and payable by Roche to FMI under this Section 8.3; provided, however, that in no case shall such reduction lower the amount of royalties
otherwise payable under this Section 8.3 by more than [...***...]. 
 8.3.4 Sales Milestones 

Roche will pay a one-time, non-refundable,
non-creditable sales milestone payment of [...***...] to FMI the first time the aggregate annual Gross Margin of [...***...] in a given Calendar Year first reach [...***...].
[...***...]. 
 8.3.5 Collaboration Products 
 
The financial terms for each Product, [...***...] that is a Collaboration Product (including royalty rates and sales milestone payments), and the diligence obligations for any such Product (including Commercial Launch obligations and Minimum
 Revenue Requirements) must be mutually agreed to in writing by the Parties, taking into consideration the relative contributions made by each Party to the development of such Product, before such Product is included in this Agreement. Following FMI’s
 decision to Commercially Launch a Collaboration Product (other than FACT or F1CDx) in any country in the Territory, FMI shall provide written notice to Roche, and if the Parties cannot agree to terms and conditions for the inclusion of such Collaboration
 Product as a Product in this Agreement within [...***...] (the “Initial Discussion Period”), then the Parties shall each select an independent Third Party expert who is neutral, disinterested and impartial, and has
significant relevant experience in the development and commercialization of pharmaceutical products (the “Expert”). Each Expert will within [...***...] select a [...***...] Expert to form a panel of [...***...]
Experts (“Panel”). The date on which such Panel is in place will be the “Arbitration Commencement Date.” Each Party shall, within [...***...] following the Arbitration Commencement Date, prepare and deliver to
both the Panel and the other Party its proposed financial terms (including royalty rates and sales milestone payments) and diligence obligations (including initial launch and minimum revenue requirements) (collectively, the “Arbitration
Offer”) to resolve the disputed matter for such Product and a memorandum (the “Supporting Memorandum”) in support thereof; provided that such Arbitration Offer shall be on the same or

  

					
		 	- 33 -	 	***Confidential Treatment Requested***

 
substantially similar terms as the last offer made by such Party to the other Party during the Initial Discussion Period. The Panel will also be provided with a copy of this Agreement. Within
[...***...] after receipt of the other Party’s Supporting Memorandum, each Party may submit to the Panel (with a copy to the other Party) a rebuttal to the other Party’s Supporting Memorandum (a “Rebuttal”), which
may include a revision, marked to show changes, of either Party’s proposed terms. Neither Party may have communications (either written or oral) with the Panel other than for the sole purpose of engaging the Panel or as expressly permitted in
this Section 8.3.5. Within [...***...] after the Panel’s receipt of each Party’s Rebuttal (or the expiration of the period for the Parties to submit a Rebuttal, if earlier), the Panel will select, between the proposals provided
by the Parties, the proposal that the Panel believes most accurately reflects an equitable result for FMI and Roche (the “Selected Agreement”). The Panel shall not have the authority to modify a proposal initially submitted by a
Party. The decision of the Panel shall be the sole, exclusive and binding remedy and the Selected Agreement shall become a binding and enforceable agreement between the Parties. The Panel will have reasonable discretion to request additional
information, hold a hearing, and extend the time frame for reaching a decision regarding the dispute at issue. The Experts’ fees and expenses will be paid by the Party whose proposal is not selected by the Panel. Each Party will bear and pay
its own expenses incurred in connection with any proceedings under this Section 8.3.5. 
 8.3.6 Penalty Payments 

Roche shall pay fees due to FMI pursuant to Sections 6.1.2.4 (Regulatory Partner), 7.3.1 (F1CDx Initial Launch Plan), and 7.3.2 (Subsequent Claim Filings and Non-Regulated Updates) (each, a “Penalty Payment”), if any, within [...***...] following Roche’s receipt of an invoice therefor. 

8.3.7 Other Payments 
 FMI shall provide Roche with monthly
invoices for any amounts that Roche owes FMI pursuant to Section 7.7 (F1CDx Report), together with supporting documentation outlining FMI’s costs and fees incurred in connection therewith, and Roche shall pay FMI such amounts within
[...***...] following Roche’s receipt of an invoice for such amounts. 
 Roche shall provide FMI with monthly invoices for Roche Regulatory
Support for each country in which Roche is the Regulatory Partner, together with supporting documentation outlining the Roche actual FTE rate, and FMI shall pay Roche such amounts within [...***...] following FMI’s receipt of an invoice
for such amounts. 
 Each Party shall provide the other Party with monthly invoices for payments owed pursuant to Section 6.1.2.1, together with
supporting documentation outlining the full amount that such Party incurred in accordance with Section 6.1.2.1 in making the Initial Filing in any Regulated Market. Each Party shall pay the invoiced amounts within [...***...] following
its receipt of each invoice. 
 8.4 Disclosure of Payments 

Each Party acknowledges that the other Party may be obligated to disclose this financial arrangement, including all fees, payments and transfers of value, as
may be advisable or required under Applicable Law. 
 9. Accounting and Reporting 

9.1 Timing of Payments 
 Roche shall calculate royalties
[...***...] (each being the last day of an “Accounting Period”) and shall pay royalties on Net Sales within the [...***...] after the end of each Accounting Period in which such Net Sales occur. 

  

					
		 	- 34 -	 	***Confidential Treatment Requested***

 9.2 Late Payment 

Any payment under this Agreement that is not paid on or before the date such payment is due shall bear interest, to the extent permitted by Applicable Law, at
[...***...] points above the average one-month Euro Interbank Offered Rate (EURIBOR), as reported by Reuters from time to time, calculated on the number of days such payment is overdue. 

9.3 Method of Payment 
 Royalties on Net Sales and all
other amounts payable by Roche hereunder shall be paid by Roche in US Dollars (the “Payment Currency”) to account(s) designated by FMI. 

9.4 Currency Conversion 
 When calculating the Sales of
any royalty-bearing Product that occur in currencies other than the Payment Currency, Roche shall convert the amount of such sales into [...***...] and then into the Payment Currency using [...***...]. 

9.5 Reporting 
 With each payment, Roche shall provide FMI
in writing for the relevant [...***...] on an aggregated basis for all Products, and thereafter on a Product-by-Product basis, the following information: 

[...***...] 
 [...***...] 

[...***...] 
 [...***...] 

[...***...] 
 [...***...] 

[...***...] 
 [...***...] 

10. Taxes 
 FMI shall pay all sales, turnover, income,
revenue, value added, and other taxes levied on account of any payments accruing or made to FMI under this Agreement. 
 If provision is made in law or
regulation of any country for withholding of taxes of any type, levies or other charges with respect to any royalty or other amounts payable under this Agreement to FMI, then Roche shall promptly pay such tax, levy or charge for and on behalf of FMI
to the proper governmental authority, and shall promptly furnish FMI with receipt of payment. Roche shall be entitled to deduct any such tax, levy or charge actually paid from royalty or other payment due FMI or be promptly reimbursed by FMI if no
further payments are due to FMI. Each Party agrees to reasonably assist the other Party in claiming exemption from such deductions or withholdings under double taxation or similar agreement or treaty from time to time in force and in minimizing the
amount required to be so withheld or deducted. 
 11. Auditing 

11.1 Right to Audit 
 In addition to the audit rights set
forth in Article 5 (Supply) and Section 6.1.2.3 (Firewall), each Party shall keep, and shall require its Affiliates and sublicensees/Sublicensees to keep, full, true and accurate books of account containing all particulars that may be necessary
for the purpose of calculating all amounts payable under this Agreement, such as with respect to royalties in the case of Roche and Cost of Services in the case of FMI. Such books of accounts shall be kept at their principal place of business. At
the expense of the auditing Party, the auditing Party shall have the right to engage an independent public accountant from a major, internationally recognized 

  

					
		 	- 35 -	 	***Confidential Treatment Requested***

 
accounting firm, to perform, on behalf of the auditing Party an audit of such books and records of the audited Party and its Affiliates, its licensees and sublicensees/Sublicensees, that are
deemed necessary by the auditing Party’s independent public accountant for the period or periods requested by auditing Party and the correctness of any financial report or payments made under this Agreement. 

Upon timely request and at least [...***...] prior written notice from the auditing Party, such audit shall be conducted in the countries specifically
requested by the auditing Party, during regular business hours in such a manner as to not unnecessarily interfere with the audited Party’s normal business activities, and shall be limited to results in the [...***...] prior to audit
notification. 
 Such audit shall not be performed more frequently than [...***...] nor more frequently than once with respect to records covering any
specific period of time. 
 All information, data documents and abstracts herein referred to shall be used only for the purpose of verifying statements,
shall be treated as the audited Party’s Confidential Information subject to the obligations of this Agreement and need neither be retained more than [...***...] after completion of an audit hereof, if an audit has been requested; nor more
than [...***...] from the end of the Calendar Year to which each shall pertain; nor more than [...***...] after the date of termination of this Agreement. 

11.2 Audit Reports 
 The auditors shall only state factual
findings in the audit reports and shall not interpret the Agreement. The auditors shall share all draft audit reports with the audited Party before the draft report is shared with the auditing Party and before the final document is issued. The final
audit report, if any, shall be shared with the audited Party at the same time it is shared with the auditing Party. 
 11.3 Over-or Underpayment 
 If the audit reveals an overpayment, such overpayment shall be credited against future payments
owed by Roche for the amount of the overpayment or, if no further payments are owed by Roche, then FMI shall reimburse Roche for the amount of the overpayment within [...***...]. If the audit reveals an underpayment, Roche shall make up such
underpayment with the next payment or, if no further payments are owed by Roche, Roche shall reimburse FMI for the amount of the underpayment within [...***...]. The audited Party shall pay for the audit costs if the underpayment/over receipt
of the audited Party exceeds [...***...] of the aggregate amount of payments owed with regard to the statements subject of the audit. Section 9.2 shall apply to this Section 11.3. 

11.4 Duration of Audit Rights 
 The failure of FMI to
request verification of any royalty calculation within the period during which corresponding records must be maintained under this Article 11 will be deemed to be acceptance of the royalty payments and reports. 

12. Intellectual Property 
 12.1 Ownership of
Inventions 
 Ownership of Inventions shall be as set forth in the Collaboration Agreement. 

12.2 Trademarks and Labeling 
 The Parties shall attempt
to use a uniform global trademark and logo for the Product; provided, that each Party may use its own trademarks and housemarks as it selects to promote the sale of 

  

					
		 	- 36 -	 	***Confidential Treatment Requested***

 
the Product in the FMI Territory, with respect to FMI, and the Territory, with respect to Roche (collectively, excluding the housemarks, the “Product Trademarks”). The Parties
shall agree on at least [...***...] Product Trademarks for each Product, with [...***...] of the trademarks being the global trademark and the other(s) being trademarks to be held in reserve in case the global trademark cannot be used in
[...***...] or more countries. The placement and size of a Party’s housemarks relative to Product Trademarks shall be approved by the JOC. Excluding the Roche housemarks, FMI shall own any global Product Trademarks used on or in
connection with Products in the Territory, and shall, at its sole cost, be responsible for procurement, maintenance, enforcement and defense of such global Product Trademarks. 

Roche shall own its trademarks, including the Roche trademark and hexagon, and may use the Roche trademarks in connection with the Product as set forth in
this Section. FMI shall not file any identical registrations or other filings in respect of any such housemarks owned by Roche. FMI shall own its housemark and any trademark it selects to promote the sale of the Product in the FMI Territory. Roche
shall not file any identical registrations or other filings in respect of any such trademarks and housemarks owned by FMI. 
 Each Party shall maintain all
registrations of such Product Trademarks owned by it, and the other Party shall not file any registrations or other filings in respect of any of such Product Trademark owned by the Product Trademark owning Party without the Product Trademark owning
Party’s prior written consent. FMI shall use Commercially Reasonable Efforts to obtain and maintain Product Trademarks, and the Parties will reasonably cooperate with one another to take reasonable measures to enforce oppositions and
litigations in relation to the Product Trademarks. 
 Each Party shall use the Product Trademarks in accordance with sound trademark and trade name usage
principles and in accordance with all Applicable Law as reasonably necessary to maintain the validity and enforceability of the Product Trademarks. Each Party recognizes that the trademarks owned by the other Party represents a valuable asset of
such other Party, and that substantial recognition and goodwill are associated with such name, logo, and trademarks. Each Party hereby agrees that, without prior written authorization of the other Party or as specifically permitted in this
Agreement, it shall not use such other Party’s trademarks for any purpose. 
 Each Party shall have the right to police its own trademarks and enforce
its own trademarks. Each Party shall have the right to audit the other Party, its Affiliates, sublicensees/Sublicensees and contractors to ensure the quality of the Products to which the trademark is associated. 

In the event either Party becomes aware of any infringement of any Product Trademark by a Third Party, such Party shall promptly notify the other Party and
the Parties shall consult with each other and jointly determine the best way to prevent such infringement. 
 12.3 Prosecution of Patent Rights 

Patent Rights shall be prosecuted as set forth in the Collaboration Agreement. 

12.4 Patent Coordination Team 
 The JPT as defined in the
Collaboration Agreement will address all issues related to Patent Rights. 
 12.5 Infringement 

Infringement shall be addressed as set forth in the Collaboration Agreement. However, if Roche is commercializing a Product in a particular country in the
Territory, then Roche shall have the first right to enforce Patent Rights in such country in the Territory. 

  

					
		 	- 37 -	 	***Confidential Treatment Requested***

 12.6 Defense 

If an action for infringement is commenced against either Party, its licensees or its sublicensees/Sublicensees, the provisions of the Collaboration Agreement
shall apply. 
 12.7 Common Interest Disclosures 
 With
regard to any information or opinions disclosed pursuant to this Agreement by one Party to each other regarding intellectual property and/or technology owned by Third Parties, the Parties agree that they have a common legal interest in determining
whether, and to what extent, Third Party intellectual property rights may affect the conduct of the activities under this Agreement. Accordingly, the provisions of the Collaboration Agreement shall apply in this regard. 

13. Representations and Warranties 
 13.1 FMI
Representations and Warranties 
 13.1.1 Safety Data 
 FMI
warrants and represents that it has, and covenants that it will, continue to disclose to Roche as soon as possible during the Agreement Term (i) the results of all preclinical testing and human clinical testing Controlled by FMI relating to any
Product and (ii) all information in its Control concerning side effects, injury, toxicity or sensitivity reaction and incidents or severity thereof with respect to any Product. 

13.1.2 Third Party Patent Rights 
 FMI warrants and represents
that, as of the Effective Date, it has no knowledge of the existence of any patent or patent application owned by or licensed to any Third Party that could prevent Roche from making, having made, using, offering for sale, selling or importing
Product in the Territory. 
 13.1.3 Ownership of Patent Rights 

As of the Effective Date and the Restatement Date, FMI warrants and represents that it is the exclusive owner of all right, title and interest in, or is the
exclusive licensee of, the FMI Patent Rights in the Territory relating to the use, sale, offer for sale, import, or export of the Products in the Territory. 

13.1.4 Ownership of Trademarks 
 Subject to the licenses granted
to Roche pursuant to Sections 2.1.1 and 2.1.3, FMI warrants and represents that it is the exclusive owner of all right, title and interest in, or is the exclusive licensee of the trademarks for the Products in the Territory. 

13.1.5 Inventors 
 FMI warrants and represents that for the
inventors of the Inventions disclosed and/or claimed in the disclosed FMI Patent Rights, FMI has obtained the assignment of, or a license under, all interest and all rights or licenses thereunder with respect to the FMI Patent Rights necessary to
grant the licenses granted hereunder. All of FMI’s employees, officers and consultants have executed agreements requiring assignment to FMI of all Inventions made by such individuals during the course of and as a result of their association
with FMI. 
 13.1.6 Grants 
 FMI warrants and represents that
to the best of FMI’s knowledge and belief, FMI has the lawful right to grant Roche and its Affiliates the rights and licenses described in this Agreement. 

  

					
		 	- 38 -	 	***Confidential Treatment Requested***

 13.1.7 Valid Claims 

As of the Effective Date, FMI warrants and represents that it is not in possession of any information that would, in its reasonable opinion, render invalid
and/or unenforceable any claims in any issued patent licensed pursuant to this Agreement. FMI has no knowledge of any inventorship disputes concerning any FMI Patent Rights. 

13.1.8 Ownership and Validity of Know-How 

As of the Effective Date, FMI warrants and represents that FMI’s Know-How relating to Products and Service
Activities is legitimately in the possession of FMI and has not been misappropriated from any Third Party, and FMI has taken reasonable measures to protect the confidentiality of its Know-How. 

13.2 Mutual Representations of the Parties 
 13.2.1
Authorization 
 As of the Effective Date and the Restatement Date, each Party warrants and represents to the other Party that the execution, delivery and
performance of this Agreement by such Party and all instruments and documents to be delivered by such Party hereunder: (i) are within the corporate power of such Party; (ii) have been duly authorized by all necessary or proper corporate
action; (iii) are not in contravention of any provision of the certificate of formation or limited liability company agreement of such Party; (iv) to the knowledge of such Party, will not violate any law or regulation or any order or
decree of any court of governmental instrumentality; (v) will not violate the terms of any indenture, mortgage, deed of trust, lease, agreement, or other instrument to which such Party is a party or by which such Party or any of its property is
bound, which violation would have a material adverse effect on the financial condition of such Party or on the ability of such Party to perform its obligations hereunder; and (vi) do not require any filing or registration with, or the consent
or approval of, any governmental body, agency, authority or any other person, which has not been made or obtained previously (other than approvals required under the HSR Act, Regulatory Approvals required for the sale of Products and filings with
Regulatory Authorities required in connection with Products). 
 13.2.2 No Claims 

As of the Effective Date and the Restatement Date, each Party warrants and represents to the other Party that there are no claims or investigations (other than
with respect to the Parties’ HSR filings), pending or threatened against such Party or any of its Affiliates, at law or in equity, or before or by any governmental authority relating to the matters contemplated under this Agreement or that
would materially adversely affect such Party’s ability to perform its obligations hereunder. 
 13.2.3 No Conflict 

Each Party warrants and represents that neither it nor any of its Affiliates is or will be under any obligation to any person, contractual or otherwise, that
is conflicting with the terms of this Agreement or that would impede the fulfillment of such Party’s obligations hereunder. 
 13.2.4 Activities 

Each Party will perform all activities under this Agreement (i) in a professional manner, (ii) in conformance with the level or care and skill
ordinarily exercised by other professional institutions in similar circumstances, and (iii) in compliance with Applicable Law. 

  

					
		 	- 39 -	 	***Confidential Treatment Requested***

 14. Indemnification 

14.1 Indemnification by Roche 
 Roche shall indemnify, hold
harmless and defend FMI and its Affiliates, and their respective directors, officers, employees, independent contractors and agents from and against any and all losses, expenses, cost of defense (including without limitation attorneys’ fees,
witness fees, damages, judgments, fines and amounts paid in settlement) and any amounts FMI becomes legally obligated to pay because of any claim or claims brought by a Third Party against it to the extent that such claim or claims arise out of any
member of the Roche Group’s actions or inactions in connection with activities under this Agreement, except to the extent such losses, expenses, costs and amounts are due to the gross negligence or willful misconduct or failure to act of FMI.

 14.2 Indemnification by FMI 
 FMI shall indemnify,
hold harmless and defend Roche and its Affiliates, and their respective directors, officers, employees, independent contractors and agents from and against any and all losses, expenses, cost of defense (including without limitation attorneys’
fees, witness fees, damages, judgments, fines and amounts paid in settlement) and any amounts Roche becomes legally obligated to pay because of any claim or claims brought by a Third Party against it to the extent that such claim or claims arise out
of FMI’s and its Affiliates’ actions or inactions in connection with activities under this Agreement, except to the extent such losses, expenses, costs and amounts are due to the gross negligence or willful misconduct or failure to act of
Roche. 
 14.3 Procedure 
 In the event of a claim by a
Third Party against a Party entitled to indemnification under this Agreement (“Indemnified Party”), the Indemnified Party shall promptly notify the other Party (“Indemnifying Party”) in writing of the claim, and the
Indemnifying Party shall undertake and solely manage and control, at its sole expense, the defense of the claim and its settlement. The Indemnified Party shall cooperate with the Indemnifying Party and may, at its option and expense, be represented
in any such action or proceeding by counsel of its choice. The Indemnifying Party shall not be liable for any litigation costs or expenses incurred by the Indemnified Party without the Indemnifying Party’s written consent. The Indemnifying
Party shall not settle any such claim unless such settlement fully and unconditionally releases the Indemnified Party from all liability relating thereto, unless the Indemnified Party otherwise agrees in writing. 

15. Liability 
 15.1 Disclaimer 

EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY PROVIDES ANY WARRANTIES, WHETHER WRITTEN OR ORAL, EXPRESS OR IMPLIED. FMI AND ROCHE DISCLAIM ALL
OTHER WARRANTIES, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO EACH OF THEIR RESEARCH, DEVELOPMENT AND COMMERCIALIZATION EFFORTS HEREUNDER, INCLUDING, WITHOUT LIMITATION, WHETHER THE PRODUCTS CAN BE SUCCESSFULLY DEVELOPED OR MARKETED, THE ACCURACY,
PERFORMANCE, UTILITY, RELIABILITY, TECHNOLOGICAL OR COMMERCIAL VALUE, COMPREHENSIVENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE WHATSOEVER OF THE PRODUCTS. EXCEPT IN THE CASE OF A BREACH OF ARTICLE 16, AND WITHOUT LIMITING THE
PARTIES’ OBLIGATIONS UNDER ARTICLE 14, IN NO EVENT SHALL EITHER FMI OR ROCHE BE LIABLE FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF THIS AGREEMENT BASED ON CONTRACT, TORT OR ANY OTHER LEGAL THEORY. 

  

					
		 	- 40 -	 	***Confidential Treatment Requested***

 16. Obligation Not to Disclose Confidential Information 

16.1 Non-Use and Non-Disclosure 

During the Agreement Term and for [...***...] thereafter, a Receiving Party shall (i) treat Confidential Information provided by Disclosing Party as
it would treat its own information of a similar nature, (ii) take all reasonable precautions not to disclose such Confidential Information to Third Parties, without the Disclosing Party’s prior written consent, and (iii) not use such
Confidential Information other than for fulfilling its obligations under this Agreement. If any Confidential Information is required to be disclosed by the Receiving Party or its Affiliates to comply with a court or administrative order, the
Receiving Party or its Affiliates will provide prompt notice to the Disclosing Party to enable the Disclosing Party to resist such disclosure. 
 16.2
Permitted Disclosure 
 Notwithstanding the obligation of non-use and
non-disclosure set forth in Section 16.1, the Parties recognize the need for certain exceptions to this obligation, specifically set forth below, with respect to press releases, patent rights,
publications, and certain commercial considerations. 
 16.3 Press Releases 

Each Party shall provide the other with a copy of any draft press release related to the activities contemplated by this Agreement at least [...***...]
prior to its intended publication for such other Party’s review. The reviewing Party may provide the releasing Party with suggested modification to the draft press release. The releasing Party shall consider, and shall not unreasonably
disregard, the reviewing Party’s suggestions in issuing its press release. 
 16.4 Publications 

During the Agreement Term, the following restrictions shall apply with respect to disclosure by any Party of Confidential Information relating to the Product
in any publication or presentation: 
  

	a)	Both Parties acknowledge that it is their policy for the studies and results thereof to be registered and published in accordance with their internal guidelines. The Parties shall have the right to jointly publish all
studies, clinical trials and results conducted or generated in accordance with this Agreement to the extent both Parties have jointly participated in or collaborated in such clinical study or trial. To the extent any study or clinical trial is
conducted solely by Roche with no participation by FMI, Roche, in accordance with its internal policies and procedures, shall have the right to publish all such studies, clinical trials and results thereof on the clinical trial registries that are
maintained by or on behalf of Roche, and FMI shall not publish any such studies, clinical trials or results thereof on its clinical trial registry, provided however, the Roche’s clinical trial registry can be accessed via a link from FMI’s
clinical trial registry. 

  

	b)	 A Party (“Publishing Party”) shall provide the other Party with a copy of any proposed
publication or presentation at least [...***...] prior to submission for publication so as to provide such other Party with an opportunity to recommend any changes it reasonably believes are necessary to continue to maintain the Confidential
Information disclosed by the other Party to the Publishing Party in accordance with the requirements of this Agreement. The incorporation of such recommended changes shall not be unreasonably refused; and if such other Party notifies
(“Publishing Notice”) the Publishing Party in writing, within [...***...] after receipt of the copy of the proposed publication or presentation, that such publication or presentation in its reasonable judgment
(i) contains an invention, solely or jointly conceived and/or reduced to practice by the other Party, for which the other Party reasonably desires to obtain patent protection or (ii) could be expected to have a material adverse effect on
the commercial value of any Confidential Information disclosed by the other Party to the Publishing Party, the Publishing Party shall prevent such publication or delay such publication for a mutually agreeable period of time. In the case of
inventions, a 

  

					
		 	- 41 -	 	***Confidential Treatment Requested***

	 	
delay shall be for a period reasonably sufficient to permit the timely preparation and filing of a patent application(s) on such invention, and in no event less than [...***...] from the
date of the Publishing Notice. 

 16.5 Commercial Considerations 

Nothing in this Agreement shall prevent a Party or its Affiliates from disclosing Confidential Information of the other Party to (i) governmental agencies
to the extent required or desirable to secure government approval for the manufacture or sale of Product in the Territory, and (ii) Third Parties acting on behalf of such Party, to the extent reasonably necessary to conduct the activities
contemplated by this Agreement, provided such Third Parties are bound by confidentiality and non-use obligations with respect to such information that are no less stringent than those included in this
Agreement. The Receiving Party may disclose Confidential Information of the Disclosing Party to the extent that such Confidential Information is required to be disclosed by the Receiving Party to comply with Applicable Law, to defend or prosecute
litigation or to comply with governmental regulations, provided that the Receiving Party provides prior written notice of such disclosure to the Disclosing Party and, to the extent practicable, takes reasonable and lawful actions to minimize the
degree of such disclosure. 
 17. Term and Termination 

17.1 Commencement and Term 
 This Agreement shall commence
upon the Effective Date and continue for the Agreement Term. 
 17.2 Termination 

17.2.1 Automatic Termination 
 This Agreement shall terminate
automatically, without any notice or other action by any Party, upon the first to occur of (i) termination of the Transaction Agreement in accordance with its terms and (ii) the mutual written consent of the Parties. 

17.2.2 Termination for Breach 
 A Party (“Non-Breaching Party”) shall have the right to terminate this Agreement in its entirety or on a country-by-country or Product-by-Product basis in the event the other Party (“Breaching Party”) is in breach of any of its material obligations under this Agreement. The Non-Breaching Party shall provide written notice to the Breaching Party, which notice shall identify the breach and, if applicable, the affected countries in which, and the affected Products with respect to which,
the Non-Breaching Party intends to have this Agreement terminate. The Breaching Party shall have a period of [...***...] after such written notice is provided (“Peremptory Notice
Period”) to cure such breach. If the Breaching Party has a dispute as to whether such breach occurred or has been cured, it will so notify the Non-Breaching Party, and the expiration of the Peremptory
Notice Period shall be tolled until the Parties agree or the arbitrators have determined in accordance with Section 19.3 that this Agreement was materially breached. It is understood and acknowledged that, during the pendency of such a dispute,
all of the terms and conditions of this Agreement shall remain in effect, and the Parties shall continue to perform all of their respective obligations under this Agreement. Upon such agreement or determination of material breach or failure to cure,
the Breaching Party may have the remainder of the Peremptory Notice Period to cure such breach. If such breach is not cured within the Peremptory Notice Period, then, absent withdrawal of the Non-Breaching
Party’s request for termination, this Agreement shall terminate in accordance with the written notice provided by the Non-Breaching Party and such termination shall be effective as of the expiration of
the Peremptory Notice Period. For clarity, (a) Roche may terminate this Agreement under this Section 17.2.2 if there is a material diminution in the Quality Standards, except as permitted under Section 2.3, or if FMI is unwilling or
unable to fulfill its obligations under 

  

					
		 	- 42 -	 	***Confidential Treatment Requested***

 
Section 7.5.2, and (b) FMI may terminate this Agreement under this Section 17.2.2 if Roche is unwilling or unable to fulfill its obligations under Section 7.6.1 and FMI may
terminate this Agreement on a country-by-country basis in the event of a Territory Revision Event. Notwithstanding the foregoing, Roche may terminate this Agreement
under this Section 17.2.2 if a Material Average Delivery Time Failure or Material Performance Standards Failure occurs by providing written notice to FMI within [...***...] of such Material Average Delivery Time Failure or Material
Performance Standards Failure, and no cure period as provided under this Section 17.2.2 shall be applicable for such termination. 
 17.2.3 Insolvency

 A Party shall have the right to terminate this Agreement, if the other Party incurs an Insolvency Event; provided, however, in the case of any involuntary
bankruptcy proceeding, such right to terminate shall only become effective if the Party that incurs the Insolvency Event consents to the involuntary bankruptcy or such proceeding is not dismissed within [...***...] after the filing thereof.

 17.2.4 Termination by Roche without a Cause 
 Roche shall
have the right to terminate this Agreement at any time after the Initial Term on a Product-by-Product and/or country-by-country basis upon six (6) months prior written notice. The effective date of termination under this Section 17.2.4 shall be the date six (6) months after Roche provides such written
notice to FMI. 
 17.3 Consequences of Termination and Expiration 

17.3.1 Termination by FMI for Breach by Roche or by Roche without a Cause, or Expiration of the Agreement Term. 

Upon any termination under Section 17.2.1, any termination by FMI for breach by Roche in accordance with Section 17.2.2, any termination by Roche
under Section 17.2.4, any Territory Revision Event, or upon expiration of the Agreement Term, the following shall apply: 
  

	a)	The rights and licenses granted by FMI to Roche under this Agreement shall terminate in their entirety or on a country-by-country basis, as
applicable, on the effective date of termination. 

  

	b)	After the effective date of termination, Roche shall, to the extent permitted by Applicable Law, assign and transfer to FMI all regulatory filings and Regulatory Approvals, all final
pre-clinical and clinical study reports and clinical study protocols, and all data, including clinical data, in Roche’s possession and control related to Product(s) in the country necessary for FMI to
continue to commercialize the Product(s). All data shall be transferred in the form and format in which it is maintained by Roche. Original paper copies shall only be transferred, if legally required. Roche shall not be required to prepare or
finalize any new data, reports or information solely for purposes of transfer to FMI. 

  

	c)	Roche shall assign all clinical trial agreements, to the extent such agreements have not been cancelled and are assignable without Roche paying any consideration or commencing litigation in order to effect an assignment
of any such agreement. 

  

	d)	FMI shall, upon transfer, have the right to disclose such filings, approvals and data to (i) governmental agencies of the country to the extent required or desirable to secure government approval for the sale of
Product(s) in the country, (ii) Third Parties acting on behalf of FMI, its Affiliates or licensees, to the extent reasonably necessary for the sale of Product(s) in the country, and (iii) Third Parties to the extent reasonably necessary to
market Product(s) in the country. 

  

					
		 	- 43 -	 	***Confidential Treatment Requested***

 17.3.2 Termination by Roche for Breach by FMI or FMI Insolvency 

Upon a material breach of a material obligation under this Agreement by FMI pursuant to Section 17.2.2 or FMI’s Insolvency pursuant to
Section 17.2.3, at Roche’s option, (i) Roche may seek damages via arbitration under Section 19.3 or (ii) as Roche’s exclusive remedy (other than for breach of confidentiality under Section 16) FMI shall pay to
Roche either a one-time payment reflecting the value of the terminated Product(s) or a royalty on sales of such terminated Product(s) based on the royalty that Roche would have paid to FMI had the Agreement
not terminated, the amount of which will be agreed to by the Parties negotiating in good faith. If the Parties cannot agree on the amount in clause (ii) above, then the determination of such amount shall be referred to a Panel in a manner
analogous to that found in Section 8.3.5. 
 Upon any termination by Roche for breach by FMI in accordance with Section 17.2.2 or for FMI’s
insolvency in accordance with Section 17.2.3, the following shall apply: 
  

	 	a)	the rights and licenses granted by FMI to Roche under this Agreement shall terminate in their entirety or on a country-by-country and Product-by-Product basis, as applicable, on the effective date of termination. 

  

	 	b)	After the effective date of termination Roche shall, to the extent Roche has the right to do so, assign and transfer to FMI all regulatory filings and Regulatory Approvals, all final
pre-clinical and clinical study reports and clinical study protocols, and all data, including clinical data, in Roche’s possession and control related to Product(s) in the country necessary for FMI to
continue to commercialize the Product(s). All data shall be transferred in the form and format in which it is maintained by Roche. Original paper copies shall only be transferred, if legally required. Roche shall not be required to prepare or
finalize any new data, reports or information solely for purposes of transfer to FMI. 

  

	 	c)	Roche shall assign all clinical trial agreements, to the extent such agreements have not been cancelled and are assignable without Roche paying any consideration or commencing litigation in order to effect an assignment
of any such agreement. 

  

	 	d)	FMI shall, upon transfer, have the right to disclose such filings, approvals and data to (i) governmental agencies of the country to the extent required or desirable to secure government approval for the sale of
Product(s) in the country, (ii) Third Parties acting on behalf of FMI, its Affiliates or licensees, to the extent reasonably necessary for the sale of Product(s) in the country, and (iii) Third Parties to the extent reasonably necessary to
market Product(s) in the country. 

 17.3.3 Direct License 

Upon termination of this Agreement pursuant to Sections 17.2.2 or 17.2.3, with respect to any existing, permitted sublicense granted by Roche under
Section 2.1.2(ii) of this Agreement (and any further sublicenses thereunder) upon the written request of Roche, (i) if the sublicense was consented to by FMI or is to Chugai, then the sublicense shall survive termination provided such
Sublicensee (a) is not then in breach of its sublicense agreement and (b) such Sublicensee agrees to be bound to FMI under the terms and conditions of such sublicense agreement, and (ii) if the sublicense was not consented to by FMI,
then FMI shall negotiate in good faith with the applicable Sublicensee the terms under which such sublicense shall survive such termination, provided that (a) such Sublicensee is not then in breach of its sublicense agreement (and, in the

  

					
		 	- 44 -	 	***Confidential Treatment Requested***

 
case of termination by FMI for breach by Roche, that such Sublicensee and any further sublicensees did not cause the breach that gave rise to the termination by FMI); and (b) such
Sublicensee agrees to be bound to FMI under the terms and conditions of such sublicense agreement. 
 17.3.4 Other Obligations 

17.3.4.1 Obligations Related to Ongoing Activities 
 Upon the
effective date of termination of this Agreement, each Party (a) shall have the right to cancel all ongoing obligations as of the effective date of termination and (b) shall complete all
non-cancellable obligations at its own expense. 
 From the date of notice of termination until the effective date
of termination, Roche and FMI shall each continue their activities, including preparatory activities, ongoing as of the date of notice of termination. However, neither Party shall be obliged to initiate any new activities not ongoing at the date of
notice of termination. 
 After the effective date of termination, neither Party shall have an obligation to perform and/or complete any activities or to
make any payments for performing or completing any activities after such effective date of termination under this Agreement, except as expressly stated herein. 

Notwithstanding the foregoing, (a) in case of termination by FMI under Section 17.2.2 or 17.2.3 or by Roche under Section 17.2.4, upon the
request of FMI, Roche shall complete any clinical studies related to the Product(s) that are being conducted by Roche for the Product(s) and are ongoing as of the effective date of termination, and (b) in case of termination by Roche under
Section 17.2.2 or 17.2.3, upon the request of Roche, FMI shall complete any clinical studies related to the Product(s) that are being conducted by FMI for the Product(s) and are ongoing as of the effective date of termination; provided,
however, that 
  

	(i)	both FMI and Roche in their reasonable judgment have concluded that completing any such clinical studies does not present an unreasonable risk to patient safety; 

 

	(ii)	neither Party shall have an obligation to recruit or enroll any additional patients after the effective date of termination; and 

  

	(iii)	FMI agrees to reimburse Roche for all of its development costs that incurred by or on behalf of Roche after the effective date of termination in completing such clinical studies as per subsection (a) above and
Roche agrees to reimburse FMI for all of its development costs that incurred by or on behalf of Roche after the effective date of termination in completing such clinical studies as per subsection (b) above. 

17.3.4.2 Ancillary Agreements 
 Unless otherwise agreed by the
Parties, the termination of this Agreement shall cause the automatic termination of all ancillary agreements related hereto, including but not limited to supply or quality agreements, if any, but shall not cause the termination of the Related
Agreements unless specifically stated in such Related Agreement. 
 17.3.4.3 Limitations on Grant-Backs; Transfer Expenses 

For purposes of clarity, irrespective of anything to the contrary in this Agreement: 
  

	a)	All transfers and licenses from Roche to FMI or other obligations of Roche under Section 17.3 are solely with respect to Product(s). 

  

					
		 	- 45 -	 	***Confidential Treatment Requested***

	b)	In connection with clinical trials, Roche may have collected human samples and related clinical information for additional limited research and development programs (“Samples”). Legal and contractual
restrictions may apply to such Samples, in particular as Samples may qualify as personal identifiable information. FMI acknowledges and accepts that notwithstanding anything herein, Roche shall not be obliged to transfer any such Samples to FMI.

  

	c)	Nothing in this Agreement shall be construed as granting FMI any license under the intellectual property of Roche or its Affiliates in existence as of the Effective Date. 

 

	d)	Except with respect to termination by FMI for Roche’s breach pursuant to Section 17.2.2, FMI shall promptly reimburse Roche for all reasonable
out-of-pocket costs and expenses (including FTE charges based on Roche’s actual FTE Rates, not to exceed the FTE Rates set forth in the Collaboration Agreement)
incurred by or on behalf of Roche for transfer of documents and materials as requested by FMI under this Article 17 (“Roche Transfer Activities”); however transfer activities corresponding to the return of material remains, data,
reports, records, documents, Regulatory Filings and Regulatory Approvals originally provided by FMI to Roche (“FMI-Originated Transfer Activities”) shall be at no expense to FMI. If FMI
desires Roche Transfer Activities other than FMI-Originated Transfer Activities, FMI shall make a payment to Roche of [...***...] (“Minimum Transfer Payment”). The Minimum Transfer
Payment shall be non-refundable, but shall be fully creditable against FMI’s reimbursement for the Roche Transfer Activities. Roche shall be under no obligation to provide Roche Transfer Activities
(beyond the FMI-Originated Transfer Activities) prior to receipt of the Minimum Transfer Payment. 

17.3.5 Royalty and Payment Obligations 
 Termination of this
Agreement by a Party, for any reason, shall not release Roche from any obligation to pay royalties or make any payments to FMI that are payable for sales of Product prior to the effective date of termination. Termination of this Agreement by a
Party, for any reason, will release Roche from any obligation to pay royalties or make any payments to FMI that would otherwise become payable on or after the effective date of termination. 

17.4 Survival 
 Article 1 (Definitions, to the extent
necessary to interpret the Agreement), Section 6.1.2.3 (Firewall, to the extent necessary to protect Third Party information not in the public domain), Article 10 (Taxes) Article 11 (Auditing), Article 12 (Intellectual Property, to the extent
relating to intellectual property existing at the time of termination), Article 14 (Indemnification, to the extent relating to claims existing at the time or termination), Article 16 (Obligation Not to Disclose Confidential Information),
Section 17.3 (Consequences of Termination and Expiration, to the extent applicable), Section 17.4 (Survival), Section 19.1 (Governing Law) and Section 19.3 (Arbitration) shall survive any expiration or termination of this
Agreement for any reason. Notwithstanding the foregoing, any provision of this Agreement that is intended by its very nature to survive expiration or termination of this Agreement shall also survive. 

18. Bankruptcy 
 All licenses (and to the extent
applicable rights) granted under or pursuant to this Agreement by FMI to Roche are, and shall otherwise be deemed to be, for purposes of Section 365(n) of Title 11, 

  

					
		 	- 46 -	 	***Confidential Treatment Requested***

 
US Code (the “Bankruptcy Code”) licenses of rights to “intellectual property” as defined under Section 101(60) of the Bankruptcy Code. Unless Roche elects to
terminate this Agreement, the Parties agree that Roche, as a licensee or sublicensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code, subject to the continued
performance of its obligations under this Agreement. 
  

	19.	Miscellaneous 

  

	19.1	Governing Law 

 This Agreement shall be governed by and construed in accordance with the laws of New
York, US, without reference to its conflict of laws principles, and shall not be governed by the United Nations Convention on International Contracts on the Sale of Goods (the Vienna Convention). 

 

	19.2	Disputes 

 Unless otherwise set forth in this Agreement, in the event of any dispute in connection with
this Agreement, such dispute shall be referred to the respective executive officers of the Parties designated below or their designees, for good faith negotiations attempting to resolve the dispute. The designated executive officers are as follows:

  

	 	For	FMI: CEO 

  

	 	For Roche:	Head of Roche Partnering or the CEO of the Roche Group in the case of Minimum Revenue Requirements. 

  

	19.3	Arbitration 

 Should the Parties fail to agree within [...***...] after such dispute has first
arisen, it shall be finally settled by arbitration in accordance with the American Arbitration Association (“AAA”) Commercial Rules (the “AAA Arbitration Rules”) as in force at the time when initiating the arbitration. The
tribunal shall consist of three arbitrators. The place of arbitration shall be New York, New York, US. The language to be used shall be English. 
 19.3.1
Arbitration 
 Each Party shall nominate one arbitrator. Should the claimant fail to appoint an arbitrator in the request for arbitration within
[...***...] of being requested to do so, or if the respondent should fail to appoint an arbitrator in its answer to the request for arbitration within [...***...] of being requested to do so, the other Party shall request the AAA to make
such appointment. 
 The arbitrators nominated by the Parties shall, within [...***...] from the appointment of the arbitrator nominated in the answer
to the request for arbitration, and after consultation with the Parties, agree and appoint a third arbitrator, who will act as a chairman of the tribunal. Should such procedure not result in an appointment within the [...***...] time limit,
either Party shall be free to request the AAA to appoint the third arbitrator. 
 Where there is more than one claimant and/or more than one respondent, the
multiple claimants or respondents shall jointly appoint one arbitrator. 
 Any Party-appointed arbitrator or the third arbitrator resigns or ceases to be
able to act, a replacement shall be appointed in accordance with the arrangements provided for in this clause. 
 The language of the arbitration shall be
English. Documents submitted in the arbitration (the originals of which are not in English) shall be submitted together with an English translation. 

  

					
		 	- 47 -	 	***Confidential Treatment Requested***

 19.3.2 Decision; Timing of Decisions 

The arbitrators shall render a written opinion setting forth findings of fact and conclusions of law with the reason therefor stated, within no later than
[...***...] from the date on which the arbitrators were appointed to the dispute. A transcript of the evidence adduced at the arbitration hearing shall be made and, upon request, shall be made available to each Party. 

The time periods set forth in the AAA Arbitration Rules shall be followed; provided, however that the arbitrators may modify such time periods as reasonably
necessary to render a written opinion in accordance with this Section 19.3.2. 
 The Arbitrator is empowered to award any remedy allowed by law,
including money damages, prejudgment interest and attorneys’ fees, and to grant final, complete, interim, or interlocutory relief, including injunctive relief. 

This arbitration agreement does not preclude either Party seeking conservatory or interim measures from any court of competent jurisdiction including, without
limitation, the courts having jurisdiction by reason of either Party’s domicile. Conservatory or interim measures sought by either Party in any one or more jurisdictions shall not preclude the arbitral tribunal from granting conservatory or
interim measures. Conservatory or interim measures sought by either Party before the tribunal shall not preclude any court of competent jurisdiction granting conservatory or interim measures. 

In the event that any issue shall arise which is not clearly provided for in this Section 19.3, the matter shall be resolved in accordance with the AAA
Arbitration Rules. 
 Any arbitration proceeding hereunder shall be confidential and the arbitrators shall issue appropriate protective orders to safeguard
each Party’s Confidential Information. Except as required by Applicable Law, neither Party shall make (or instruct the arbitrators to make) any public announcement with respect to the proceedings or decision of the arbitrators without prior
written consent of the other Party. The existence of any dispute submitted to arbitration, and the award, shall be kept in confidence by the Parties and the arbitrators, except as required in connection with the enforcement of such award or as
otherwise required by Applicable Law. 
 Notwithstanding anything to the contrary in this Agreement, any and all issues regarding the scope, construction,
validity and/or enforceability of any Patent Rights shall be determined in a court of competent jurisdiction under the local patent laws of the jurisdictions having issued the Patent Rights in question. 

Notwithstanding anything to the contrary in this Agreement, any and all issues regarding a breach or alleged breach of a Party’s obligations under
Article 16 (Obligation Not to Disclose Confidential Information) shall be determined in a court of competent jurisdiction under the laws of New York, with express exclusion of its conflict of laws principles. 

19.4 Assignment 
 Neither Party shall have the right to
assign the present Agreement or any part thereof to any Third Party other than Affiliates without the prior written approval of the other Party. 
 19.5
Compliance with Applicable Law 
 Each Party shall comply with Applicable Law in conducting activities and carrying out responsibilities under this
Agreement, including the U.S. Foreign Corrupt Practices Act of 1977 (as amended, collectively hereinafter the “FCPA”) and anti-bribery laws in the countries in the Territory where Roche has its principal place of business and where
it conducts activities under this Agreement. 

  

					
		 	- 48 -	 	***Confidential Treatment Requested***

 19.6 Debarment 

Each Party represents and warrants that it has never been debarred under 21 U.S.C. §335a, disqualified under 21 C.F.R. §312.70 or §812.119,
sanctioned by a Federal Health Care Program (as defined in 42 U.S.C §1320 a-7b(f)), including without limitation the federal Medicare or a state Medicaid program, or debarred, suspended, excluded or
otherwise declared ineligible from any other similar Federal or state agency or program. In the event a Party receives notice of debarment, suspension, sanction, exclusion, ineligibility or disqualification under the above-referenced statutes, such
Party shall [...***...]. 
 Each Party agrees that, to the best of its knowledge, none of its employees or agents conducting activities on its behalf
under the Agreement is currently or will be during the Agreement Term, debarred under 21 U.S.C. §335a, disqualified under 21 C.F.R. §312.70 or §812.119, sanctioned by a Federal Health Care Program (as defined in 42 U.S.C §1320 a-7b(f)), including without limitation the federal Medicare or a state Medicaid program, or debarred, suspended, excluded or otherwise declared ineligible from any other similar Federal or state agency or program.
In the event a Party learns that any such employee or agent becomes so debarred, sanctioned, suspended, excluded or declared ineligible or is the subject of proceedings that may result in such debarment, sanction, suspension, exclusion or
ineligibility, it will promptly so notify the other Party and will no longer allow such employee or agent to conduct activities under this Agreement. 

19.7 Independent Contractor 
 No employee or
representative of either Party shall have any authority to bind or obligate the other Party to this Agreement for any sum or in any manner whatsoever or to create or impose any contractual or other liability on the other Party without said
Party’s prior written approval. For all purposes, and notwithstanding any other provision of this Agreement to the contrary, FMI legal relationship to Roche under this Agreement shall be that of independent contractor. 

19.8 Unenforceable Provisions and Severability 
 If any of
the provisions of this Agreement are held to be void or unenforceable, then such void or unenforceable provisions shall be replaced by valid and enforceable provisions that will achieve as far as possible the economic business intentions of the
Parties. However the remainder of this Agreement will remain in full force and effect, provided that the material interests of the Parties are not affected, i.e. the Parties would presumably have concluded this Agreement without the unenforceable
provisions. 
 19.9 Waiver 
 The failure by either Party
to require strict performance and/or observance of any obligation, term, provision or condition under this Agreement will neither constitute a waiver thereof nor affect in any way the right of the respective Party to require such performance and/or
observance. The waiver by either Party of a breach of any obligation, term, provision or condition hereunder shall not constitute a waiver of any subsequent breach thereof or of any other obligation, term, provision or condition. 

19.10 Appendices 
 All Appendices to this Agreement shall
form an integral part to this Agreement. 

  

					
		 	- 49 -	 	***Confidential Treatment Requested***

 19.11 Entire Understanding 

This Agreement contains the entire understanding between the Parties hereto with respect to the within subject matter and supersedes any and all prior
agreements, understandings and arrangements, whether written or oral, including the Original Agreement. 
 19.12 Amendments 

No amendments of the terms and conditions of this Agreement shall be binding upon either Party hereto unless in writing and signed by both Parties. 

19.13 Invoices 
 All invoices that are required or
permitted hereunder shall be in writing and sent by FMI to Roche at the following address or other address as Roche may later provide: 
 F.
Hoffmann-La Roche Ltd 
 Kreditorenbuchhaltung 

4070 Basel 
 Switzerland 

19.14 Notice 
 All notices that are required or permitted
hereunder shall be in writing and sufficient if delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally recognized overnight courier or sent by
registered or certified mail, postage prepaid, return receipt requested, addressed as follows: 
  

			
	 if to FMI, to:
	 	 Foundation Medicine, Inc.

150 Second Street
 Cambridge, MA 02141

Attn: Legal Department

Facsimile No.: (617) 418-2201

		
	 if to Roche, to:
	 	 F. Hoffmann-La Roche Ltd

Grenzacherstrasse 124
 4070 Basel

Switzerland
 Attn: Legal Department Facsimile No.: +41 61 688 13
96

 or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in
accordance herewith. The effective date of any notice shall be: (a) the date of the addressee’s receipt, if delivered personally, by courier, or by registered or certified mail; or (b) the date of receipt if received by 5:00 p.m.
local time on a Business Day or, if not, the first Business Day after receipt, if sent by facsimile. 
 19.15 Subcontractors 

Subject to Section 2.1.2, either Party may perform any of its obligations under this Agreement, including under the Tactical Plans, Post Approval Plans,
and F1CDx Initial Launch Plans, through one or more subcontractors or consultants; provided that (i) such Party remains responsible for the work allocated to, and payment to, such subcontractors and consultants to the same extent it would if it
had done such work itself, and such Party shall be liable for any act or omission of such subcontractor and consultant that is a breach of any of such Party’s obligations under this Agreement as though the same were a breach by such Party, and
the other Party shall have the right to proceed directly against such Party without any obligation to first proceed against such 

  

					
		 	- 50 -	 	***Confidential Treatment Requested***

 
subcontractor or consultant; (ii) the subcontractor or consultant undertakes in writing commercially reasonable obligations of confidentiality and
non-use regarding Confidential Information, that are substantially the same as those undertaken by the Parties with respect to Confidential Information pursuant to Article 16 hereof; and (iii) the
subcontractor or consultant undertakes in writing to assign or exclusively license back (with the right to sublicense) all intellectual property with respect to Product developed in the course of performing any such work under the Tactical Plans,
Post Approval Plans, and F1CDx Initial Launch Plans to the subcontracting Party. Notwithstanding the above, if the work to be done by the subcontractor or consultant is material to the performance of a Party under this Agreement, then the Party
engaging such subcontractor or consultant shall seek the consent of the other Party, which consent shall not be unreasonably withheld. 
 19.16 Force
Majeure 
 Both Parties shall be excused from the performance of their obligations under this Agreement to the extent that such performance is prevented
or delayed by force majeure and the nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse shall be continued so long as the condition constituting force majeure continues and the nonperforming Party takes
reasonable efforts to remove the condition. For purposes of this Agreement, force majeure means conditions beyond the reasonable control of the Parties, including an act of God, war, civil commotion, terrorist act, labor strike or lock-out, epidemic, failure or default of public utilities or common carriers, destruction of production facilities or materials by fire, earthquake, storm or like catastrophe, and failure of plant or machinery
(provided that such failure could not have been prevented by the exercise of skill, diligence, and prudence that would be reasonably and ordinarily expected from a skilled and experienced person engaged in the same type of undertaking under the same
or similar circumstances). Notwithstanding the foregoing, a Party shall not be excused from making payments owed hereunder because of a force majeure affecting such Party. 

19.17 Rules of Construction 
 Each of the terms
“including,” “include,” and “includes” as used herein shall mean including, without limiting the generality of any description preceding each such term. As used herein, the term “day” shall mean a calendar
day. 
 [Signature Page Follows] 

  

					
		 	- 51 -	 	***Confidential Treatment Requested***

 IN WITNESS WHEREOF, the Parties have entered into this Agreement as of the Restatement Date. 

 

			
	Foundation Medicine, Inc.
	
	 /s/ Melanie Nallicheri

	Name:	 	Melanie Nallicheri
	Title:	 	CBO & Head Biopharma
	Date:	 	February 28, 2018

  

									
	F. Hoffmann-La Roche Ltd	 		 	
			
	/s/ Dr. Joerg
Kazenwadel                                        
     	 		 	 /s/ Stefan Arnold

	Name:	 	Dr. Joerg Kazenwadel	 		 	Name:	 	Stefan Arnold
	Title:	 	Head of R&D Out-Partnering	 		 	Title:	 	Head Legal Pharma
	Date:	 	February 28, 2018	 		 		 	

 Appendix 1.22 

Existing Third Party Rights 
 [...***...]

 [...***...] 
 [...***...] 

[...***...] 
 [...***...] 

[...***...] 

  

					
		 		 	***Confidential Treatment Requested***

 Appendix 2.3 

Product Specifications for the Initial Products as of the Effective Date 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

  
 A-1 

***Confidential Treatment Requested*** 

 [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...]

 [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

  
 A-2 

***Confidential Treatment Requested*** 

 [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...]

 [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

  
 A-3 

***Confidential Treatment Requested*** 

 [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...]

 [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

  
 A-4 

***Confidential Treatment Requested*** 

 [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...]

 [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

  
 A-5 

***Confidential Treatment Requested*** 

 [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...]

 [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

  
 A-6 

***Confidential Treatment Requested*** 

 [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...]

 [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

  
 A-7 

***Confidential Treatment Requested*** 

 [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...]

 [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

[...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] 

  
 A-8 

***Confidential Treatment Requested*** 

 Appendix 7.3.1 

Countries where Roche has launched FoundationOne 

as of the Restatement Date 

[...***...] 
 [...***...] 

[...***...] 
 [...***...] 

[...***...] 
 [...***...] 

[...***...] 
 [...***...] 

[...***...] 
 [...***...] 

[...***...] 
 [...***...] 

[...***...] 
 [...***...] 

[...***...] 
 [...***...] 

[...***...] 
 [...***...] 

[...***...] 
 [...***...] 

[...***...] 
 [...***...] 

[...***...] 
 [...***...] 

[...***...] 
 [...***...] 

[...***...] 

  

					
		 		 	***Confidential Treatment Requested***

 Appendix 7.7 

Localization of Professional Services Section of F1CDx Report 

Professional Services localization – in scope: 

[...***...] 
 Professional Services localization
– not in scope: 
 If so requested by Roche and permitted (or required) by Applicable Law, FMI shall not be required to make any localization
changes not reflected in the “in scope” list above. For the avoidance of doubt, the Parties agree that the following services are specifically not in scope: 

[...***...] 

  

					
		 		 	***Confidential Treatment Requested***cosm_ex101.htm

EXHIBIT 10.1
  
 SHARE EXCHANGE AGREEMENT
  
 THIS SHARE EXCHANGE AGREEMENT is made as of the 26th day of June, 2018 and is 
  
 AMONG 
  
 THE PERSONS IDENTIFIED ON SCHEDULE A TO THIS AGREEMENT AS THE SELLERS,
  
 (together, the “Sellers”)
  
 AND
  
 MARATHON GLOBAL INC., a corporation incorporated under the laws of the Province of Ontario
  
 (“Marathon”)
  
 AND
  
 KANEH BOSM BIOTECHNOLOGY INC., a corporation incorporated under the laws of the Province of British Columbia
  
 (“KBB”)
  
 RECITALS:
  
  	A.	Marathon has an aggregate of seventeen million (17,000,000) common shares issued and outstanding.
	  
	  

	B.	KBB owns an aggregate of eight million five hundred thousand (8,500,000) common shares in the capital Marathon, representing 50% of the issued and outstanding common shares of Marathon.
	  
	  

	C.	KBB is a reporting issuer in the provinces of British Columbia, Alberta and Ontario with its common shares listed for trading on the Canadian Securities Exchange.
	  
	  

	D.	The Sellers are the registered and beneficial owners of an aggregate of the remaining eight million five hundred thousand (8,500,000) common shares in the capital of Marathon, representing 50% of the issued and outstanding common shares of Marathon (the “Purchased Shares”).
	  
	  

	E.	The Sellers wish to sell to KBB, and KBB wishes to purchase from the Sellers, all of the Purchased Shares on the terms and conditions set forth in this Agreement.
	  
	  

	F.	Upon completion of the transactions contemplated in this Agreement, KBB will be the sole shareholder of Marathon.

  
  	 
	- 1 -
	 
 
	 

   
 IN CONSIDERATION of the premises and mutual covenants hereinafter contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by each of the parties hereto, the parties agree with one another as follows:
  
  	1.	Definitions and Interpretation
	  
	  

	1.1 	Definitions. Whenever used in this Agreement, the following words and terms will have the respective meanings ascribed to them below:

  
  	  
	1.1.1 	“Agreement” means this Share Exchange Agreement, all of the Schedules to this Share Exchange Agreement and all instruments supplemental to or in amendment or confirmation of this Share Exchange Agreement.
	  
	  
	  

	  
	1.1.2	“Assets” means the undertaking, property and assets of Marathon or KBB, as the case may be, as a going concern of every kind and description, wheresoever situated.
	  
	  
	  

	  
	1.1.3 	“Business” means in the case of KBB, as applicable, its current business as presently conducted, as disclosed in the KBB Public Record.
	  
	  
	  

	  
	1.1.4	 “Closing” means the completion of the purchase and sale of the Purchased Shares pursuant to this Agreement.
	  
	  
	  

	  
	1.1.5 	“Closing Date” means the date on which the purchase and sale of all of the issued and outstanding Marathon Shares is completed, which shall be the date mutually agreed by Marathon and KBB.
	  
	  
	  

	  
	1.1.6 	“Closing Time” means 10:00 a.m. (Toronto time) on the Closing Date or such other time on such date as the parties may agree as the time at which the Closing will take place.
	  
	  
	  

	  
	1.1.7 	“Damages” has the meaning given in Section 6.1.
	  
	  
	  

	  
	1.1.8 	“Encumbrance” means any lien, pledge, hypothecation, charge, mortgage, security interest, encumbrance, claim, infringement, interference, option, right of first refusal, pre-emptive right, community property interest or restriction of any nature (including any restriction on the voting of any security, any restriction on the transfer of any security or other asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any asset and any restriction on the possession, exercise or transfer of any other attribute of ownership of any asset).
	  
	  
	  

	  
	1.1.9 	“Exchange” means the Canadian Securities Exchange.
	  
	  
	  

	  
	1.1.10 	“Governmental Authority” means any federal, provincial, state, municipal, county or regional government or governmental authority, domestic or foreign and includes any department, commission, board, administrative agency or regulatory body thereof.

   
  	 
	- 2 -
	 
 
	 

  
  	  
	1.1.11 	“IFRS” means International Financial Reporting Standards.
	  
	  
	  

	  
	1.1.12 	“Intellectual Property Rights” means all patents and inventions, trademarks, trade names and styles, logos and designs, service marks, trade dress, industrial designs, internet domain names, world wide websites, website names, electronic mail addresses, copyrights, trade secrets, technical information, engineering procedures, designs, know-how and processes (whether confidential or otherwise), software, other industrial property (including applications for any of these) and other similar rights and properties.
	  
	  
	  

	  
	1.1.13 	“KBB Financial Statements” means the audited consolidated financial statements of KBB for the fiscal years ended February 29, 2017 and February 28, 2016, and the unaudited consolidated financial statements of KBB for the period ended November 30, 2017, copies of which have been filed by KBB on SEDAR.
	  
	  
	  

	  
	1.1.14 	“KBB Public Record” means all publicly available press releases, material change reports, annual information forms, information circulars, financial statements and other documents that have been disclosed by KBB to the public and filed with any applicable Canadian or other securities regulatory authority or otherwise posted on SEDAR.
	  
	  
	  

	  
	1.1.15 	“KBB Shares” means the common shares in the capital of KBB as they are presently constituted.
	  
	  
	  

	  
	1.1.16 	“Marathon Shares” means the common shares in the capital of Marathon as they are presently constituted.
	  
	  
	  

	  
	1.1.17 	“Payment Shares” has the meaning given in Section 2.2.
	  
	  
	  

	  
	1.1.18 	“Person” includes an individual, corporation, partnership, joint venture, trust, unincorporated organization, the Crown or any agency or instrumentality thereof or any other juridical entity.
	  
	  
	  

	  
	1.1.19 	“Purchase Price” has the meaning given in Section 2.2.
	  
	  
	  

	  
	1.1.20 	“Purchased Shares” has the meaning given in the recitals above.
	  
	  
	  

	  
	1.1.21 	“SEDAR” means the System for Electronic Document Analysis and Retrieval.
	  
	  
	  

	  
	1.1.22 	“Subsidiary” (“Subsidiaries” in the plural) means, with respect to a specified body corporate, any body corporate of which more than 50% of the outstanding shares ordinarily entitled to elect a majority of the board of directors thereof (whether or not shares of any other class or classes will or might be entitled to vote upon the happening of any event or contingency) are at the time owned directly or indirectly by such specified body corporate and will include any body corporate, partnership, joint venture or other entity over which it exercises direction or control.
	  
	  
	  

	  
	1.1.23 	“Taxes” means all levies and assessments imposed by any Governmental Authority, including but not limited to all income, sales, use, ad valorem, value added, franchise, withholding, payroll, employment, excise or property taxes, together with any applicable interest or penalty.

  
  	 
	- 3 -
	 
 
	 

   
  	1.2 	Gender and Number. In this Agreement, words importing the singular include the plural and vice versa and words importing gender include all genders.
	  
	  

	1.3 	Article and Section Headings. Article and Section headings contained in this Agreement are included solely for convenience, are not intended to be full or accurate descriptions of the content of any Article or Section and will not be considered to be part of this Agreement.
	  
	  

	1.4 	Schedules. The following Schedules are an integral part of this Agreement:
	  
	  

		Schedule A – The Sellers, Purchased Shares and Payment Shares
	  
	  

	1.5 	Accounting Terms. Unless otherwise indicated, all accounting terms not otherwise defined have the meanings assigned to them, and all calculations are to be made and all financial data to be submitted are to be prepared, in accordance with IFRS.
	  
	  

	1.6 	Arm’s Length. For purposes of this Agreement, Persons are not dealing “at arm’s length” with one another if they would not be considered to be dealing at arm’s length with one another for purposes of the Income Tax Act (Canada), as amended.
	  
	  

	1.7 	Statutory Instruments. Unless otherwise specifically provided in this Agreement, any reference in this Agreement to any law, by law, rule, regulation, order, act or statute of any government, Governmental Authority or other regulatory body will be construed as a reference to those as amended or re-enacted from time to time or as a reference to any successor thereof.
	  
	  

	2.	Purchase and Sale
	  
	  

	2.1 	Purchased Shares. Upon and subject to the terms of this Agreement, the Sellers agree to sell, assign and transfer, free and clear of all Encumbrances, and KBB agrees to purchase, all of the Purchased Shares, as at the Closing Time on the Closing Date, in accordance with subsection 2.3.1 below.
	  
	  

	2.2 	Purchase Price. The aggregate purchase price (the “Purchase Price”) payable by KBB to the Sellers for the Purchased Shares shall be the issuance to the Sellers of an aggregate of 15,000,000 KBB Shares (the “Payment Shares”) as fully paid and non-assessable. The Payment Shares will be allocated among the Sellers as set forth in Schedule A.

  
  	 
	- 4 -
	 
 
	 

   
  	2.3 	Acknowledgements and Agreements of the Sellers. Each of the Sellers acknowledges and agrees as follows with respect to the sale of the Purchased Shares and the receipt of the Payment Shares by such Seller pursuant to this Agreement:

   
  	  
	2.3.1 	Effective as at the Closing Time (i) the Sellers shall be deemed to have sold, assigned and transferred the Purchased Shares to KBB, (ii) KBB shall be delivered one or more share certificates registered as directed by KBB representing the total number of Marathon Purchased Shares, (iii) the Payment Shares shall be issued to the Sellers, allocated among the Sellers pursuant to section 2.2 above, and evidenced by certificates delivered to the Sellers representing the Payment Shares, and (iv) any certificates representing the Purchased Shares held by the Sellers shall be cancelled and thereafter shall be of no further force or effect.
	  
	  
	  

	  
	2.3.2 	Such Seller has been independently advised as to the applicable hold periods imposed in respect of the Payment Shares by the securities legislation in the jurisdiction in which such Seller resides, and such Seller confirms that no representation has been made respecting the applicable hold periods for the Payment Shares and that such Seller is aware of the risks and other characteristics of the Payment Shares and of the fact that such Seller may not resell the Payment Shares except in accordance with applicable securities legislation and regulatory policy until expiry of the applicable hold periods and compliance with the other requirements of applicable law. Such Seller acknowledges that the certificates representing the Payment Shares will contain legends denoting the applicable resale restrictions, if any, and such Seller will not resell the Payment Shares except in accordance with the provisions of applicable securities legislation and Exchange rules.
	  
	  
	  

	  
	2.3.3 	Such Seller has been advised that no prospectus has been filed in connection with the issuance and granting of the Payment Shares and as the Payment Shares are being issued and granted to the Sellers pursuant to exemptions from the prospectus requirements of applicable securities laws:

   
  	  
	(a)	most of the civil remedies applicable to the issuance and granting of securities by way of prospectus provided for in such laws are not available to such Seller;
	  
	  
	  

	  
	(b)	such Seller may not receive information that would be provided if no such exemptions were available; and
	  
	  
	  

	  
	(c)	KBB is relieved of certain obligations in respect of offerings by way of prospectus which would otherwise apply under applicable securities laws.

   
  	  
	2.3.4 	Such Seller will comply with any requirements imposed by the Exchange or securities legislation as a result of the shareholdings of such Seller in KBB exceeding certain thresholds, such requirements to include, without limitation, the filing of insider and early warning reports under applicable Canadian securities laws.

  
  	 
	- 5 -
	 
 
	 

   
  	3.	Representations and Warranties

  
  	3.1 	Representations and Warranties of Marathon. Marathon represents, warrants and covenants to KBB as follows, and acknowledges that KBB is relying on these representations, warranties and covenants in entering into this Agreement and in completing the transactions contemplated hereby:

   
  	  
	3.1.1 	Organization and Good Standing – Marathon is duly incorporated or organized and validly existing under the laws of the Province of Ontario.
	  
	  
	  

	  
	3.1.2 	Bankruptcy – No bankruptcy, insolvency or receivership proceedings have been instituted or are pending against Marathon, and Marathon is able to satisfy its liabilities as they become due.
	  
	  
	  

	  
	3.1.3 	Due Authorization – Marathon has all necessary power, authority and capacity to enter into this Agreement and to perform its obligations under this Agreement. The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby have been duly authorized by all necessary action on the part of Marathon.
	  
	  
	  

	  
	3.1.4 	Authorized and Issued Capital – The authorized capital of Marathon consists of an unlimited number of common shares and an unlimited number of special shares, issuable in series, of which 17,000,000 Marathon Shares have been validly issued and are outstanding as fully paid and non-assessable. The Sellers are the registered owners of all of the Purchased Shares and the Purchased Shares are held by them as set out in Schedule A.
	  
	  
	  

	  
	3.1.5 	Enforceability of Obligations – This Agreement constitutes a valid and binding obligation of Marathon enforceable against Marathon in accordance with its terms, provided that enforcement may be limited by bankruptcy, insolvency, liquidation, reorganization, reconstruction and other similar laws generally affecting enforceability of creditors’ rights and that equitable remedies such as specific performance and injunction are in the discretion of the court from which they are sought.
	  
	  
	  

	  
	3.1.6 	Subsidiaries – Marathon does not have any Subsidiaries.
	  
	  
	  

	  
	3.1.7 	Assets - Marathon is party to a Distribution and Equity Acquisition Agreement (the “Distribution Agreement”) dated March 19, 2018, as amended, with Cosmos Holdings Inc. (“Cosmos”). The execution and delivery of this Agreement and the performance by Marathon and the Sellers, and their respective obligations hereunder as agreed to by Marathon and Cosmos, do not and will not result in or constitute a breach of any term or provision of, or constitute a default, under the Distribution Agreement or constitute an event which would permit Cosmos to terminate the Distribution Agreement or to accelerate other obligations of Marathon.

  
  	 
	- 6 -
	 
 
	 

  
  	3.2 	Representations and Warranties of the Sellers: Each Seller severally (and not jointly or jointly and severally) makes the following representations and warranties to KBB and acknowledges that KBB is relying on such representations and warranties in entering into this Agreement and in completing the transactions contemplated under this Agreement:

   
  	  
	3.2.1 	The Purchased Shares – Such Seller is the legal and beneficial owner of the number of Purchased Shares shown as held by such Seller on Schedule A and on Closing KBB will acquire good and marketable title to such Purchased Shares free and clear of all Encumbrances.
	  
	  
	  

	  
	3.2.2 	Litigation (Shares) – There is no suit, action, litigation, arbitration proceeding or governmental proceeding, including appeals and applications for review, in progress, pending or threatened against such Seller relating to the Purchased Shares.
	  
	  
	  

	  
	3.2.3 	Enforceability of Obligations – When executed and delivered, this Agreement will constitute valid and legally binding obligations enforceable against such Seller in accordance with its terms subject, however, to limitations with respect to enforcement imposed by law in connection with bankruptcy or similar proceedings and to the extent that equitable remedies such as specific performance and injunction are in the discretion of the court from which they are sought.
	  
	  
	  

	  
	3.2.4 	Residence – Such Seller is resident in the jurisdiction set out opposite its name on Schedule A.
	  
	  
	  

	  
	3.2.5 	Corporate Seller – If the Seller is a corporation:

   
  	  
	(a)	it is duly incorporated or organized and validly existing in its jurisdiction of incorporation and is in good standing with respect to the filing of annual reports; and
	  
	  
	  

	  
	(b)	it has all necessary power, authority and capacity to enter into this Agreement and to perform its obligations under this Agreement; and the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby have been duly authorized by all necessary action on the part of such Seller.

   
  	3.3 	Representations and Warranties of KBB. KBB hereby represents, warrants and covenants to Marathon and the Sellers as follows and acknowledges that Marathon and the Sellers are relying on these representations, warranties and covenants in entering into this Agreement and in completing the transactions contemplated under this Agreement:

  
  	 
	- 7 -
	 
 
	 

   
  	  
	3.3.1 	Organization and Good Standing – KBB is duly incorporated or organized and validly existing under the laws of the Province of British Columbia, Canada.
	  
	  
	  

	  
	3.3.2 	Bankruptcy – No bankruptcy, insolvency or receivership proceedings have been instituted or are pending against KBB, and KBB is able to satisfy its liabilities as they become due.
	  
	  
	  

	  
	3.3.3 	Capacity to Carry on Business – KBB has all necessary corporate power, authority and capacity to own its Assets and to carry on its business as presently owned and carried on by it and KBB is duly licensed, registered and qualified as a corporation to do business and is in good standing in each jurisdiction in which the nature of its business makes such qualification necessary.
	  
	  
	  

	  
	3.3.4 	Due Authorization – KBB has all necessary power, authority and capacity to enter into this Agreement and to perform its obligations under this Agreement. The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby have been duly authorized by all necessary action on the part of KBB.
	  
	  
	  

	  
	3.3.5 	Authorized and Issued Capital – The authorized capital of KBB consists of an unlimited number of common shares, of which 38,009,108 KBB Shares have been validly issued and are outstanding as fully paid and non-assessable.
	  
	  
	  

	  
	3.3.6 	Absence of Conflicting Agreements – The execution and delivery of this Agreement and the performance by KBB and its obligations hereunder do not and will not:

   
  	  
	(a)	result in the violation of any applicable laws;
	  
	  
	  

	  
	(b)	result in or constitute a breach of any term or provision of, or constitute a default under, any constating documents of KBB or any agreement to which KBB is a party or its Assets are bound; or
	  
	  
	  

	  
	(c)	constitute an event which would permit any party to any agreement with KBB to terminate such agreement or to accelerate the maturity of any indebtedness or other obligation of KBB.

   
  	  
	3.3.7 	Consents – There are no consents, authorizations, licenses, agreements, permits, approvals or orders of any Person or Governmental Authority required to permit KBB to complete the transactions contemplated by this Agreement other than those that have already been obtained by KBB and disclosed by KBB to Marathon.
	  
	  
	  

	  
	3.3.8 	Rights and Privileges – There are no rights, privileges or advantages presently enjoyed by KBB which might be lost as a result of the consummation of the transactions contemplated under this Agreement.
	  
	  
	  

	  
	3.3.9 	Enforceability of Obligations – This Agreement constitutes a valid and binding obligation of KBB enforceable against KBB in accordance with its terms, provided that enforcement may be limited by bankruptcy, insolvency, liquidation, reorganization, reconstruction and other similar laws generally affecting enforceability of creditors’ rights and that equitable remedies such as specific performance and injunction are in the discretion of the court from which they are sought.

   
  	 
	- 8 -
	 
 
	 

  
  	  
	3.3.10 	Books and Records – The books and records of KBB are fully and accurately maintained and its books of account provide for all excise, sales, business and property taxes and other rates, charges, assessments, levies, duties, taxes, contributions, fees, licenses and other governmental charges of whatsoever kind and nature that have become due and payable or, to the extent such amount is material, that may become due and payable before the Closing Time. The minute books of KBB are complete and accurate in all material respects and reflect all material actions taken and resolutions passed by the directors and shareholders, as the case may be, of KBB, since the date of incorporation or organization.
	  
	  
	  

	  
	3.3.11 	Financial Statements – The KBB Financial Statements are true and correct in every material respect and present fairly the Assets, liabilities and financial position of KBB as at November 30, 2017, and the results of its operations to that date, in accordance with IFRS applied on a basis consistent with that of previous periods.
	  
	  
	  

	  
	3.3.12 	No Other Liabilities – There are no liabilities, contingent or otherwise, of KBB which are not disclosed or reflected in the KBB Financial Statements except those incurred in the ordinary course of business and KBB has not guaranteed, or agreed to guarantee, any debt, liability or other obligation of any Person. There are no liabilities of any Person capable of creating an Encumbrance on any of KBB’s Assets.
	  
	  
	  

	  
	3.3.13 	Non-Arm’s Length Obligations – KBB is not indebted to any shareholder, affiliate, director, officer or employee of KBB except as shown on the KBB Financial Statements and none of the shareholders or any affiliate, officer, director or employee of KBB is now indebted or under obligation to KBB on any account.
	  
	  
	  

	  
	3.3.14 	Absence of Changes – Since November 30, 2017, KBB’s Business has been carried on in the normal course and:

   
  	  
	(a)	no dividend or other distribution on any shares in the capital of KBB has been made, declared or authorized and KBB has neither purchased nor redeemed nor agreed to purchase or redeem any of the shares in its capital;
	  
	  
	  

	  
	(b)	no payment of any kind has been made or authorized to or on behalf of any officers, directors or shareholders of KBB; and KBB (i) has not paid or agreed to pay any compensation, pension, bonus, share of profits or other benefit to, or for the benefit of, any employee, director or officer of KBB except in the ordinary course of business and (ii) has not increased or agreed to increase the compensation of any director, officer or management employee except in the ordinary course of business;

  
  	 
	- 9 -
	 
 
	 

   
  	  
	(c)	there has not been any material adverse change in the financial position or condition of KBB or any damage, loss or other material adverse change in circumstances affecting KBB’s Business or Assets or the right or capacity of KBB to carry on business;
	  
	  
	  

	  
	(d)	KBB has not transferred, assigned, sold or otherwise disposed of any of its Assets except in the ordinary course of business and has not mortgaged, pledged, subjected to lien, granted a security interest in or otherwise encumbered any of its Assets;
	  
	  
	  

	  
	(e)	KBB has not discharged or satisfied any Encumbrance or paid any obligation or liability (fixed or contingent) other than liabilities included in the KBB Financial Statements and liabilities incurred since incorporation in the ordinary course of business;
	  
	  
	  

	  
	(f)	KBB has not suffered an extraordinary loss, or waived any rights of material value, or entered into any material commitment or transaction not in the ordinary course of business; and
	  
	  
	  

	  
	(g)	KBB has not incurred or assumed any obligation or liability (fixed or contingent), except secured and unsecured current obligations and liabilities incurred in the ordinary course of business.

   
  	  
	3.3.15 	Subsidiaries –KBB has the following Subsidiaries:

   
 	 Subsidiary Name
	  
	 Jurisdiction
	  
	 Ownership
	  

	 Kaneh Bosm BioTechnology Inc.
	  
	 British Columbia
	  
	 100
	 % 

	 Canna Colombia Holdings Inc.
	  
	 Ontario
	  
	  
	100	%

  
  	  
	3.3.16 	Since November 30, 2017, other than in respect of the transactions contemplated by this Agreement:

   
  	  
	(a)	KBB has not incurred any liabilities or obligations (whether accrued, absolute, contingent or otherwise), which continue to be outstanding; and
	  
	  
	  

	  
	(b)	there has not been any material change in the financial condition, operations or prospects of KBB not fully disclosed in the KBB Public Record.

  
  	  
	3.3.17 	Litigation (KBB) – There is no suit, action, litigation, arbitration proceeding or governmental proceeding, including appeals and applications for review, in progress, pending or to the knowledge of KBB, threatened against or relating to KBB. There is not presently outstanding against KBB any judgement, decree, injunction, rule or order of any court, Governmental Authority, commission, agency, instrumentality or arbitrator.

  
  	 
	- 10 -
	 
 
	 

   
  	  
	3.3.18 	Litigation (Shares) – There is no suit, action, litigation, arbitration proceeding or governmental proceeding, including appeals and applications for review, in progress, pending or threatened against KBB relating to the Payment Shares.
	  
	  
	  

	  
	3.3.19 	Compliance with Applicable Laws – KBB has conducted and is conducting its Business in compliance in all material respects with all applicable laws, rules and regulations in each jurisdiction in which its Business is carried on. KBB has not received any notices to the effect that its Business or Assets are not in full compliance with all of the requirements of applicable federal, provincial or local environmental, health and safety statutes and regulations.
	  
	  
	  

	  
	3.3.20 	Compliance with Securities Laws – KBB is in compliance with its timely disclosure obligations under applicable securities laws, and no order ceasing or suspending trading in securities of KBB or prohibiting the transactions contemplated hereby has been issued and no proceedings for such purpose are ongoing or pending, or to the best knowledge of KBB, threatened.
	  
	  
	  

	  
	3.3.21 	Tax Matters – As of the date of this Agreement, KBB has duly and timely filed all tax returns and reports required by law to have been filed by it (except for such tax returns and reports with respect to which the failure to timely file would not have a materially adverse effect on KBB), has duly and correctly reported all income and other amounts required to be reported and has paid all Taxes to the extent that such Taxes have been assessed by the relevant taxation authority. KBB has duly and timely paid all installments of Taxes required to be paid by it and has made full provision on its books for all Taxes that are not yet due, that will become due and which relate to periods ending immediately prior to the date of this Agreement. There are no actions, suits, proceedings, investigations, audits or claims now pending or, to the knowledge of KBB, threatened against KBB in respect of any Taxes and there are no matters under discussion with any taxation or other Government Authority relating to any such matters. KBB has made all elections required to be made under any legislation relating to income or other taxes payable by it in connection with any distributions by it and all such elections were true and correct. KBB has not before the date of this Agreement:

   
  	  
	(a)	acquired any asset from a Person with whom it was not dealing at arm’s length; or
	  
	  
	  

	  
	(b)	disposed of anything to a Person with whom it was not dealing at arm’s length for proceeds less than the fair market value.

  
  	 
	- 11 -
	 
 
	 

   
  	  
	3.3.22 	The Payment Shares – On Closing the Payment Shares:

   
  	  
	(a)	will be issued to the Sellers as fully paid and non-assessable KBB Shares;
	  
	  
	  

	  
	(b)	will be duly registered in the names of the Sellers in the books and registers of KBB; and
	  
	  
	  

	  
	(c)	will be conditionally approved for listing and posting for trading on the Exchange, subject only to satisfying any conditions stipulated by the Exchange for listing.

   
  	  
	3.3.23 	KBB Public Record – The KBB Public Record is, in all material respects, accurate and complete and omits no facts, the omission of which makes the KBB Public Record or any particulars therein, materially misleading or incorrect at the time such statements were made. KBB has not filed any confidential material change reports which are, as of the date of this Agreement, maintained on a confidential basis. Except as disclosed in the KBB Public Record, there is no fact known to KBB which has, or so far as KBB which has, or so far as KBB can reasonably foresee, will have a material adverse effect, or which would otherwise be material to any person intending to make an investment in KBB.
	  
	  
	  

	  
	3.3.24 	Title to Properties – KBB has good and marketable title to all its Assets, real and personal, including without limitation those reflected in the KBB Financial Statements or acquired since the date of such statements (except as otherwise permitted in this Agreement or as since transferred, sold or otherwise disposed of in the ordinary course of business), free and clear of all Encumbrances.
	  
	  
	  

	  
	3.3.25 	Intellectual Property Rights – KBB has all Intellectual Property Rights which are necessary to the conduct of its Business. KBB’s Intellectual Property Rights are valid and subsisting and held by KBB with good and marketable title and are in good standing free and clear of all Encumbrances. All registrations with respect to KBB’s Intellectual Property Rights have been made and kept renewed and are in full force and effect. To the knowledge of KBB, the operation of KBB’s Business does not infringe the Intellectual Property Rights of any other Person. To the knowledge of KBB, there are no outstanding moral rights attaching to any copyright owned or used by KBB that have not been waived in favour of KBB.
	  
	  
	  

	  
	3.3.26 	Condition of Assets – All material tangible Assets of KBB used in or in connection with its Business are in good condition, repair and, where applicable, working order, having regard to ordinary wear and tear resulting from the use and age thereof.
	  
	  
	  

	  
	3.3.27 	Shareholders’ Agreements – There is no agreement among any of the shareholders of KBB with respect to KBB and their rights and obligations as shareholders of KBB to which KBB is a party.
	  
	  
	  

	  
	3.3.28 	Disclosure – None of the foregoing representations, warranties and statements of fact contains any untrue statement of material fact or omits to state any material fact necessary to make any such representation, warranty or statement not misleading to a prospective holder of Payment Shares seeking full information concerning the matters which are the subject of such representations, warranties and statements.

   
  	 
	- 12 -
	 
 
	 

  
  	3.4 	Survival. The representations, warranties and covenants made by the parties in sections 3.1, 3.2, and 3.3 shall terminate (and be of no further force or effect) on the earlier of: (a) the termination of this Agreement in accordance with its terms; and (b) the Closing Time.
	  
	  

	3.5 	Investigation. No investigation by or on behalf of Marathon or the Sellers into the Business, operations prospects, Assets, or condition (financial or otherwise) of KBB will diminish in any way the effect of any representations or warranties made by KBB in this Agreement or will relieve KBB of any of its obligations under this Agreement.

   
  	4.	Covenants

 
  	4.1 	Covenants of Marathon, and the Sellers. Until the earlier of the Closing Time or the termination of this Agreement in accordance with its terms, each of the Sellers and Marathon severally (and not jointly or jointly and severally) hereby covenants and agrees with KBB as follows:

   
  	  
	4.1.1 	Necessary Consents. The Sellers and Marathon shall use commercially reasonable efforts to obtain all approvals or consents as are required to complete the transactions contemplated by this Agreement, including those of the directors and shareholders of Marathon or any applicable Governmental Authority; and if applicable, of Cosmos with respect to the Distribution Agreement.
	  
	  
	  

	  
	4.1.2 	Satisfaction of Conditions Precedent. Each of the Sellers and Marathon shall use commercially reasonable efforts to satisfy or cause to be satisfied the conditions precedent to the transactions contemplated herein which are within his, her or its control.
	  
	  
	  

	  
	4.1.3 	All other Actions. The Sellers and Marathon shall cooperate fully with KBB, and will use all commercially reasonable efforts to assist KBB in its efforts to complete the transactions contemplated by this Agreement, unless such cooperation and efforts would subject the Sellers or Marathon to any extraordinary cost or liability or would be in breach of any applicable statutory or regulatory requirements.

   
  	4.2	Covenants of KBB. KBB hereby covenants and agrees with the Sellers and Marathon as follows:

   
  	  
	4.2.1 	Necessary Consents. KBB shall use commercially reasonable efforts to obtain all approvals or consents as are required to complete the transactions contemplated by this Agreement, including those of the directors and shareholders of KBB, the Exchange or any applicable Governmental Authority.
	  
	  
	  

	  
	4.2.2	Satisfaction of Conditions Precedent. KBB shall use commercially reasonable efforts to satisfy or cause to be satisfied the conditions in section 5.1 and 5.3 which are within its control.

  
  	 
	- 13 -
	 
 
	 

   
  	  
	4.2.3 	All other Actions. KBB shall cooperate fully with the Sellers and Marathon and will use all commercially reasonable efforts to assist the Sellers and Marathon in their efforts to complete the transactions contemplated by this Agreement, unless such cooperation and efforts would subject KBB to any extraordinary cost or liability or would be in breach of any applicable statutory or regulatory requirements.
	  
	  
	  

	  
	4.2.4 	Material Changes. KBB shall promptly advise Marathon in writing of any event, change or development that has or is reasonably expected to have an adverse effect in respect of the KBB or the transactions contemplated hereunder.

   
  	5.	Conditions Precedent

  
  	5.1 	Conditions Precedent for the Benefit of Marathon. The obligation of Marathon to complete the transactions contemplated by this Agreement are subject to the satisfaction of, or compliance with, at or before the Closing Time, each of the following conditions precedent (each of which is hereby acknowledged to be inserted for the exclusive benefit of Marathon and may be waived by it in whole or in part):

   
  	  
	5.1.1 	Truth of Representations and Warranties – The representations and warranties of KBB and the Sellers contained in this Agreement will be true and correct on and as of the Closing Date as though made at and as of the Closing Date.
	  
	  
	  

	  
	5.1.2 	Covenants and Agreements – Each of KBB and the Sellers will have satisfied and complied with all covenants and agreements in this Agreement agreed to be performed or caused to be performed by him, her or it on or before the Closing Time.
	  
	  
	  

	  
	5.1.3 	Consents – All consents, approvals, orders and authorizations of or from Governmental Authorities or the Exchange required in connection with the completion of the transactions contemplated by this Agreement will have been obtained on or before the Closing Time on terms and conditions satisfactory to Marathon, including the conditional approval of the listing of the Payment Shares.
	  
	  
	  

	  
	5.1.4 	No Material Adverse Change – No material adverse change (nor any condition, event or development involving a prospective material adverse change) shall have occurred in the Business, Assets, operations, capital or financial condition of KBB.
	  
	  
	  

	  
	5.1.5 	Closing Documents – KBB and the Sellers will have tendered the documents to be delivered by them at Closing in accordance with this Agreement.

  
  	5.2 	Non-satisfaction of Conditions. If any of the conditions set forth in Section 5.1 are not fulfilled or waived to the reasonable satisfaction of Marathon, Marathon may, acting reasonably, terminate this Agreement by notice in writing to KBB. In such event, Marathon will be released from all obligations under this Agreement and KBB will also be so released unless they were reasonably capable of causing such condition or conditions to be fulfilled or they have breached any of their representations, warranties, covenants or agreements in this Agreement.

   
  	 
	- 14 -
	 
 
	 

  
  	5.3 	Conditions Precedent for the Benefit the Sellers. The obligations of each of the Sellers to complete the transactions contemplated by this Agreement are subject to the satisfaction of, or compliance with, at or before the Closing Time, each of the following conditions precedent (each of which is hereby acknowledged to be inserted for the exclusive benefit of each of the Sellers and may be waived by him, her or it in whole or in part):

   
  	  
	5.3.1 	Truth of Representations and Warranties – The representations and warranties of each of KBB and Marathon contained in this Agreement will be true and correct on and as of the Closing Date as though made at and as of the Closing Date.
	  
	  
	  

	  
	5.3.2 	Covenants and Agreements – Each of KBB and Marathon will have complied with all covenants and agreements in this Agreement agreed to be performed or caused to be performed by it on or before the Closing Time.
	  
	  
	  

	  
	5.3.3 	Consents – All consents, approvals, orders and authorizations of or from Governmental Authorities or the Exchange required in connection with the completion of the transactions contemplated by this Agreement will have been obtained on or before the Closing Time on terms and conditions satisfactory to the Sellers, including the conditional approval of the Exchange to the listing of the Payment Shares.
	  
	  
	  

	  
	5.3.4 	No Material Adverse Change – No material adverse change (nor any condition, event or development involving a prospective material adverse change) shall have occurred in the Business, Assets, operations, capital or financial condition of KBB.
	  
	  
	  

	  
	5.3.5 	The Payment Shares – When issued, the Payment Shares, will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities law.
	  
	  
	  

	  
	5.3.6 	Closing Documents – KBB and Marathon will have tendered the documents to be delivered by it at Closing in accordance with this Agreement.

   
  	5.4 	Non-satisfaction of Conditions. If any of the conditions set forth in Section 5.3 are not fulfilled or waived to the reasonable satisfaction of the Sellers, the Sellers may, acting reasonably, terminate this Agreement by notice in writing to KBB and Marathon. In such event the Sellers and Marathon will be released from all obligations under this Agreement and KBB will also be so released unless it was reasonably capable of causing such condition or conditions to be fulfilled or it has breached any of its representations, warranties, covenants or agreements in this Agreement.
	  
	  

	5.5 	Waivers. Each of the parties on his, her or its behalf, may waive any condition for his, her or its benefit in this Agreement, in whole or in part, without prejudice to any right of rescission or any other right in the event of the non-fulfilment of any other condition or conditions. A waiver will only be binding if it is in writing.

  
  	 
	- 15 -
	 
 
	 

  
  	6.	Indemnification
	  
	  

	6.1	Indemnification by KBB. KBB agrees to indemnify and save harmless Marathon from and against any and all losses, debts, obligations, liabilities, expenses, costs and damages (including reasonable legal fees) (collectively, the “Damages”) suffered or incurred by Marathon as a result of any breach of, or untruth of, any of the covenants, warranties or representations contained in section 3.3 and 4.2 of this Agreement.
	  
	  

	6.2 	Indemnification by Marathon. Marathon agrees to indemnify and save harmless KBB from and against any and all Damages suffered or incurred by KBB as a result of any breach of, or untruth of, any of the covenants, warranties or representations contained in section 3.1, or 4.1 of this Agreement.
	  
	  

	7.	Closing Arrangements
	  
	  

	7.1 	The closing of this transaction shall take place at the offices of Irwin Lowy LLP, located at 365 Bay Street, Suite 400, on the Closing Date.
	  
	  

	7.2 	On the Closing Date, Marathon and the Sellers shall deliver, or cause to be delivered, to KBB such documents as may reasonably be required to perfect the transactions contemplated by this Agreement and KBB shall deliver, or cause to be delivered, to Marathon and the Sellers such documents as may reasonably be required to perfect the transactions contemplated by this agreement.
	  
	  

	8.	Notices
	  
	  

	8.1 	Delivery of Notice. Any notice, direction or other instrument required or permitted to be given by any party under this Agreement will be in writing and will be sufficiently given if delivered personally or by courier, or transmitted by fax or email means during the transmission of which no indication of failure of receipt is communicated to the sender:

  
  	  
	8.1.1 	in the case of Marathon and the Sellers:

  
 Marathon Global Inc.
 5264 Cedar Springs Road
 Burlington, Ontario L7P 0B9
 Attention: Gavin Treanor
 Email: gtreanor3187@gmail.com
 with a copy to: 
  
 Irwin Lowy LLP
 365 Bay Street, Suite 400
 Toronto, Ontario M5H 2V1
  
 Attention: Steven Agnew
 Facsimile #: (416) 361-2519
 Email: sagnew@irwinlowy.com
  
  	 
	- 16 -
	 
 
	 

  
  	  
	8.1.2 	in the case of KBB:

   
 Kaneh Bosm BioTechnology Inc.
 Suite 810-789 West Pender Street
 Vancouver, British Columbia V6C 1H2
  
 Attention: Chief Financial Officer
 Email: theo@pashleth.com
  
  	8.2 	Receipt of Notice. Any such notice, direction or other instrument, if delivered personally, will be deemed to have been given and received on the date on which it was received at such address and, if sent by fax or email, will be deemed to have been given and received on the date of transmission in accordance with this Section.

   
  	9.	Termination
	  
	  

	9.1 	Grounds for Termination. This Agreement may be terminated at any time before the Closing:

  
  	  
	9.1.1	by the mutual agreement of KBB and Marathon;
	  
	  
	  

	  
	9.1.2 	by either Marathon or KBB if it is not in material breach of its obligations under this Agreement, and if there has been a breach by the other of any of its representations and warranties or covenants hereunder and in either case such breach has not been cured within ten days after written notice, specifying such breach, to such Party; or
	  
	  
	  

	  
	9.1.3 	by KBB or Marathon if the Closing Date is not on or before June 30, 2018 or such later date as may be agreed in writing by KBB and Marathon.

   
  	9.2 	Effect of Termination. If this Agreement is terminated as provided in Section 9.1, it will, except as provided herein, forthwith become void, and, subject to Sections 3.4, 5.2 and 5.4 none of the parties or their respective officers, directors, employees, agents, or shareholders will have any liability or obligation with respect to the terminated provisions of the Agreement. Sections 3.4, 5.2, 5.4, 11.3 and 11.4 will survive termination of this Agreement and will continue to be in effect notwithstanding the termination of this Agreement.
	  
	  

	10.	Power of Attorney
	  
	  

	10.1 	Each of the Sellers hereby severally and irrevocably appoints Marathon as their attorney to take any action that is required and hereby authorizes any director or officer of Marathon, on behalf of Marathon, to sign any documents on their behalf, including without limitation, for the purposes of all Closing matters and deliveries of documents and to do and cause to be done all such acts and things as may be necessary or desirable in connection with the transactions contemplated hereunder, including the sale, assignment and transfer of the Purchased Shares to KBB. Without limiting the generality of the foregoing, Marathon may, on behalf of itself and the Sellers, extend the Time of Closing, modify or waive such conditions as are contemplated herein, negotiate, settle and deliver the final forms of this Agreement and any other documents that are necessary or desirable to give effect to the transactions contemplated herein.

   
  	 
	- 17 -
	 
 
	 

  
  	11.	General Provisions

  
  	11.1 	Entire Agreement. This Agreement, including all the Schedules hereto, together with the agreements and other documents to be delivered pursuant hereto, constitutes the entire agreement among the parties pertaining to the subject matter hereof and supersedes any and all prior agreements, understandings, negotiations and discussions, whether oral or written, of the parties and there are no warranties, representations or other agreements among the parties in connection with the subject matter hereof except as specifically set forth herein and therein.
	  
	  

	11.2 	Costs and Expenses. KBB agrees that it will pay, up to an aggregate of $5,000.00, all fees and expenses and all applicable taxes thereon in connection with the purchase and sale of the Purchased Shares and the transactions contemplated by this Agreement, including the reasonable expenses of Marathon in connection with therewith (including all reasonable fees, expenses and disbursements of Marathon’' legal counsel). All such fees and expenses incurred by Marathon or on its behalf shall be payable by KBB immediately upon receiving an invoice therefor and shall be payable whether or not the purchase and sale of the Purchased Shares is completed.
	  
	  

	11.3 	Confidentiality. Until the Closing Time, and in the event of the termination of this Agreement without consummation of the transactions contemplated by this Agreement, for a period of two years from the date of this Agreement, each party to this Agreement will keep confidential any information obtained from the other parties, provided that a party may disclose confidential information (i) to those of its representatives and professional advisors who have a need to know the information in connection with providing advice with respect to this Agreement and the transactions contemplated thereby if such representatives and advisors commit to protect such information in a manner consistent herewith or (ii) if such disclosure is required by law or the rules of the Exchange or over Governmental Authority or (iii) if such information has been made public other than as a result of a breach of this Section. If this Agreement is terminated without consummation of the transactions contemplated thereby, promptly after such termination all documents, work papers and other written material obtained from a party in connection with this Agreement and not theretofore made public (including all copies and photocopies thereof), shall be returned to the party that provided such material.
	  
	  

	11.4 	Public Announcements. Neither KBB nor Marathon will, without the prior consent of the others, make any disclosure regarding the existence, purpose, scope, content, terms or conditions of this Agreement or other agreements relating to this Agreement except in order to comply with a legal obligation, the requirements of a competent Government Authority or the requirements of the Exchange; provided that, where practicable, a copy of any proposed announcement or statement will be furnished to the other parties in advance of the proposed date of publication. Nothing herein will prevent disclosure of the terms of this Agreement to a corporate party’s directors, officers, employees or agents or its financial, legal, accounting or other advisors.

  
  	 
	- 18 -
	 
 
	 

   
  	11.5 	Waiver. The failure of a party in any one or more instances to insist upon strict performance of any of the terms of this Agreement or to exercise any right or privilege arising under it will not preclude it from requiring by reasonable notice that any other party duly perform its obligations or preclude it from exercising such a right or privilege under reasonable circumstances, nor will waiver in any one instance of a breach be construed as an amendment of this Agreement or waiver of any later breach.
	  
	  

	11.6 	Assignment. None of the parties will assign, transfer, charge or otherwise encumber the benefit (or any part thereof) or the burden (or any part thereof) of this Agreement without the prior written consent of the other parties, such consent not to be unreasonably withheld.
	  
	  

	11.7 	Further Assurances. Each of the parties hereto will from time to time at the request of any of the other parties hereto and without further consideration, execute and deliver all such other additional assignments, transfers, instruments, notices, releases and other documents and will do all such other acts and things as may be necessary or desirable to assure more fully the consummation of the transactions contemplated hereby.
	  
	  

	11.8 	Time. Time will be of the essence of this Agreement.
	  
	  

	11.9 	Amendment. This Agreement may be amended or varied only by agreement in writing signed by each of the parties. Unless the context otherwise so requires, a reference to this Agreement includes a reference to this Agreement as amended or varied from time to time.
	  
	  

	11.10 	Several. Unless otherwise provided, each and every covenant, representation or warranty of the Sellers contained herein is several (and not joint or joint and several).
	  
	  

	11.11 	Severability. If any provision of this Agreement is determined to be invalid or unenforceable in whole or in part, such invalidity or unenforceability will attach only to such provision or part thereof and the remaining part of such provision and all other provisions hereof will continue in full force and effect.
	  
	  

	11.12 	Governing Law. This Agreement will be governed by and interpreted in accordance with the laws from time to time in force in the Province of Ontario and each of the parties hereby attorns to the non-exclusive jurisdiction of the courts of the Province of Ontario, sitting in Toronto.
	  
	  

	11.13 	Benefit of Agreement. This Agreement will enure to the benefit of and be binding upon each of the parties hereto who is a corporation and their respective successors and permitted assigns and upon each of the parties hereto who is an individual and their respective executors, personal representatives, heirs, successors and permitted assigns.

  
  	 
	- 19 -
	 
 
	 

   
  	11.14 	Counterparts. This Agreement may be executed in as many counterparts as are necessary. It will be binding on each party when each party hereto has signed and delivered one such counterpart. Delivery may be made by facsimile or other electronic transmission. When a counterpart of this Agreement has been executed by each party, all counterparts together will constitute one agreement.

   
 THE PARTIES, intending to be contractually bound, have executed this Agreement as of the date and year first above written.
  
 	 MARATHON GLOBAL INC. 
	  
	 KANEH BOSM BIOTECHNOLOGY INC.
	  

	  
	  
	  
	  
	  
	  

	 By: 
	 /s/ Gavin Treanor 
	  
	 By: 
	 /s/ Eugene Beukman
	  

	  
	 (Authorized Signatory)
	  
	  
	 (Authorized Signatory)
	  

  
  	 
	- 20 -
	 
 
	 

   
 SELLERS:
  
 	 VIRIDITAS CAPITAL LTD.
	  
	  

	  
	  
	  
	  

	 By:
	 /s/ 
		
	  
	 (Authorized Signatory)
	  
	  

  
  
 	 COSMOS HOLDINGS INC.
		
	  
	  
	  
	  

	 By:
	 /s/ Grigorios Siokas 
		  

	  
	 (Authorized Signatory)
	  
	  

	  
	  
	  
	  

	 ZALTINE LTD.
		
	  
	  
	  
	  

	 By:
	 /s/
	  
	  

	  
	 (Authorized Signatory)
		

  
 	 SIGNED, SEALED & DELIVERED In the presence of:
	  
 
	
	  
	  

	 /s/
	 /s/ Gavin Treanor

	  
	  
	  

	 Witness
	  
	 Gavin Treanor

  
  	 
	- 21 -
	 
 
	 

  
 SCHEDULE A
  
 THE SELLERS, PURCHASED SHARES AND PAYMENT SHARES 
  
 	 Shareholder
	  
	 Shareholder Address
	  
	 Number of Purchased Shares Held
	  
	  
	 Number of Payment Shares to be Received
	  

	 Viriditas Capital Ltd.
	  
	 5264 Cedar Springs Road, Burlington Ontario, L7P 0B9
	  
	  
	2,000,000	  
	  
	  
	4,000,000	  

	 Cosmos Holdings Inc.
	  
	 141 West Jackson Blvd., Suite 4236, Chicago, IL 60604
	  
	  
	2,500,000	  
	  
	  
	5,000,000	  

	 Gavin Treanor
	  
	 5264 Cedar Springs Road, Burlington Ontario, L7P 0B9
	  
	  
	1,000,000	  
	  
	  
	2,000,000	  

	 Zaltine Ltd. 
	  
	 4100 - 66 Wellington Street West, Toronto, ON M5K 1B7
	  
	  
	3,000,000	  
	  
	  
	4,000,000	  

	  
	  
	 Total
	  
	  
	8,500,000	  
	  
	  
	15,000,000	  

  
  
  	 - 22 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}]]